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I. Abstract
CD8 T cells are potent immune effector cells capable of vast clonal expansion and
clearance of infected or cancerous cells. After control of the pathogenic insult, CD8 T
cells develop into quiescent, long-lived memory populations that are poised to mediate
rapid protection upon reencounter with cognate antigen. These properties make control of
CD8 T cell responses a highly desirable outcome of vaccine strategies and
immunotherapy. Therefore, understanding how the effector function and memory
differentiation of CD8 T cells are controlled at a molecular level is of great importance.
In the context of infection with gammaherpesviruses (γHV), which form a latent infection
that persists for the life span of the host, CD8 T cells play a vital role in control of γHV
associated lymphomagenesis. The following studies utilize murine gammaherpesvirus
(MHV)-68 and a novel model of γHV-associated B cell lymphoma, EM61 to dissect the
mechanisms of CD8 T cell mediated control of γHV associated lymphomagenesis. These
studies indicate γHV-specific CD8 T cells control EM61 through mechanisms that
partially overlap with those used to control viral replication, however, we note important
differences as well. We additionally describe γHV-specific, tissue-resident, memory CD8
T cells (TRM) that form after infection with MHV-68. In the absence of CD4 T cell help,
which causes reactivation of γHV during latency, the γHV-specific TRM compartment
exhibits changes that are distinct from those observed in the context of acute viral
infection. Additional work focused on the molecular control of CD8 T cells by the BTBZF family transcription factor (TF), Zbtb20, which restricts CD8 T cell memory
differentiation. Using single cell techniques, we identify programs of transcriptional and
epigenetic regulation associated with memory CD8 T cell differentiation that underly
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enhanced memory cell formation in the absence of Zbtb20. Furthermore, using a sensitive
technique to interrogate Zbtb20-DNA binding, we describe DNA motifs and genomic
annotations from the direct genomic targets of Zbtb20 in CD8 T cells. Together, this
work provides new knowledge relevant to the response and control of CD8 T cells to
infection and cancer.
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Introduction
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1.1

The CD8 T cell response to infection and cancer
A hallmark of adaptive immunity is the memory CD8 T cell (TM). Eliciting TM

responses through vaccination is a promising approach for treating viruses that are
typically refractory to standard humoral immunity 1. Similarly, the efficacy of adoptive T
cell immunotherapies is improved by transferring TM, rather than terminally
differentiated effector T cells 2,3. Therefore, understanding the mechanisms controlling
the formation of TM is an important endeavor for the amelioration of ubiquitous human
diseases. The following sections describe the general process of TM formation in the
context of infection and key properties of TM useful to immunotherapy.
1.1.1

General characteristics of the CD8 T cell response to infection
Naïve CD8 T cells rapidly proliferate and differentiate into effector CD8 T cells

(TEFF) following recognition of cognate antigen, derived from viral or bacterial
pathogens, presented by activated antigen presenting cells. During differentiation, CD8 T
cells acquire cytolytic capabilities and strongly upregulate effector cytokines such as
IFNγ and TNFα. After eliminating the source of antigen, the expanded TEFF population
contracts and a subset develops into memory CD8 T cells (TM). The portion of TEFF that
survives this contraction phase is largely derived from the memory precursor effector
population (MPEC), identified by high expression of the IL-7 receptor CD127 and low
expression of killer cell lectin-like receptor subfamily G, member 1 (KLRG1) 4–6. The
MPEC population gives rise to all memory T cell subsets, including effector memory
(TEM), central memory (TCM) and resident memory (TRM) 5. The converse of the MPEC
phenotype, high expression of KLRG1 and low expression of CD127, denotes effector
cells known as terminal effector cells (TECs). Terminal effector cells generally decline
2

and fail to convert to memory cells 5. Memory CD8 T cells, imbued with the ability to
rapidly produce an effector response upon pathogen reencounter, are a highly desirable
product of vaccination 1. A key trait of TM underlying the effectiveness of this
evolutionary strategy for host-defense is the ability of TM to persist. In humans,
individual memory CD8 T cells survive for 1-12 months and populations of pathogenspecific TM may be maintained through homeostatic turnover for life 7. This longevity is
supported by specialized metabolic programs. Specifically, TM have a quiescent
metabolic phenotype, defined by decreased utilization of glycolysis and increased
reliance on oxidative phosphorylation (OXPHOS) to produce ATP needed for survival 8,9.
Additionally, TM have increased mitochondrial biomass relative to TEFF which underlies
the metabolic advantage TM use to rapidly respond to secondary challenge 10,11. In
addition to the general characteristics of TM described here, the TM compartment contains
multiple subsets whose functional specialization is described subsequently.
1.1.2

Memory CD8 T cell subsets
Secondary and subsequent recall responses are important for both host protection

and vaccination prime-boost strategies 12,13. The memory CD8 T cells which mediate
recall responses can be divided into groups based on expression of surface molecules
which correspond to differences in proliferative capacity, cytotoxicity, tissue residence
and self-renewal. Classically, TM are divided into effector memory (TEM) and central
memory (TCM) by lack or presence, respectively, of surface molecules L-selectin
(CD62L) and chemokine receptor CCR7 14. These two surface proteins bestow particular
trafficking properties on TM, resulting in preferential partitioning of TM subsets between
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circulation (blood and lymphatics) and secondary lymphoid organs (lymph nodes and
spleen).
Expression of CD62L promotes migration of T cells into lymph nodes (LNs)
through high endothelial venules (HEV) by binding to oligosaccharides collectively
referred to as peripheral node addressin (PNAd) 14. This binding causes lymphocyte
rolling behavior proximal to the HEV lumen and allows for recognition of chemokine
CCL21 tethered to the HEV lumen through CCR7 14. Interaction of CCL21-CCR7 results
in activation of lymphocyte function-associated antigen 1 (LFA1) which binds
intercellular adhesion molecule 1 (ICAM1) and precipitates T cell arrest and
transmigration into the LN 14. Entry of T cells into LNs through HEV initiates a process
of T cell migration through the lymphatics during which they scan antigen presenting
cells in LNs for cognate antigen before converging in lymphatic ducts connecting the
lymphatics to the blood through subclavian veins 14–16. In human adults, the process of
lymphatic migration completes in 10-20 hours barring recognition of antigen and
approximately 2 liters of fluid are returned to blood circulation from the lymphatics daily
17

. The spleen is a secondary lymphoid organ that lacks afferent lymphatic vessels and is

involved in the recognition of blood-borne pathogens. The spleen’s anatomy is divided
between the red and white pulp. The red pulp is erythrocyte-rich, hence its name, and
functions to remove aging and opsonized cells 18–21. The white pulp is layered around
arterioles emanating from the central artery and is composed of white blood cells
(leukocytes) 18–21. The layer proximal to the arteriole is named the periarteriolar lymphoid
sheath (PALS) and is predominantly composed of T cells 18–21. Subsequent layers contain
germinal centers 18–21. T cells entering the spleen are released passively at arteriole
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termini, therefore, CD62L-mediated rolling is not required for T cell entry into the spleen
14

. However, multiple studies have highlighted the importance of CCR7 and its ligands

(CCL21 and CCL19) for guiding T cells recently released from circulation to the PALS
22,23

. The exact processes regulating T cell exit from the spleen are still unknown.
Accounting for the physiology of the secondary lymphoid organs described above

facilitates an understanding of the localization of TEM and TCM. Both of these memory
subsets are capable of recirculating, however, TCM are predominantly found in secondary
lymphoid organs while TEM mostly patrol the circulatory system, transiently leaving
circulation and entering tissues 24. In the spleen, TCM localize mostly to the white pulp
and TEM transit through the red pulp, infrequently residing in the white pulp 25. Functional
attributes of these subsets correspond to their migratory patterns. The TEM compartment
constitutively maintains elevated effector potential and retains the capacity to rapidly
produce effector cytokines in response to reencounter with cognate antigen in the
periphery 26–28. The TCM compartment maintains a heightened ability to proliferate and redifferentiate upon antigen reencounter relative to the TEM subset 26–28. Thus, together
these two subsets are capable of mediating a rapid effector response (TEM) and a slower,
but robust, secondary expansion of effector T cells (TCM).
The classic division of TM into TEM and TCM provides a useful basis for
understanding the specialization of the CD8 T cell memory compartment. However,
studies have identified additional useful methods for making delineations in the TM
compartment. Expression of the fractalkine receptor CX3CR1 can be used to make
functional delineations within the TM compartment. Work in models of viral infection
have noted that either intermediate or high expression of CX3CR1 can be used to classify
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TM subsets with different self-renew capacities and abilities for surveying peripheral
tissues 29. In the context of infection with a bacterial agent (listeria), expression of
CX3CR1 reportedly identifies a population of TM that predominantly partitions into the
red pulp in the spleen 30, expresses elevated levels of granzyme B and mediates enhanced
target cell killing 31. Furthermore, work by Herndler-Brandstetter and Ishigame (2018)
used levels of CX3CR1 expression to aid in the identification of TECs that transiently
expressed KLRG1 during the effector phase and survived to form TM with functional
properties that were distinct from effector cells never expressing KLRG1 5.
A leap in the understanding of the TM response came with the description of TM
residing professionally in peripheral tissues without recirculation. Subsequently, a deluge
of studies described the phenotypic and functional capacities of these cells. We now
appreciate that tissue-resident memory CD8 T cells (TRM) are a vital TM subset that
occupy sentinel positions in peripheral tissues, often forming a first line of defense
against re-exposure to pathogenic agents. To maintain residence in tissues, TRM express
particular patterns of surface molecules. Similar to TEM, TRM lack expression of
lymphoid-homing molecules and instead often express integrins, such as CD103 and
CD49a (VLA-1α), that tether TRM to tissues. Additionally, TRM often express CD69 to
prevent egress from tissues into circulation along gradients of sphingosine-1-phosphate
32

. Chemokine receptor expression patterns also aid TRM localization to specific tissues,

for example, CCR9 aids the formation of TRM in the gut 32. Other adaptations enabling
long-term tissue residence and rapid effector responses are discussed in following
sections. Together, TCM, TEM and TRM constitute the basis of the CD8 T cell memory
compartment.
6

1.1.3

Memory CD8 T cells and cancer
Immunotherapy for cancer is a promising treatment modality for patient

populations with unresectable or metastatic tumors. Memory CD8 T cells and the
properties that underly their rapid recall response may be leveraged in the
immunotherapy setting. Adoptive cell immunotherapies for cancer have shown
remarkable efficacy in mediating regression of unresectable and liquid tumors 33. There is
a correlation between persistence of the transferred cells and improved clinical responses
34

. Furthermore, less differentiated, more memory-like subsets of T cells derived from

patients and engineered to express tumor-specific chimeric antigen receptors (CAR T
cells) mediate more potent antitumor responses than terminally differentially effector T
cells 2,3,35. This is due, in part, to the enhanced metabolic state of memory T cells, which
is optimized for long-term persistence and underlies their superior effector responses as
compared to primary effector cells 11,36,37. Efforts to obtain stem-like memory T cell
products (products with increased capacity for self-renewal and multipotency to
differentiate into all CD8 T cell subsets) for adoptive transfer therapies have utilized a
number of different strategies. These strategies, which modify the in vitro expansion
protocols for T cell products, include replacing IL-2 with cytokines such as IL-7 or IL-15
38,39

40

, reducing TCR stimulation 39, coculture with stromal cells expressing Notch-ligands

, WNT-pathway agonism through inhibition of GSK-3β 41,42, antioxidant treatment to

reduce levels of reactive oxygen species 43, inhibition of AKT 44 or inhibition of
chromatin modifying bromodomain and extra-terminal motif (BET) proteins 45.
Accumulating pre-clinical and clinical evidence suggests approaches generating more
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stem-like memory cells for adoptive transfer produce more persistent T cell products with
more robust anti-tumor capacity 41–43,46–50.
Another approach to immunotherapy seeks to invigorate the endogenous immune
response to cancers by agonizing or antagonizing molecules on the surface of immune
cells that tune the immune cell response. Several of these promising strategies, commonly
referred to as checkpoint blockade therapies, are focused on promoting tumor clearing
CD8 T cell responses. Association between tumor-infiltrating lymphocytes and survival
in cancer patients has long been appreciated 51. Additional work has shown that TRM may
be an especially prognostic T cell subset for predicting melanoma patient outcome to
checkpoint blockade therapy 52. This is exemplified by the formation of long-lived TEM
and TRM responses in patients with elite responses to checkpoint blockade 53. As
described in this section, in both the context of adoptive cell therapy and checkpoint
blockade, memory CD8 T cell responses are key to successful immunotherapy.
Additional examples of TM properties that may be useful to immunotherapy strategies are
highlighted in the relevant sections describing the control of the CD8 T cell response.
1.2

Control of the CD8 T cell response
The CD8 T cell response requires a complex signal integration network composed

of signaling cascades, transcription factors, epigenetic regulation and metabolic
adaptations. The following section describes important components of the network
guiding aspects of the CD8 T cell response such as effector function, differentiation,
persistence and recall. Understanding this regulatory network is critical to efforts to
predict and control immune cell function for therapeutic purposes.
1.2.1

Activation and environmental cues
8

Productive activation of the CD8 T cell response begins with the recognition of
cognate peptide presented on MHC class I by antigen presenting cells (APCs) through the
T cell receptor (TCR). Activated APCs additionally provide co-stimulation needed to
achieve full, productive T cell activation. TCR ligation/costimulation begins a series of
signaling cascades that collaborate to enact the transcriptional and metabolic programs of
an activated T cell. Briefly, recognition of cognate antigen presented on MHC class I
through TCR results in the phosphorylation of Immunoreceptor Tyrosine-based
Activation Motifs (ITAMs) on the cytosolic portions of TCR-associated CD3 molecules
by lymphocyte-specific protein tyrosine kinase (LCK), which is brought to the TCR
complex by association with the intracellular tail of CD8 molecules actively recognizing
MHC class I. Subsequently, phosphorylated ITAMs recruit Zeta chain of T cell receptor
associated protein kinase 70 (Zap70), which is itself phosphorylated by LCK to enable
further downstream signaling events. These signaling events branch out to activate
several major downstream transcriptional regulators. These branches include 1) the
Ras/MAPK/ERK pathway, which results in AP-1 activation. 2) The PI3K/AKT and
PI3K/ PKCθ pathways, which results in activation of mTOR and NF-κB respectively. 3)
The release of intracellular calcium stores from the endoplasmic reticulum, resulting in
activation of Calcineurin/NFAT. Physical cooperation between AP-1 and NFAT
transcription factors enables binding of composite DNA motifs and is necessary for
productive activation of CD8 T cells 54. The activation of mTOR drives a number of
cellular growth programs necessary for CD8 T cells to rapidly undergo clonal expansion
and form a productive TEFF response. In particular, mTOR activates transcription factor
MYC to promote transcription of Slc2a1 (GLUT1) for the import of glucose as well as
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glutamine importers (Slc38a1/Slc38a2) 55. Furthermore, AMPK, which senses the ratio of
AMP/ATP, can attenuate mTOR activity upon sensing low cellular ATP levels 55.
Therefore, mTOR integrates extracellular signaling to promote cellular growth programs
and ensures adequate cellular energy levels are maintained. This helps support the
metabolic program, discussed later, needed for rapid clonal expansion. To achieve
productive activation and avoid anergy, antigen presenting cells (APCs) activated by
danger cues provide costimulation in addition to TCR ligation. Costimulation is
canonically provided by CD80/86 molecules on APCs ligating CD28 receptors on T
cells. This results in a substantially greater signal through the PI3K/AKT pathways
relative to the signal derived from TCR stimulation necessary to fully activate a
productive TEFF response 56.
After activation, CD8 T cells respond to environmental signals present in the
inflammatory cytokine milieu. Different types of infection result in unique mixtures of
cytokines that tailor the CD8 T cell response. Comparisons of viral infection with
vesicular stomatitis virus (VSV) versus bacterial infection with Listeria monocytogenes
(LM) highlighted that differentiation kinetics of the effector CD8 T cell response vary
with respect to pathogenic insult. Infection with LM generated a CD8 T cell response
characterized by a large pool of TECs, whereas VSV infection generated a comparatively
large population of MPECs 57. The production of cytokine IL-12 in mice infected with
LM was found to enhance the generation of TEC populations, supporting previous
observations from Joshi et al. (2007) linking IL-12 with TEC formation through
upregulation of transcription factor T-bet 58. Similar to IL-12, type-I interferon promotes
the TEC fate and the expression of T-bet 59. Opposing roles for TGF-β and IL-15 have
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been described for controlling the TEFF phase. TGF-β appears to promote TEFF contraction
by lowering intracellular levels of antiapoptotic factor Bcl-2, therefore promoting TEC
apoptosis 60. On the other hand, IL-15 promotes survival of TEC and further supports
mitochondrial biogenesis in, and homeostatic proliferation of, TM 61. The cytokine IL-2
promotes TEC formation and cytotoxicity through the high affinity IL-2 receptor
complex containing CD25 62. TEC are partially identified by high expression of the IL-7
receptor alpha (CD127) and signaling induced through IL-7 is critical for the
maintenance of TM 63. However, the exact contribution of IL-7 to TM formation is not
entirely elucidated. IL-7 signaling increases levels of antiapoptotic factor Bcl-2 in CD8 T
cells 63. Further study of CD8 T cells with a knock-in mutation abrogating Jak/STAT5
and PI3 kinase (PI3K) signaling through CD127 found that while a defect in TM
maintenance persisted, normal levels of Bcl-2 were present 64. Thus, Bcl-2 alone was
insufficient to restore the TM maintenance defect caused by faulty IL-7 signaling. Other
work has identified a role for IL-7 in promoting the metabolism of fatty acids needed for
TM longevity 65. Altogether, numerous cytokines are responsible for tailoring the TEFF
response and establishing formation of long-lived TM.
1.2.2

Contribution of transcriptional and epigenetic controls
Contributions of a number of transcription factors (TFs) to the CD8 T cell

response have been described. These factors contribute to the initial TEFF response and
the quality or size of the TM population. During the TEFF response, the differentiation of
TEC is promoted by TFs such as IRF4, T-bet, Blimp-1, Id2, YY1, STAT4 and Zeb2,
while the differentiation of MPEC and/or TM is promoted by TFs including
Eomesodermin, Bcl6, Runx3, Nr4a1, Nr3c1, STAT3, Tcf1, BACH2, Foxo1, Id3 and
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Zeb1 66–68. Some transcription factors seem to be important for maintaining a state of
elevated responsiveness in TM. Transcription factors E2A 69 and AP-1 are associated with
regulation of the epigenetic landscape of CD8 T cells. In fact, AP-1 motif enrichment has
been noted around enhancers for genes with increased chromatin accessibility in TM such
as Ifng, Prdm1 and Tbx21 69. Similarly, E2A maintains accessibility at gene enhancers
that promote memory-like differentiation 69.
Tissue resident CD8 T cells (TRM) exist in a state of increased potentiation to
exert effector function relative to TCM and therefore seem to require certain ‘pro-effector’
transcription factors for their formation 67,70,71. For example, the transcription factors
Blimp-1 and T-bet promote a TEC fate, yet are required for the formation of TRM in
certain compartments 58,72–76. In contrast, the transcription factors Runx3 and Nr4a1
promote an MPEC fate and are required for efficient TRM formation 77–80. Another
transcription factor, Eomesodermin, is vital for the maintenance of TCM but is absent in
TRM. Furthermore, enforced expression of Eomesodermin severely suppresses TRM
differentiation 76,81,82. This illustrates that TRM require a collaboration between
traditionally ‘pro-memory’ and ‘pro-effector’ transcription factors. Additional TFs
promoting TRM formation in certain tissues include Hobit and HIC1 73,74,83.
The chromatin accessibility state plays a crucial role in the moderation of the
CD8 T cell response and adds an additional layer of transcriptional regulation. As a basic
conceptualization, epigenetic modifications control transcription from regions of the
genome by either promoting ‘open’ or ‘closed’ DNA conformations. An open
conformation promotes TF and transcriptional machinery binding leading to transcription
of mRNA, whereas closed conformations restrict the access of TFs and transcriptional
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machinery. The opening or closing of chromatin is a highly regulated and dynamic
process that occurs through several different mechanisms. Chromatin consists of DNA
wrapped around a histone octamer composed of two of each of the histones; H2A, H2B,
H3 and H4. 147 base pairs of DNA wrap around each histone octamer and this DNAhistone complex is referred to as a nucleosome. Closed areas of chromatin consisting of
nucleosomes tightly packed together are referred to as heterochromatin, and open areas,
where nucleosomes are dispersed, are referred to as euchromatin. Heterochromatin is late
to replicate during cell division and mostly contains inactive genes. Euchromatin contains
the majority of active genes. Epigenetic regulation occurs through enzyme-mediated
modifications to DNA or histones that change the availability of associated genes for
transcription. Trimethylation, mediated by histone methyltransferases (HMTs), of H3
lysine residues on H3K4, H3K36 and H3K79 results in open chromatin and active
transcription 84. However, trimethylation of H3K9, H3K27 and H4K20 results in the
repression of transcription 84. Histone acetylation and deacetylation is another important
mechanism of epigenetic regulation, mediated by histone acetyltransferases (HAT) and
histone deacetylases (HDACs) 85. Histone acetylation results in more open chromatin and
increased DNA accessibility 85. Importantly, epigenetic modifications are heritable by
daughter cells in subsequent cell divisions 86. In the context of CD8 T cells, this is
especially important as clonal expansion results in large numbers of cell divisions and
provides ample opportunity for epigenetic modification to affect cell fate decisions. This
has been demonstrated for multiple epigenetic regulators that contribute to the
differentiation of CD8 T cells from the naïve phase, through the effector phase and
ultimately to memory.
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Several factors have been identified that contribute to the differentiation and
function of CD8 T cells through the epigenetic control of chromatin accessibility. Factors
whose presence positively contribute to the generation of memory CD8 T cells include
histone deacetylase HDAC3 87 and histone acetyltransferase CBP 88. Factors that promote
effector programs include the methyltransferase EZH2 89,90, the methylcytosine
dioxygenase TET2 91, the methyltransferase Dnmt3a 92,93 and the methyltransferase
Suv39h1 94. The availability of substrate for epigenetic regulation through acetylation and
methylation is linked to the global metabolic state of a given cell. Citrate, an intermediary
product of the TCA cycle is exported from mitochondria and converted to acetyl-CoA,
which is subsequently used as a donor for HAT-mediated histone acetylation. Another
TCA product exported from mitochondria is α-ketoglutarate (αKG), which is used as a
cofactor for histone and DNA demethylation. Histone methyltransferases use S-adenosylmethionine (SAM) as their source for methyl groups, which is synthesized from the
essential amino acid methionine 95,96. In CD8 T cells, studies have shown that enhancing
intracellular levels of Acetyl-CoA drives increased histone acetylation and open
chromatin that result in improved effector function in the context of CD8 T cell-mediated
tumor control 97,98. Additional contributions of metabolism to the differentiation of CD8
T cells are discussed in the following section.
1.2.3

Metabolism
Upon recognition of cognate antigen and proper costimulation, naïve CD8 T cells

switch from a metabolically quiescent state into a metabolically active state. Whereas
naïve CD8 T cells have relatively low energy demands for supporting homeostasis and
survival that are met primarily through oxidative phosphorylation (OXPHOS), the
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generation of highly proliferative, cytotoxic TEFF requires a different metabolic program.
The program supporting TEFF is characterized by high utilization of both glycolysis and
OXPHOS 99. This enables TEFF to generate the ATP and synthetic intermediates needed
to sustain both clonal expansion and the generation of effector molecules 99. After
contraction of the TEFF response, differentiated TM adopt a quiescent metabolic state,
adapted for persistence in a similar fashion to naïve CD8 T cells 100. Despite the shared
quiescent nature of TM and naïve T cells, TM uniquely possess certain metabolic features
that help fuel rapid secondary responses 11. For example, TM maintain enhanced
mitochondria, characterized by elevated mitochondrial biomass 10 and extensive networks
of fused mitochondria with efficient organization of cristae 101. As a result, TM possess an
elevated ability to perform OXPHOS relative to their basal needs, an ability described by
the spare respiratory capacity (SRC) readout of metabolic flux assays. These adaptations
drive TM formation and can be leveraged to promote tumor clearance in adoptive cell
therapies (ACT). Adoptive cell transfer strategies promoting a more memory-like
metabolic phenotype with increased OXPHOS capacity result in increased tumor
clearance and improved adoptive cell longevity 2,3,102. The period of in vitro culture
wherein ACT are expanded and/or genetically modified provides an ideal opportunity to
modulate cell metabolism for increased therapeutic potential. Restricting glucose
consumption, either through metabolically inactive glucose analogs 103 or inhibition of
glycolysis-promoting signaling through Akt inhibition 104, during this period has
demonstrated promise in murine models of ACT. Activating AMPK, which reduces
anabolic metabolism focused on glycolysis and promotes catabolic OXPHOS, with
chemical agonist metformin drives the formation of TM 105. Additionally, some evidence
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suggests that metformin treatment pushes CAR T cells to adopt a more memory-like
phenotype and improves CAR T cell therapy against solid tumors 106. Other studies have
also found that improving the OXPHOS capacity of ACT products can lead to improved
therapeutic capacity. Enhancing OXPHOS and mitochondrial biogenesis through
overexpression of PGC1α led to improved ACT versus a solid tumor model 107. Similarly,
increasing the OXPHOS capacity of CAR T cell products using 4-1BB intracellular CAR
signaling domains as opposed to CD28 intracellular signaling domains leads to enhanced
TM formation and persistence 108. Accordingly, CAR T cell products that utilize 4-1BB
costimulatory domains display remarkable in vivo persistence in patients and display
fewer signs of exhaustion 109,110. Thus, the metabolic status of CD8 T cells therapies is an
important consideration for the design of effective cellular therapies. Further insights into
how metabolism alters CD8 T cell function, differentiation and persistence will continue
to generate new opportunities for leveraging therapeutic windows associated with an
entire class of metabolic enzymes and signaling molecules.
To establish residency in a tissue, CD8 T cells adapt to survive outside of
circulation in the periphery. It was demonstrated that TRM in skin import exogenous free
fatty acids for fuel, rather than synthesizing fatty acids de novo like conventional memory
T cells 65,105,111,112. This may be an adaptation to low glucose availability for de novo fatty
acid synthesis in skin 113,114. Other groups have linked the mitochondrial function in TRM
to proper detection of extracellular ATP via the cell-surface, ATP-gated, ion channel,
P2RX7 115 and determined that the transcription factor Bhlhe40 is associated with proper
TRM metabolism 116. Active areas of investigation include determining which metabolic
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properties are specific to TRM and to what extent different tissues require specific
metabolic adaptations for long-term persistence.
1.3

Gammaherpesvirinae
Gammaherpesvirinae belong to the evolutionarily ancient and prolifically

successful order of viruses, Herpesvirales. The viruses of this order share a distinctive
structure; an icosahedral capsid containing a linear double-stranded DNA genome of 125290kb, which is surrounded by a protein matrix termed the tegument and then by a lipid
envelope containing membrane-associated proteins. Herpesvirales is divided into three
families; the Herpesviridae contain mammal, bird and reptile viruses, the
Alloherpesviridae contain fish and frog viruses and the Malacoherpesviridae contain
viruses identified in mollusks 117–119. Thus, viruses of the order herpesvirales infect a
broad range of phyla, ranging from vertebrate to invertebrate. The family Herpesviridae
is further divided into three subfamilies: Alphaherpesvirinae, Betaherpesvirinae and
Gammaherpesvirinae. Analysis of sequenced genomes from present-day Herpesviridae
estimates these three subfamilies diverged from a common ancestor some 400 million
years ago, a roughly equivalent timeframe to the divergence of amphibians and the
common ancestor giving rise to mammals, birds and reptiles 120,121. Subsequently,
coevolution with their hosts during speciation likely contributed to the evolution of the
101 currently described members of the Herpesviridae family 122,123. Members of
Herpesviridae are typically species specific, however, there are reports of notable and
sometimes fatal examples of species-jumping herpesviruses 124. For example, malignant
catarrhal fever in ruminant species such as goats, cattle and white-tailed deer is caused by
the Gammaherpesviruses alcelaphine herpesvirus 1 (AHV-1) and ovid herpesvirus 2
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(OHV-2). These viruses are endemic to wildebeest and sheep respectively in which they
cause no significant morbidity 124. Another general feature of Herpesviridae is their
ability to form latent infection and persist for the life span of the host without being
cleared 125. The Alpha- (αHV), Beta- (βHV) and Gammaherpesviruses (γHV)
characteristically have different tissue tropisms. Viruses in the αHV family, such as
herpes simplex virus 1 & 2 (HSV1&2) which infect humans, are neurotropic and
establish latency in neurons. Neurons provide a long-lived and quiescent population for
the latent persistence of αHV. The βHV have a broad tissue tropism during initial lytic
infection and then form latent infection in cells of the myeloid lineage and other
hematopoietic progenitors. The γHV are lymphotropic, many form latent infections in B
cells and some form latent infections in T cells. Notably, γHV are associated with the
development of lymphoproliferative diseases, lymphomas and non-lymphoid cancers 126.
Herpesviruses are extremely prevalent in human populations. The αHV HSV-1 is
estimated to affect 67% of the global population 127, while estimates place the
seroprevalence of the βHV human cytomegalovirus (HCMV) around 83% globally 128,
with 60% infected in developed countries and almost 100% infected in developing
countries 129. Lastly, the etiologic agents of γHV infection in humans are Epstein-Barr
virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV). The γHV are divided
into two genera, rhadinoviruses (KSHV) and lymphocryptoviruses (EBV).
Rhadinoviruses have been identified in a broad range of mammalian species, while
lymphocryptoviruses are found predominantly in primates. The human γHV are
particularly successful: EBV affects >90% of the human population, while KSHV
demonstrates greater variance of seroprevalence, ranging from <10% to >80% depending
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on geographic location 130,131. High prevalence and association with significant
lymphoproliferative and malignant disease makes understanding the pathogenesis and
immune control of γHV imperative for the protection of human health. Furthermore,
study of the interactions between a coevolved immune response and pathogen provides
an opportunity for the discovery of critical host-pathogen dynamics broadly applicable to
the human immune system.
1.3.1

Pathogenesis of Gammaherpesvirinae
The high specificity of human γHV precludes their study in immunologically

tractable murine models. Therefore, a vital tool for dissecting the relationship between
γHV and their hosts is murine gammaherpesvirus 68 (MHV-68). MHV-68 is a natural
pathogen of rodents used to study the relationship between γHV and their hosts for over
four decades 132. Genome comparison of MHV-68, a rhadinovirus, with the human
rhadinovirus KSHV found homology between 60 of the approximately 80 open reading
frames (ORFs) contained within both viruses 133. The pathogenesis of both human and
mouse γHV infections occurs in three comparable stages: acute (lytic) infection, latency
and reactivation. Acute infection with productive lytic replication in mucosal epithelial
cells results in infection of dendritic cells that traffic into B cell zones in secondary
lymphoid organs 134. Subsequently, B cells are infected and γHV switch into latency, a
state in which only the few viral genes necessary for viral genome maintenance are
expressed. The reservoir of viral latency is primarily in B cells, however, a level of
latency exists in other cell types such as dendritic cells, macrophages and epithelial cells.
Latency is maintained in the host for life with periodic, productive reactivation that
enables viral shedding and infection of new hosts 125.
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1.3.2

Disease associations with gammaherpesviruses and therapy
The human γHV are associated with substantial disease in immunocompromised

individuals. Programs of viral latency which function to promote the longevity of the host
cell are normally limited by the immune system. However, in immunocompromised
patients these brakes are removed and γHV-promoted cell survival and proliferation go
unchecked, leading to malignancy. Consistent with B cells as the primary reservoir of
viral latency, a number of lymphoproliferative disorders are characteristically associated
with γHV. Accordingly, the two human γHV, EBV and KSHV, are among the viruses the
World Health Organization classifies as class I carcinogens in addition to human
papilloma virus (HPV), Merkel cell polyomavirus (MCPyV), hepatitis B and C viruses
and human T-cell lymphotropic virus 1 (HTLV-1) 135. In AIDS and other
immunocompromised patients, the lymphoproliferative diseases directly associated with
EBV are primary effusion lymphomas, Burkitt lymphoma, plasmablastic lymphoma,
diffuse large B cell lymphoma, Hodgkin lymphoma, plasmacytic hyperplasia and
polymorphic B cell hyperplasia. EBV is the etiologic agent of infectious mononucleosis
(mono or ‘kissing disease’) and implicated in the pathogenesis of nasopharyngeal
carcinoma 136. Furthermore, immunosuppressed transplant recipients infected with EBV
are at risk of developing post-transplantation lymphoproliferative disease 137. For KSHV,
the associated diseases in AIDS patients are Kaposi’s sarcoma, multicentric Castleman’s
disease and primary effusion lymphoma 138.
A number of autoimmune diseases have been linked to EBV, such as systemic
lupus erythematosus, Sjogren’s syndrome, rheumatoid arthritis and mixed connective
tissue disease 139. Although the strength of the links between EBV and the
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aforementioned diseases remains tenuous, recent progress has strengthened the
association between EBV and multiple sclerosis (MS), a chronic autoimmune
demyelinating disease of the central nervous system. Researchers have long suspected a
causal link between EBV and MS140–143, however, the >90% seroprevalence of EBV in
the general population poses a particular challenge to appropriately controlling studies.
Additionally, the interval between viral infection and onset of MS disease is on the order
of decades. Awareness of the links between viral infection and long-term chronic disease
were thrust into the forefront of public attention by SARS-CoV-2 and the large
population (up to >40% of those infected) experiencing lasting symptoms after infection
144,145

. As a result, the current environment is especially good for studying links between

viral infection and chronic disease, with billions of dollars of investment aimed towards
understanding these nebulous phenomena 146. Recently, two studies have provided strong
evidence of causality. In one, antibodies recognizing high-affinity molecular mimicry
between an EBV-encoded protein (EBNA1) and the central nervous system protein glial
cell adhesion molecule (GlialCAM) were detected and in vivo studies demonstrated that
immunization against EBNA1 exacerbated disease in an MS model 147. In another, a
longitudinal study was performed on serum samples collected from >10 million active
duty military service personnel 148. Analysis of this large cohort enabled statistical
analysis of EBV serostatus in 955 personnel diagnosed with MS. From this analysis, it
was determined the risk of MS increased 32-fold after infection. For comparison,
smoking increases the risk of lung cancer 15-30-fold 146. Curiously, this study and others
noted cytomegalovirus infection (βHV) is associated with decreased risk of MS 148,149.
Possibly, co-infection with HCMV preoccupies enough of the immune response that
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adverse, MS-initiating, immune reactions to EBV are reduced 150. This illustrates an
interesting health outcome related to the interaction of two persistent herpesviruses. In
mice, infection with MHV-68 can be used to enhance the symptoms of experimental
autoimmune encephalomyelitis (EAE), resulting in disease more closely recapitulating
MS in humans 151–156.
It is estimated that EBV was linked to 240,000-360,000 new cases of cancer and
140,000-210,000 cancer deaths worldwide in 2020 157. Multiple sclerosis affects >2.5
million people worldwide 158. The significant malignant, lymphoproliferative and
autoimmune disease associated with γHV has prompted development of therapeutic
measures. Towards the prevention of initial EBV infection, clinical trials are underway to
evaluate the safety and efficacy of vaccines developed by Moderna, Inc. (mRNA-1189,
NCT05164094, recruiting) and the National Institute of Allergy and Infectious Diseases
(NIAID) (EBV gp350-Ferritin Vaccine, NCT04645147, recruiting). Additionally,
Moderna, Inc. is developing mRNA-1195 for control of long-term EBV sequelae such as
MS and post-transplant lymphoproliferative disease. There is evidence that the effector
function of EBV-specific CD8 T cells is decreased during MS attacks and that adoptive
transfer of EBV-specific CD8 T cells ameliorates MS disease 159,160. Accordingly, phase
1/2 trials are underway (ATA188, Atara Biotherapeutics, NCT03283826, recruiting) to
test the administration of an off-the-shelf, allogeneic, EBV-specific CD8 T cell product in
MS patients. The approach of using adoptive EBV-specific T cell therapy is well
established for EBV-associated post-transplant lymphoproliferative disease 161–165, as
well as other EBV-associated lymphomas 166–169. It is interesting to consider the longterm consequences of eliminating EBV or other γHV from the human disease repertoire.
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The Hygiene Hypothesis suggests that low exposure to pathogens early in life may lead
to a greater risk of immune-mediated diseases later in life 170. Over the 30 years since this
hypothesis was formalized, numerous studies have associated low-exposure to multiple
human pathogens, environmental factors and microbiota with increases in immunerelated disease 171–173. The Hygiene Hypothesis was reformulated to the ‘Old Friends
Hypothesis’ to reflect that many infectious diseases and microbiota have a long coevolutionary history with humans and that certain levels of exposure in early life may be
important for the development of normal immunoregulation 174,175. Evidence that γHV
may play a role in promoting normal immune function comes from mouse studies using
MHV-68. These studies have found evidence that infection can delay onset of type 1
diabetes 176, protect lupus-prone mice from disease onset 177, and recently, that MHV-68
protects mice from allergic asthma 178. The human γHV are ‘old friends’ from a coevolutionary standpoint and increased disease is associated with increasing age of
infection 179,180. This makes it especially important that epidemiological considerations of
vaccination are carefully studied 181. Failure to generate a potent, long-lasting vaccine
response could simply increase the age of infection. Thus, depriving recipients of
potential benefits to normal immunoregulation conferred by γHV infection during
childhood and increasing the severity of disease experienced in adulthood. Additionally,
applying a rapid selective pressure to γHV could have unintended consequences on viral
evolution. Despite these cautionary notes, the global disease burden associated with γHV
infection mandates therapeutic development. The lessons learned from large-scale
vaccination against γHV may prove broadly instructive for the scientific and medical
communities.
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1.4

The BTB-ZF family transcription factor Zbtb20
As previously described, transcription factors (TFs) contribute to the CD8 T cell

response. Our lab discovered that the BTB-ZF family transcription factor Zbtb20 is one
such factor. In this section, the role of BTB-ZF family TFs in the immune response is
discussed, as well as biochemical characteristics that underly their mechanism of
transcriptional regulation. Then, the role of Zbtb20 in transcriptional regulation and
human disease is considered, followed by a discussion of the described role of Zbtb20 in
CD8 T cells.
1.4.1

Biochemical features of BTB-ZF transcription factors
BTB-ZF proteins are TFs defined by shared structural components including an

N-terminal BTB domain which mediates protein-protein interaction and a C-terminal
series of C2H2/Krüppel-type zinc finger (ZF) DNA-binding domains. Between the BTB
and ZF domains lies a stretch of 100-375 amino acids that form a linker that is generally
predicted to be unstructured 182. The unstructured nature of the linker permits the BTB
and ZF domains to bind with flexibility but does not preclude further function of the
region. For example, the linker regions of some BTB-ZF proteins recruit the
transcriptional repressor proteins ETO or mSin3A 183,184. Additionally, the linker region
is a target of post-translational modifications such as acetylation, phosphorylation and
sumoylation which modify the activity of BTB-ZF proteins 185. There are 49 proteins
classified as BTB-ZF proteins encoded by the human genome 186. The BTB domain is
conserved evolutionarily from Drosophila to mammals and named for three Drosophila
genes, broad-complex, tram-trac and bric à brac 187. Occasionally, the BTB domain is
termed the POZ (poxvirus and zinc finger) domain, as many poxvirus proteins contain
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this domain 188. This alternative naming scheme for the BTB domain is used in some
literature and BTB-ZF proteins are instead referred to as POK (POZ and Krüppel-type
zinc fingers) proteins. Homodimeric and heterodimeric interactions with BTB-ZF
proteins are mediated by the BTB domain and dimerization appears essential for BTB-ZF
function 189. Some of the identified heterodimerizing BTB-ZF proteins are LRF
(Leukemia/lymphoma-related Factor, Zbtb7a) and BCL6 (B cell Lymphoma 6, Zbtb27)
190

, BCL6 and MIZ-1 (Myc-interacting zinc finger protein-1, Zbtb17) 191 and BCL6 and

BCL6B (BAZF, Zbtb28) 192. Furthermore, some BTB-ZF proteins may oligomerize
193,194

. The BTB domains also mediate interaction with proteins other than BTB-ZF

transcription factors. For example, the BTB domain of BCL6 and other BTB-ZF proteins
can bind transcriptional regulators such as nuclear co-repressor (NCoR), silencing
mediator for retinoid and thyroid hormone receptors (SMRT), BCL6 interacting corepressor (BCOR), SIN3 transcription regulator family members A/B (SIN3A/B) and the
nucleosome remodeling deacetylase (NuRD) complex 185. The NuRD complex, which
contains histone deacetylases (HDAC1/2) and other chromatin remodelers, is implicated
in transcriptional repression or activation, DNA repair and DNA replication 195. The BTB
domain may also recruit E3-ubiquitin ligase complexes through cullin 3 (CUL3) binding.
In this context, CUL3 binding promotes proteosomal degradation of BTB-ZF-interacting
proteins. Indeed, this appears to be an important function of PLZF and BCL6 BTB
domains, as mice lacking CUL3 partially phenocopy PLZF- or BCL6-deficient mice 196.
Because BTB-ZF proteins form obligate dimers, there are two potential BTB binding
sites available for binding to transcriptional regulators. Indeed, the crystal structure of
BCL6 binding the SMRT co-repressor confirmed 2:2 binding stoichiometry 197. The

25

binding of co-repressors with BCL6 does not appear to be cooperative, meaning that one
BCL6 dimer could, in principle, bind two different co-repressors simultaneously 198. The
ability to form BTB-ZF heterodimers and to recruit different combinations of
transcriptional regulators to a single BTB-ZF dimer may provide a general mechanism
for tuning BTB-ZF TF activity and binding specificity.
The composition of BTB-ZF protein domains suggests a general mechanism of
transcriptional regulation by BTB-ZF TFs. Formation of BTB-ZF dimers through BTB
domains enables flexible binding of ZF domains to DNA. BTB domains additionally
recruit regulatory machinery to modulate transcriptional activity in a fashion that may be
dependent on post-translational modifications in the linker region. Differences in number
and position of the zinc finger motifs play a role in the specificity of ZF domains. A
number of DNA binding motifs have been identified for BTB-ZF proteins using ChIP-seq
199–203

and one by cyclic amplification and selection of targets (CAST) 204. Liu et al.

(2016) noted large variations in BCL6 binding between B cells, CD4 T cells and
macrophages, suggesting cell-type specific regulatory function 200. Interestingly, Masuda
et al. (2016) noted that pulldown of LRF (Zbtb7a) could not be achieved via in-house
generated (2 tested) or commercially available (3 tested) antibodies. Furthermore, they
tested precipitation using N-terminal and C-terminal tags and found that only C-terminal
tags were successful 203. This suggests that interaction of the N-terminal BTB domain
with bulky machinery for transcriptional regulation, such as NuRD, inhibits antibody
binding. Some BTB-ZF proteins (Zbtb4 and ZBTB38) have the capacity to bind
epigenetic patterns of methylated cytosine and KAISO (Zbtb33) can bind both
methylcytosine patterns and a non-methylated DNA motif 205,206. Areas of ongoing
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investigation into general function of BTB-ZF proteins include answering if the binding
of ZF domains to DNA from a single BTB-ZF dimer can mediate long-range DNA
interactions and if both ZF domains must bind DNA. The ability to mediate long-range
interactions or bind DNA through a single ZF domain would add further flexibility to
general BTB-ZF function.
1.4.2

BTB-ZF family proteins and immunity
Numerous BTB-ZF TFs control immune related processes such as hematopoietic

development, immune cell response and differentiation. Members of the BTB-ZF family
that regulate aspects of myeloid cell development, differentiation or response include
LRF, Zbtb46, BCL6, PLZF and Zbtb20 185. Regulation of B cells occurs through BTB-ZF
proteins BCL6, LRF, Miz1, Zbtb32, Zbtb24, Zbtb1 and Zbtb20 207. CD4 and CD8 T cells
are regulated by Miz1, Fazf, ThPOK, LRF, Mazr, PLZF, HIC1, BCL6, Zbtb35 and
Zbtb20 185,208. Relevant to memory CD8 T cell formation, several of these factors
regulate differentiation during the CD8 T cell response. BCL6 promotes memory CD8 T
cell formation and maintenance 209. Absence of ThPOK resulted in reduced clonal
responses during both the primary and secondary CD8 T cell responses. Additionally,
upregulation of effector molecules and IL-2 was reduced during the secondary response
in ThPOK-deficient memory CD8 T cells 210. A thorough analysis revealed several
important aspects of the CD8 T cell response were regulated by Zbtb32. CD8 T cells
deficient in Zbtb32 produced more effector molecules and larger effector and memory
responses 211. Furthermore, Zbtb32-deficient CD8 T cells were more resistant to
exhaustion in an LCMV clone 13 infection model 211. Intriguingly, Zbtb32 was found to
directly interact with Blimp-1 in CD8 T cells on target genes encoding Eomesodermin
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and CD27 211. The interaction between Zbtb32 and Blimp-1 is an example of a BTB-ZF
protein binding a well described CD8 T cell regulator as part of its function. It illustrates
the flexibility of BTB-ZF proteins to mediate protein-protein interactions and highlights
the importance of understanding BTB-ZF binding partners when considering mechanism
of BTB-ZF function. A final example of CD8 T cell regulation by the BTB-ZF family
comes from studies of tissue-resident memory CD8 T cells (TRM) in the intestine. The
expression of BTB-ZF protein HIC1 is restricted to the immune cells of the intestinal
lamina propria and HIC1-deficient T cells fail to populate the lamina propria 83.
Additional study found that HIC1 was a critical regulator of intestinal TRM differentiation
and that overexpression increased intestinal TRM 212. Specific HIC1 expression in
intestinal TRM provided a provisional basis for the tissue-specific transcriptional network
mediating TRM formation in the intestine 212. Together, it is clear that this family of
transcription factors performs critical functions in the regulation of immunity. Members
of the BTB-ZF protein family are particularly important as pertains to the CD8 T cell
response as they regulate CD8 T cell effector vs. memory differentiation, tissue-resident
memory formation, the quality of the effector response and exhaustion.
1.4.3

Described functions of Zbtb20
The BTB-ZF TF Zbtb20 has a role in multiple aspects branches of the immune

system as previously described. Here, these roles are examined in closer detail and the
broader context of Zbtb20 function in other biological processes and human disease is
considered. Zbtb20 was discovered contemporaneously in hematopoietic lineage cells
(dendritic cells, B cells and T cells) 213 and neurons 214. Two decades of subsequent
studies further elucidated critical functions performed by Zbtb20 in the hematopoietic
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lineage, neurons and other cell types. Global knock out of Zbtb20 in mice results in postneonatal lethality, with an average survival of 45 days, while heterozygous Zbtb20+/mice exhibited no discernable differences 215. In addition to disruption of hippocampal
development, a phenotype previously observed in mice with either ectopic
overexpression or deletion of Zbtb20 in neurons 216,217, global dysregulation of glucose
homeostasis was observed 215. Research into the role of Zbtb20 in neuronal function and
neural patterning in the brain remain areas of intensive investigation. Some work seeks to
fully elucidate the mechanistic link between Zbtb20 and normal development of
hippocampal neurons 218,219, while other work has described important roles for Zbtb20 in
regulating astrocyte development and the astrocyte ischemic response in experimental
stroke models 220–222. A significant literature on the importance of Zbtb20 to neural
development from animal models preceded the discovery of a link between abnormalities
in human Zbtb20 and neurodevelopmental disorders 223–225. In one study, major
depressive disorder was linked to hypermethylation of the Zbtb20 locus using
monozygotic twin pairs discordant for the disorder 225. Another, found a range of
neurodevelopmental, cognitive and psychiatric disorders were linked to Zbtb20 224, while
a third reported that missense mutations in Zbtb20 cause Primrose syndrome 223.
Primrose syndrome is characterized by increased postnatal growth, macrocephaly,
disturbed behavior, calcified pinnae, deafness, dysmorphic facial features, progressive
muscle wasting and diabetes 226–228. The missense mutations initially reported in
association with Primrose syndrome appeared to generate mutant Zbtb20 proteins with
dominant negative characteristics, meaning they were capable of suppressing the function
of wild type Zbtb20 in an in vitro assay 223. Several additional mutations have been
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described 228–230, and follow-up studies continue to refine our understanding of how these
mutations affect neurodevelopment. For example, expression of some variants affect
synaptic structure when expressed in mice 231. Furthermore, one variant with a single
amino acid differing in a ZF domain suppressed astrocyte function normally promoted by
wild type Zbtb20, providing further experimental evidence that Primrose syndrome
Zbtb20 mutants function as dominant negative proteins 222. Patients with Primrose
syndrome often present with dysregulation of particular metabolic patterns, particularly,
reduced glucose tolerance 232. This appears to concur with murine studies describing
control of metabolic processes by Zbtb20 215,233,234. Some of these metabolic processes
may be directly targeted by Zbtb20.
There is evidence for direct regulation of some genes by Zbtb20. One such gene is
Fructose-1,6-bisphosphatase (Fbp1), a gluconeogenic enzyme responsible for conversion
of fructose-1,6-bisphosphate to fructose 6-phosphate during glucose metabolism that also
plays a role in regulating insulin secretion from pancreatic β islet cells 233,235. Zbtb20
reportedly targets the promotor of Fbp1 and reduces signal from an Fbp1-promoted
luciferase reporter plasmid 233. Further study has identified repressive Zbtb20 binding in
the promotor regions of alpha-fetoprotein (Afp), a protein produced during fetal
development by the fetal liver 236,237. Another hepatic gene directly targeted by Zbtb20 is
carbohydrate response element binding protein (ChREBP), which is involved in the
conversion of excess dietary carbohydrates into tryglycerides through de novo lipogenesis
234

. Interestingly, while Zbtb20 and other BTB-ZF TFs are typically considered

transcriptional repressors, mice lacking Zbtb20 in the liver have decreased expression of
ChREBP and in vitro studies indicate that Zbtb20-binding enhances activity of the
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ChREBP promotor 234. Zbtb20 also binds to and enhances the expression of the Prokr2
gene in neurons, which is a critical mediator of the circadian clock 238. Another gene
whose expression is reportedly enhanced by direct promotor-binding by Zbtb20 is Prl,
which encodes for the hormone prolactin and is secreted from the pituitary gland 239.
Finally, a report of Zbtb20 genomic targeting in leukocytes indicated that Zbtb20 binds to
and represses the expression of the Nfkbia gene in macrophages, which encodes the
suppressor of NF-κB, IκBα 240. Through the repression of IκBα, Zbtb20 enables the full
activation of macrophages through the toll-like receptor (TLR)- NF-κB signaling axis.
Although not a genomic target of regulation by the Zbtb20 protein, the circularized
Zbtb20 RNA transcript (CircZbtb20) has been described as critical for the formation of
group 3 innate lymphoid cells (ILC3s) 241. In this context, CircZbtb20 targets and
stabilizes the transcripts encoding the ILC3 lineage-promoting TF Nr4a1. Additional
reports in leukocytes, discussed later, have ascribed important functions to Zbtb20,
although, direct genomic binding of Zbtb20 was not queried. Together, studies of Zbtb20
binding have identified important genomic targets of Zbtb20 that appear to have cisregulatory functions on adjacent genes in certain cell types. Interestingly, Zbtb20 binding
can either repress or potentiate transcription of target genes. It is unclear if these targets
are recognized by Zbtb20 in a cell type-specific manner or if potential binding in other
cell types has the same potentiation/repressive function. Possibly, heterodimerization of
Zbtb20 with other BTB-ZF proteins or differential interactions through the BTB domain
may account for the differences in transcriptional activation and repression.
Three important studies in lymphocytes have determined important roles for
Zbtb20 in B cells, CD8 T cells and regulatory T cells. One study identified an intestinal

31

population of thymus-derived regulatory T cells (Tregs) with constitutive expression of IL10 whose development and function depends on Zbtb20 242. These Tregs maintained
expression of Zbtb20 and deletion of Zbtb20 resulted in a loss of intestinal epithelial
integrity 242. Subsequently, a dextran sodium sulfate model of experimental colitis
resulted in severe disease and death in mice lacking Zbtb20, however, mice could be
rescued by adoptive transfer of Zbtb20-expressing Tregs 242. In B cells, differentiation of
long-lived plasma cells is promoted by Zbtb20 and mice lacking Zbtb20 in the lymphoid
compartment mount a less robust antibody response 243. Interestingly, this study found
that in plasma cells Zbtb20 expression was regulated by IRF4 243. Another regulatory
mechanism of Zbtb20 expression has been described in cardiomyocytes, where an RNAbinding protein named Cpeb4 repressed expression of Zbtb20 at a post-transcriptional
level 244. It is unclear to what extent IRF4 and Cpeb4 regulate Zbtb20 expression across
diverse cell types and cellular contexts. In T cells, IRF4 signaling is activated
downstream of TCR ligation 245 and is a potential, but unexplored, link between Zbtb20
and T cell activation. The third and final study examining the role of Zbtb20 in CD8 T
cells is discussed further in the next section.
1.4.4

Contribution of Zbtb20 to CD8 T cell response
Our lab discovered a role for Zbtb20 in the CD8 T cell response, using OT-I

transgenic CD8 T cells with a cre/flox system that deletes functional Zbtb20 upon
expression of granzyme B after OT-I activation (KO) 246. Compared to wild type OT-I
(WT), KO cells formed more MPECs and fewer TECs during response to infection with
attenuated listeria monocytogenes expressing OT-I cognate peptide (LM-actA-OVA).
KO cells isolated during the CD8 T cell response to LM-actA-OVA tended to produce
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more effector cytokines, such as IFNγ, TNFα, and IL-2, for the duration of the transition
from effector to memory. Furthermore, KO cells responding to LM-actA-OVA at both
effector and memory timepoints displayed enhanced glycolytic and mitochondrial
capacity, a phenotype that could be recapitulated in vitro using IL-2 and IL-15 to skew
OT-I cells towards effector or memory respectively. These observed differences in
metabolic status are in line with the known role of Zbtb20 as a regulator of metabolic
processes 215,232,234 and suggests that Zbtb20 may act through metabolic pathways to
affect CD8 T cell differentiation. Interestingly, KO OT-I cells skewed towards memory
in vitro with IL-15 were able to perform higher levels of oxidative phosphorylation
(OXPHOS) relative to WT during blockade of a variety of metabolic pathways.
Specifically, KO maintained elevated levels of OXPHOS under single deprivation of
either long-chain fatty acids (LCFA), glutamine or pyruvate. This advantage was
maintained for each combination of inhibition except for combination of glutamine and
LCFA blockade. This finding indicated KO cells could more flexibly adapt to using
different mitochondrial fuel sources than WT cells, except when restricted to pyruvate.
An important finding was that memory KO cells had enhanced recall properties.
Equivalent numbers of KO and WT memory cells that formed in response to LM-actAOVA and were maintained for at least 80 days. However, reactivation of these memory
cells at either day 28 or 80 using an orthogonal pathogen (MHV-68-OVA) resulted in
numerically larger secondary responses. Adoptive transfer of equal numbers of day 80
KO and WT memory cells into mice bearing subcutaneous, day 4 MC38-OVA tumors
resulted in clearance of tumors by KO transfer and tumor growth in mice receiving WT
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cells. Thus, KO cells at a day 80 memory timepoint mediate stronger protection versus a
tumor model upon secondary reactivation.
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§II
Materials and Methods
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Materials and methods for chapter 3
Mice and virus infections
Female C57BL/6 mice were purchased from Charles River Laboratories and The
Jackson Laboratory (Bar Harbor, ME). Female perforin (C57BL/6-Prf1tm1Sdz/J) and
female IFNγ (B6.129S7-Ifngtm1Ts/J) knockout mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). All mice were housed in the Dartmouth-Hitchcock
Medical Center Center for Comparative Medicine and Research. The Animal Care and
Use Program of Dartmouth College approved all animal experiments. MHV-68 (clone
G2.4) originally obtained from Dr. A. A. Nash (University of Edinburgh, U.K.) was
grown and titered using NIH 3T3 cells as previously described 247. Viral infections with
MHV-68 were performed by administering 4X103 PFU intranasally to mice anesthetized
with isoflurane.
Generation of B cell lymphoma line and lymphoma challenge
B cell lines were generated from E-Myc transgenic mice on a C57BL/6
background (Jackson Labs, stock #002728), as described previously 248,249. Briefly, mice
were monitored until they showed signs of illness, then spleens, thymi and lymph nodes
were removed and single cell suspensions prepared. These were cultured at graded cell
concentrations until colonies of cells were evident. Cells were then passaged for 4-6
weeks until lines capable of growing at dilute cell concentrations emerged. Lines
expressing PpyRE9 luciferase 250 and the ORF61 epitope of MHV-68 were generated by
transduction with pCIGAR retroviruses 251 expressing these sequences. The ORF61
epitope was expressed as a minigene under the control of the CMV immediate early
promoter, separated by an IRES sequence from a clover fluorescent selectable marker.
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Luciferase was introduced with an independent recombinant retrovirus. This ORF61- and
luciferase-expressing B cell lymphoma line was named EM61. Mice were challenged
with EM61 either intraperitoneally (i.p.) or intravenously (i.v.) and monitored for signs of
distress. The percent of mice protected from EM61 was reported as the time required
after EM61 inoculation for mice to display signs of morbidity at which point mice were
euthanized. All experiments were approved by the Institutional Animal Care and Use
Committee of Dartmouth College.
Inducible lacZ hybridoma assay
B lymphoma cells either encoding ORF61 (EM61) or not encoding the epitope
(EM) were cultured with ORF61-specific lacZ-inducible T cell hybridomas to test for
expression of the ORF61 epitope, as previously described 252,253. Briefly, 105 hybridoma
cells were cultured with 105 tumor cells overnight in a 96 well plate. For positive control
wells, 1mg/ml ORF61 peptide was added to the cultures. LacZ activity was assayed by
fixation with cold formaldehyde/glutaraldehyde, then the substrate X-gal added to each
well in potassium ferrocyanide/ferricyanide/magnesium chloride solution. After 4 hours
numbers of blue cells were counted in each well using a microscope.
CD4 and CD8 depletion
In the model of viral recrudescence, CD4+ T cells were depleted by i.p. injections
of 500 μg/mouse anti-CD4 antibody (GK1.5, BioXcell, Cat#:BE0003-1) on days -1 and 0
relative to infection, followed by 250 μg/mouse 3 days post-infection and twice weekly
thereafter. In other experiments, the depletion of CD8+ T cells was accomplished by
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injecting 500 μg/mouse anti-CD8 antibody (YTS 169.4, BioXcell, Cat#:BE0117) on days
-1 and 0 relative to EM61 challenge, followed by 250 μg/mouse every 3 days thereafter.
Tissue preparation and intravascular staining
Single-cell suspensions were generated by macerating spleens or other lymphoid
tissue through nylon filters. Peritoneal cells were collected by lavage of the peritoneal
cavity with 5mL of PBS containing 2% FBS v/v and 1% EDTA. For applicable
experiments, intravascular staining was performed based on previously published
protocols 254, with some modification as described subsequently. Where applicable, 3μg
anti-mouse CD8b PE (YTS156.7.7) was injected in the tail vein in a 300μL bolus diluted
in PBS. Antibody was allowed to circulate for 1.5 minutes before initiation of CO2
euthanasia. Euthanasia via CO2 was performed for 2.5 minutes. Following euthanasia,
blood was collected via cardiac puncture. Then, mice were perfused with 20mL PBS
containing 1% EDTA through the right ventricle after an incision was made in the left
ventricle. Spleen and lungs were collected followed by lymph nodes and processed
immediately. Spleen and lung were placed in 70um tube-top-style filters in 10cm petri
dishes containing 15 mL of TCTM (+10% FBS) (referred to subsequently as ‘media’).
Spleens were immediately mashed through filters using syringe plungers and transferred
to 50mL conical tubes containing 25mL media. The volume of media was then brought
up to ~45-50mL by rinsing new media through the filter use to mash the spleen.
Lungs were processed immediately following splenic processing. the lung was
taken out of the petri dish and placed on a dry petri-dish top. Then, scissors were used to
finely mince the lung. The minced lung was transferred back to the filter and a syringe
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plunger was used to mash the lung fragments. The media containing the lung cells was
then transferred to a 50mL tube containing 25mL media. The volume of media was then
brought up to ~45-50mL by rinsing new media through the filter used to mash the lung
(NOTE: for the lung I typically rinse the filter with a volume of media into the 50mL
conical, and then give the lung one final mashing before rinsing again). Spleen and lung
samples were then spun down and washed once in 5mL media to remove any excess IV
antibody. Lung samples were further cleaned using a percoll gradient. Lung samples were
resuspended in 2mL 40% percoll then underlaid with 2mL 80% percoll. These
suspensions were then centrifuged at 20°C at 400RCF for 20 minutes with 3 acceleration
and 0 brake.
Tetramer and antibody staining
MHC/peptide complexes folded with the ORF61534-531 peptide (TSINFVKI) at a
concentration of 1.5mg/mL conjugated to allophycocyanin were obtained from the
National Institutes of Health Tetramer Core Facility (Emory University, Atlanta, GA).
Samples were stained with ORF61-tetramer at a 1:400 dilution in staining buffer (PBS
with 2% bovine growth serum) at room temperature for 1 hour in the dark. Subsequently,
samples were washed twice and stained for other surface markers. Samples were FcR
blocked then stained with antibodies and live/dead stain (LIVE/DEAD™ Fixable NearIR Dead Cell Stain, Invitrogen, Cat#: L10119) for 30 minutes on ice shielded from light.
The antibodies used for cell surface staining were as follows; from Biolegend, anti-mouse
Ly-6G BV510 (1A8), anti-mouse/human CD11b PE (M1/70), anti-mouse CD19 PE
(ID3/CD19), anti-mouse/human B220 FITC (RA3-6B4), rat IgG2a-κ isotype control PE
(RTK2758), rat IgG2a-κ isotype control FITC (RTK2758), anti-mouse I-A/I-E PerCP
39

(M5/114.15.2), anti-mouse Ly-6C APC (HK1.4), anti-mouse Ly-6C PE/Cy7 (HK1.4),
anti-mouse CD11c APC (N418), anti-mouse CD8α BV510 (53-6.7), anti-mouse CD69
FITC (H1.2F3), anti-mouse CD103 BV421 (2E7), anti-mouse CXCR3 BV421 (CXCR3173) and anti-mouse CD4 PerCP/Cyanine5.5 (RM4-5). From Invitrogen, anti-mouse
CD25 APC (PC61.5) and anti-mouse CD8α PE (53-6.7). After surface staining, all
samples were washed twice and either analyzed by flow cytometer or prepared for
intracellular FoxP3 staining. Intracellular staining for FoxP3 was accomplished by fixing
and permeabilizing cells for 30 minutes on ice using eBioscience™
Fixation/Permeabilization Concentrate (Invitrogen, Cat#: 00-5123-43) diluted in
Fixation/Perm Diluent (Invitrogen, Cat#: 00-5223-56). Samples were then washed once
with 1X permeabilization buffer (10X Permeabilization Buffer, Invitrogen, Cat#: 008333-56), resuspended in 1X permeabilization buffer containing anti-mouse/rat FoxP3
PE (FJK-16s) and stained for 30 minutes on ice. Samples were washed twice with 1X
permeabilization buffer, resuspended in staining buffer, and analyzed with flow
cytometry. All antibodies were used at a dilution of 1:200 except for those used to stain
F4/80 and CD11b from peritoneal lavages, which were used at a 1:2000 dilution, and
anti-mouse FoxP3, which was used at 1:100. Flow cytometry was performed using a
CytoFLEX S (Beckman Coulter).
In vivo IFNγ blockade
Blockade of IFNγ was achieved by administering 1mg/mouse IFNγ blocking
antibody (R4-6A2, BioXcell, Cat#:BE0054) i.p. on days -1 and 0 relative to EM61
challenge and then every 2 days for the duration of the experiment.
Plaque assay
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Titers of MHV-68 in the lungs were determined by plaque assay which has been
described 247. Briefly, lungs were harvested, mechanically homogenized and resuspended
in 1mL DMEM. Homogenates were then subjected to one freeze-thaw cycle. 10-fold
serial dilutions of homogenate were overlaid on monolayers of NIH 3T3 cells and
incubated for 1 hour at 37°C. Subsequently, 2mL of DMEM containing 7.5% w/v
carboxymethyl-cellulose and 10% v/v BGS was added and monolayers were cultured for
5 days at 37°C. Media was then aspirated and monolayers were fixed with 100%
methanol at room temperature for 30 minutes. After 30 minutes, the methanol was
removed and monolayers were stained overnight with 8% Giemsa stain (Sigma-Aldrich).
Giemsa stain was then aspirated and the monolayers were washed with water before
enumerating plaques.
In vivo imaging
For all images acquired, mice were administered 3mg of luciferin (D-luciferin,
sodium salt, GoldBio, Cat#: LUCNA) by i.p. injection followed by a period of exactly 2
minutes before acquiring luminescent signal using a Xenogen, IVIS-200 (PerkinElmer).
Therapeutic ORF61 peptide, anti-PD-L1 blockade and tumor measurement in MHV-68
infected, intradermal B16 melanoma bearing mice
Mice infected 30 days prior with MHV-68 as described previously received
intradermal injections of 1.5X105 B16 melanoma cells in 60μL PBS. On days 7, 9 and 11
post-tumor injection, 0.5μg ORF61 peptide in 30μL PBS was injected intratumorally and
200μg anti-PD-L1 (clone B7-H1, Cat. No. BE0361, BioXcell) was administered in a 100
μL retro-orbital injection diluted with PBS. Tumor growth was monitored via caliper
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measurement. The criterion for endpoint in survival studies was when a tumor dimension
reached 1.5cm in diameter.
Statistical analysis
GraphPad Prism 8 was used to analyze all data presented. As designated in the
figure legends, ANOVA with multiple comparisons was used when comparing more than
two groups and two-tailed unpaired Student’s t tests were used for comparisons of two
groups. Protection curves were analyzed by log-rank (Mantel-Cox) tests. The p values
deemed significant are denoted in the figure legends. Numbers of animals used for
individual experiments are shown in figure legends.
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Materials and methods for chapter 4
Mice and bacteria
Female C57BL/6 mice were purchased from Charles River Laboratories. Zbtb20–
fl/fl mice were generated by Dr. W. J. Zhang (Second Military Medical University,
China) 236. OT-I mice (003831) and CD45.1 mice (002014) were originally purchased
from The Jackson Laboratory (Bar Harbor, ME). Granzyme B (GZB)–cre mice were
kindly provided by Dr. R. Ahmed (Emory University). CD45.1 OT-I mice and GZB-cre
Zbtb20-flox CD45.1 OT-I mice were generated and maintained in-house at Dartmouth
College. LM-actA–OVA was kindly provided by Dr. J. Harty (University of Iowa). All
mice were housed in the Dartmouth Center for Comparative Medicine and Research. The
Animal Care and Use Program of Dartmouth College approved all animal experiments.
Adoptive cell transfer and listeria infection
Splenocytes were harvested from CD45.1 OT-I mice (WT) or GZB-cre Zbtb20fl/fl CD45.1 OT-I mice (KO) and naive CD8 T cells purified using EasySep Mouse
Naive CD8 T Cell Isolation Kits (catalog no. 19858A; STEMCELL Technologies). Fifty
thousand naive OT-I cells were retro-orbitally injected into congenic B6 recipient mice.
The next day, recipient mice were retro-orbitally infected with 1X106 CFU LM-actA–
OVA.
Cell preparation for single cell
For isolation of CD8 T cells 10 and 35 days after infection, single-cell
suspensions were generated from four mice per recipient group by grinding spleens
through nylon filters. CD8 T cells were enriched from these suspensions using Stemcell’s
EasySep™ Mouse CD8 T Cell Isolation Kit (#19853). These samples were FcR blocked
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then stained with antibodies and live/dead stain (LIVE/DEAD™ Fixable Violet Dead
Cell Stain Kit, # L34955) for 30 minutes on ice shielded from light. The antibodies used
for cell surface staining from BioLegend were as follows; PE anti-mouse CD8b Antibody
(YTS156.7.7) and APC anti-mouse CD45.1 Antibody (A20). Samples were subsequently
washed twice and ~1X106 congenically marked OT-I cells were purified using
fluorescence activated cell sorting for each group of recipients. The samples purified in
this way from each group of recipients were then suspended in 100μL buffer and labeled
with 1μg per sample of the following Total-seq A antibodies from BioLegend:
TotalSeq™-A0198 anti-mouse CD127 (A7R34), TotalSeq™-A0250 anti-mouse/human
KLRG1 (2F1/KLRG1), TotalSeq™-A0073 anti-mouse/human CD44 (IM7) and
TotalSeq™-A0112 anti-mouse CD62L (MEL-14). Samples were labeled for 30 minutes
on ice and subsequently washed with 1mL PBS twice.
Single-cell RNA sequencing
Single-cell RNA sequencing (RNAseq) library preparation was carried out by the
Center for Quantitative Biology Single Cell Genomics Core and the Genomics and
Molecular Biology Shared Resource at Dartmouth. Droplet based, 39-end single-cell
RNAseq was performed using the 10x Genomics Chromium platform, and libraries were
prepared using the Single Cell v3 39 Reagent Kit according to the manufacturer’s
protocol (10x Genomics, Pleasanton, CA). Recovery of Ab-DNA tags (ADTs) from
single cells (i.e., cellular indexing of transcriptomes and epitopes by sequencing
[CITEseq]) was performed by adding 1 ml of ADT additive primer (10 mM, 59CCTTGGCACCCGAGAATT*C*C-39) to the cDNA amplification reaction and
following the 10x protocol for separation of the ADT and mRNA-derived cDNA
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fractions. ADT libraries were further amplified using 1 ml sample index PCR primer (10
mM, 59ATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGC*T*C-39)
and 1 ml Illumina RPI_X index primer, in which X represents a unique index sequence
per sample. ADT and mRNA libraries were normalized to 4 mM and pooled at a 1:9 ratio
before loading onto a NextSeq 500 instrument. Libraries were sequenced using 75 cycle
kits, with 28 bp on read1 and 56 bp for read2.
Data analysis for single-cell RNAseq
The Cell Ranger Single-Cell Software Suite (10x Genomics) was used to perform
barcode processing and transcript counting after alignment to the mm10 reference
genome with default parameters. A total of 7267 cells in the conditional KO and 10119
cells in the WT were analyzed for 10784 genes. Analysis of the gene-level transcript
counts output by Cell Ranger was performed in R (Version 3.5.2 and 4.1.1) on the
merged KO and WT datasets 255 using the Seurat R package (Version 3.1.4 and 4.1.2)
256,257

. All ribosomal genes and genes with counts in fewer than 25 cells were excluded.

Cells with mitochondrial DNA content >10% or nonzero counts for fewer than 500 genes
or more than 3000 genes were also removed. For day 30, additional contaminant cells
were removed by filtering the following genes from the analysis c("C1qa", "C1qb",

"C1qc", "Fcer1g", "Cd74"). The filtered gene expression data were normalized using
the SCTransform method 258 and subsequent computations were performed on the matrix
of corrected counts. Unsupervised clustering was performed using Seurat implementation
of shared nearest neighbor modularity optimization with the resolution parameter set to
0.2 259. For data visualization, single-cell gene expression data were projected onto a
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reduced dimensional space as computed by the Uniform Manifold Approximation and
Projection (UMAP) 260 method for the first 30 principal components of the expression
data. The variance-adjusted Mahalanobis (VAM) 261 method was used to compute cellspecific scores for pathways from Molecular Signature Database collections (Version
7.0) 262–264 that were filtered to remove pathways with fewer than five members or more
than 200 members. We identified differentially expressed genes and pathways between
KO and WT cells using Wilcoxon rank-sum tests applied to either the normalized counts
for each gene or the VAM scores for each pathway with p values adjusted using the
Bonferroni method.
Cellular metabolic analysis using COMPASS
COMPASS is a computational approach to studying cellular metabolic states
based on single-cell RNA-seq data and flux balance analysis (FBA) 265. For this analysis,
the CPM (count per million) matrix, filtered as previously described, was passed through
COMPASS (v0.9.9.5). The resulting reaction penalty matrix was generated with options
“species=mus_musculus, model=RECON2_mat, and-function=mean, penaltydiffusion=knn, lambda=0.25, num-neighbors=30, num-processes=100 , microclustersize=30”. This resulted in a reaction value of 963 microclusters, which were then
assigned to the corresponding cells. The downstream analysis was completed in R
(v4.1.0). First, reactions are filtered out that are close to constant (range<1e-3) or 0
(penalty<1e-4). Then, following the COMPASS documentation, reaction activity scores
were obtained by taking the negative log of the output matrix and normalizing by
subtracting the minimum value. Next, metabolic differences between Zbtb20 KO OT-I
and WT OT-I were determined. For each comparison, unpaired Wilcoxon rank-sum tests
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and Cohen’s D statistic was used to evaluate which reactions are more active in Zbtb20
KO OT-I than in WT OT-I. The resulting p-values were adjusted with the BenjaminiHochberg (BH) method, reactions with significantly differential activity were defined as
having an adjusted p-value <0.05. Subsequently, results of the differential reaction
activity scoring were annotated based on RECON 2 266. To examine metabolic differences
at the subsystem level, confident reactions with 0 or 4 confidence and subsystems with
non-negligible size were visualized with dot plots. Rank plots were generated based on
the difference between the percentage of reactions significantly upregulated and
downregulated in Zbtb20 KO OT-I vs WT OT-I. All diagrams were generated with
ggplot2 (v3.3.5).
Single-cell ATAC sequencing
For single cell ATAC-seq, 1x106 cells were incubated with nuclei lysis buffer for
5’, followed by 3 washes of 1mL each in nuclei wash buffer according to 10x Genomics
ATAC v1 protocol (CG000169). Nuclei were resuspended in Nuclei Resuspension Buffer
(10x Genomics), tagmented, and loaded onto a Chromium Chip E targeting 10,000 cells
for capture. Libraries were sequenced on a NextSeq500 instrument targeting 25,000
reads/cell and data processed using the cellranger-ATAC v1.1 pipeline.
Data analysis for single-cell ATAC sequencing
For analysis of scATAC sequencing barcoded fragment files loaded into Signac
(Version 4.1.2) 267 for analysis using the standard Signac/Seurat pipeline. Fragments were
mapped to peaks and assigned to cells using “Feature Matrix” function. Nucleosome
signal strength and TSS enrichment were determined using “NucleosomeSignal” and
“TSSEnrichment”. Macs2 was implemented to call peaks using the Signac “CallPeaks”
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function. Per Signac analysis guidelines. Outliers were removed and the first principle
component was omitted for UMAP representation.
ChromVar motif analysis
Signac (Version 4.1.2) was used to test for overrepresentation of DNA motifs in
the set of differentially accessible peaks between KO and WT using the ChromVar
feature. We tested for the motifs present in the JASPAR database 268 for mouse.
CUT&RUN
For CUT&RUN experiments, Zbtb20 with an N-terminal 3XFLAG tag was
expressed in HEK 293 cells or primary mouse CD8 T cells by transfection or
transduction respectively using pCIGAR retroviruses 251. CUT&RUN experiments were
carried out using EpiCypher’s CUT&RUN kit version 1.0 (#14-1048) as directed by the
CUTANATM user manual version 1.0. Briefly, 500,000 cells (either HEK 293 or CD8 T
cells) expressing Zbtb20-3XFLAG were crosslinked with 1% formaldehyde for 5 minutes
and subsequently quenched with 125mM glycine. Considerations for performing
CUT&RUN on crosslinked cells as described in the CUTANATM user manual version 1.0
were then applied for the remainder of the procedure. The anti-FLAG (M2) antibody
from Sigma-Aldrich was used for detection of Zbtb20-3XFLAG by CUT&RUN.
Library preparation and sequencing for CUT&RUN
CUT&RUN library preparation and sequencing was performed according to the
method described in the CUTANATM Library Kit Manual v1.0 (EpiCypher). Briefly, 5ng
of CUT&RUN DNA fragments were prepared for Illumina sequencing using the NEB
Ultra II DNA kit with the following modifications: Step 3B.2 – 1.1x AmPure bead
cleanup; Step 4.1.3 – PCR amplification with 45s @98C for initial denaturation followed
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by 14 cycles of 15s @98C, 10s @ 60C and 1m @ 72C final extension. Libraries were
quantified by qubit and run on a Fragment Analyzer (Agilent) for sizing. Libraires were
pooled and sequenced to a depth of 10M, 75bp paired-end reads/sample on a NextSeq500
instrument.
CUT&RUN data processing and peak calling
Sequence quality of raw reads was determined using FastQC (v0.11.9) 269 prior to
read trimming using Cutadapt (v2.4) 270 for adapter sequences with parameters “-nextseq-trim 20 --max-n 0.8 --trim-n -m 1”. Bowtie2 (v2.4.2) 271 was used to map reads
to hg38 (for human samples) or mm10 (for mouse samples) with parameters “--local -no-mixed --no-discordant”. Unmapped or multi-mapping reads were filtered from
alignment files prior to duplicate identification and removal using MarkDuplicates
(Picard Tools 272. Samtools (v1.11) 273 was used to sort alignments into nucleosome-free
regions (fragment length <=125bp) or nucleosomal-regions (fragment length >150bp)
and were processed separately in downstream analysis. Peaks calls for ZBTB20 (human
samples) and Zbtb20 (mouse samples) were generated using the MACS2 (v2.2.7.1) 274
call peak command in narrowpeak mode with parameters “-f BAMPE --keep-dup all -p
1e-4” and -c set to the corresponding IgG IP controls. The P-value threshold (-p) was set
to the less conservative threshold of 1e-4 to facilitate robust identification of reproducible
peaks across replicates using the Irreproducible Discovery Rate (IDR) approach, which
requires sampling of both signal and noise distributions. IDR (v.2.0.4.2) 275 was run with
parameters “--input-file-type narrowpeak --rank signal.value --peak-merge-method avg”.
Peaks achieving an IDR value <= 0.05 were considered as reproducible and kept for
further analysis. Remaining peaks were filtered for those with a fold change at peak
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summit >= 4-fold to enrich the final peak set for those with most substantial enrichment
above background. Peak calls for H3K4me3 were generated using the same options
however MACS2 was run in broadpeak mode. For all peak calling, effective genome size
was provided using option -g, with a value of 2913022398 for human data, and
2652783500 for mouse. Signal-to-noise was assessed for each sample using Fraction of
reads in peaks (FRiP), calculated for each sample. Called peaks were filtered for overlap
with the ENCODE human blacklist (human: ENCFF356LFX, mouse: ENCFF547MET),
mitochondrial regions, or unplaced and unlocalized scaffolds. H3K4me3 was used as a
positive control in all experiments and produced the expected distribution around
transcription start sites (TSSs), indicating successful application of the assay. Barcodes
counts for each of the CUTANA H3K4 MetStat Spike-in Control dNucs (designer
nucleosomes) were determined from FASTQ files to assess on- vs off-target signal.
Expected results were obtained in all experiments, indicating adequate on-target signal
was achieved. Spike-in E. coli DNA was mapped to reference genome K12 MG1655
(obtained from NCBI) using Bowtie2 (v2.4.2) with identical settings to those described
for human and mouse. The ratio of unique reads E. coli mapped reads to total reads was
used to determine a sample-specific scale factor as described in Orlando et al, 2014 276,
and were used for normalization of CUT&RUN signal in downstream analyses. For
visualization, normalized signal tracks were generated using deepTools (v 3.3.0) 277
command BamCoverage with parameters “–binSize 20 –smoothLength 60 –scaleFactor
sfi” where sfi corresponds to the sample specific scale factor calculated using E.coli spikein DNA. Peak annotation was performed using the annotatePeak() function (ChIPseeker
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R-package). Sequences flanking +/- 2kb were used to define promoter regions. R-

50

packages TxDb.Hsapiens.UCSC.hg38.knownGene
TxDb.Mmusculus.UCSC.mm10.knownGene were used to annotate peaks to genomic
features for human and mouse peaks, respectively. Peaks > 10kb from the nearest gene
were annotated as “distal intergenic”. Visualization of specific peak regions and signal
intensity was performed using R package Gviz 279.
De Novo Motif Discovery from Peaks
To discover possible enriched sequence motifs among the Zbtb20 CUT&RUN
peaks, we performed de novo motif discovery with MEME-ChIP, part of the MEME
Suite of analysis tools 280. High resolution coordinates for peak summits were obtained
from peak calling performed on replicate-merged alignment files for nucleosome-free and
nucleosomal reads separately. Peaks were called with the MACS2 (v2.2.7.1) call peak
command against corresponding IgG samples (option -c) with parameters “-f BAMPE -keep-dup all” and a stringent significance threshold of Q<0.05 (option -q). Peaks were
filtered for those in mitochondrial regions, overlapping with the ENCODE blacklist (see
above section for details), or located on unplaced/unlocalized scaffolds. Sequences
flanking +/-250 bp around peak summits were obtained using the subseq() function (from
R-package subSeq) in conjunction with R-packages
BSgenome.Mmusculus.UCSC.mm10.masked and BSgenome.Hsapiens.UCSC.hg38, for
mouse and human peaks respectively. For peaks located in nucleosome-free regions,
MEME-ChIP (v5.4.1) was run with parameters “-order 2 -centrimo-ethresh 0.001 -memenmotifs 10 -centrimo-local” and parameter “-ccut 0” to allow for motif discovery across
the entire 500 bp region. For peaks located in nucleosomal regions, MEME-ChIP was run
with identical paramaters except for “-ccut” which was set to 100 to limit motif discovery
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to the 100 bp surrounding peak summits. To identify motif instances in the reproducible
IDR peak set, peaks were scanned for newly discovered motifs using FIMO 281 with
default options, in addition to parameter “--parse-genomic-coord” and a pre-determined
background model set with parameter “--bgfile”. Background models were determined
using command fasta-get-markov with model order parameter “-m” set as 2. Motif
matches were considered as those passing a significance threshold of Q-value <0.2.
GREAT pathways and genes
Peaks from CUT&RUN in CD8 T cells were associated with genes and pathways
using GREAT version 4.0.4 282. Association rules were set to basal plus extension with
proximal associations set to 5kb upstream and 1kb downstream plus distal associations up
to 1000kb. Curated regulatory domains were included. Pathways found in the GO
Biological Processes, GO Molecular Function and MGI Mouse Phenotype databases
were retrieved.
Antibody staining
Samples were FcR blocked then stained with antibodies and live/dead stain
(LIVE/DEAD™ Fixable Near-IR Dead Cell Stain, Invitrogen, Cat#: L10119) for 30
minutes on ice shielded from light. The antibodies used for cell surface staining are as
follows; from Biolegend, anti-mouse CD8α BV510 (53-6.7), anti-mouse CD8β PE
(YTS156.7.7), anti-mouse CX3CR1 BV421 (SA011F11), anti-mouse CX3CR1 PE
(SA011F11), anti-mouse/human KLRG1 FITC (2F1/KLRG1), anti-mouse CD45.1 APC
(A20), anti-mouse CD45.1 BV421 (A20) and anti-mouse CD127 APC (A7R34). From
Cell Signaling; Anti-rabbit IgG (H+L) F(ab')2 Fragment AF488 (Cat. #4412), anti-JunB
(C37F9), anti-JunD (D17G2), anti-c-Jun (60A8), anti-FosB (5G4) and anti-c-Fos (9F6).
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After surface staining, all samples were washed twice and either analyzed by flow
cytometer or prepared for intracellular staining. Intracellular staining was accomplished
by fixing and permeabilizing cells for 30 minutes on ice using eBioscience™
Fixation/Permeabilization Concentrate (Invitrogen, Cat#: 00-5123-43) diluted in
Fixation/Perm Diluent (Invitrogen, Cat#: 00-5223-56). Samples were then washed twice
with 1X permeabilization buffer (10X Permeabilization Buffer, Invitrogen, Cat#: 008333-56), resuspended in 1X permeabilization buffer containing primary antibodies
directed against AP-1 Jun and Fos subunits and stained for 30 minutes on ice. Samples
were washed twice with 1X permeabilization buffer then resuspended in
1Xpermeabilization buffer containing fluorophore-conjugated secondary anti-rabbit IgG
and stained for 30 minutes on ice. Samples were washed twice with 1X permeabilization
buffer, resuspended in staining buffer and analyzed with flow cytometry. All antibodies
were used at a dilution of 1:200 except for those used to stain AP-1 components, which
were used at 1:100 and the secondary anti-rabbit IgG, which was used at 1:400. Flow
cytometry was performed using a CytoFLEX S (Beckman Coulter).
Statistical analysis
GraphPad Prism 8 was used to analyze all data presented. As designated in the
figure legends, either two-tailed paired or unpaired Student’s t tests were used for
comparisons of two groups. The p values deemed significant are denoted in the figure
legends. Numbers of animals used for individual experiments are shown in figure
legends. Other statistical analyses were reported by the relevant computational tools.
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§III
Control of B cell lymphoma by γ-herpesvirus induced memory CD8 T cells and
characterization of the γ-herpesvirus-specific, tissue-resident CD8 T cell compartment
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Abstract
Persistent infection with γ-herpesviruses (γHV) can cause lymphomagenesis in
immunocompromised patients. Murine γ-herpesvirus (MHV)-68 is an important tool for
understanding immune factors contributing to γHV control, however, modeling control of
γHV-associated lymphomagenesis has been challenging. Current model systems require
very long incubation times or severe immune suppression, and tumor penetrance is low.
In the following study, we describe the generation of a B cell lymphoma on the C57BL/6
background which is driven by the Myc oncogene and expresses an immunodominant
CD8 T cell epitope from MHV-68. We determined MHV-68-specific CD8 T cells in
latently infected mice use either IFNγ or perforin/granzyme to control γHV-associated
lymphoma, but perforin/granzyme is a more potent effector mechanism for lymphoma
control than IFNγ. Consistent with previous reports, CD4 depleted mice lost control of
virus replication in persistently infected mice. However, control of lymphoma remained
intact in the absence of CD4 T cells. Collectively these data show the mechanisms of T
cell control of B cell lymphoma in γHV infected mice overlap with those necessary for
control of virus replication, but there are also important differences. Additionally, the
contribution of tissue-resident memory CD8 T cells (TRM) to immune control of
persistent γHV infection is undescribed. To address this gap in knowledge, we performed
intravascular staining on mice infected with MHV-68. Interestingly, CD4 depleted mice
did display a difference in the composition of their lung TRM compartment and in the
distribution of certain CD8 T cells between red and white pulp in the spleen. These
differences are distinct from those described for CD4-depleted mice infected with
influenza. We additionally determine γHV-specific CD8 T cells populate mouse B16
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melanoma and can be repurposed for tumor immunotherapy. These studies establish 1) a
tool for further dissecting immune surveillance against, and optimizing adoptive T cell
therapies for, γHV-associated lymphomas, 2) the first characterization of the TRM
response to MHV-68 both with and without CD4 T cell help and 3) proof of principle
γHV-specific CD8 T cells in hosts with persistent γHV infection can be utilized for tumor
immunotherapy.
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Introduction
Persistent infection with the human γ-herpesviruses (γHV) Epstein-Barr virus
(EBV) and Kaposi’s sarcoma herpesvirus (KSHV) can result in lymphomagenesis or
Kaposi’s sarcoma, respectively, in immunocompromised individuals 283–286. The study of
immune mechanisms important for the control of such γHV pathology in model
organisms is hampered by the host-specificity of EBV and KSHV. An important tool to
address this issue is the murine γ-herpesvirus 68 (MHV-68) infection model. MHV-68 is
a natural pathogen of rodents and shares important pathological and genetic similarities to
human EBV and KSHV 125. Like EBV and KSHV, MHV-68 is lymphotropic and
establishes a latent infection predominantly in B cells that persists for the life of the host
125,287

. In the following study, we use MHV-68 to develop a model for dissecting the

immune factors contributing to control of γHV-induced B cell lymphomas.
Studies of MHV-68 have established that there are different immunologic
requirements for γHV control during different phases of infection. Intranasal infection of
mice with MHV-68 initially results in an acute, lytic infection in alveolar epithelial cells
and requires CD8 T cells for resolution before forming a latent infection in B cells
132,247,288

. Further analysis focused on the effector mechanisms CD8 T cells require for

this control. Activated CD8 T cells elaborate several effector mechanisms in response to
target recognition. The lytic mechanisms perforin/granzyme and FasL directly initiate
target cell apoptosis and the cytokines interferon-gamma (IFNγ) and tumor necrosis
factor alpha (TNFα) are also important effector molecules produced by CD8 T cells 289.
Each of these mechanisms participate in CD8 T cell-mediated control of both viral
infections and tumors. During acute MHV-68 infection perforin/granzyme, FasL or IFNγ
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effector mechanisms are each individually dispensable for control of viral replication in
the lung 290–292. During latent MHV-68 infection, both perforin/granzyme and IFNγ
contribute to preventing viral reactivation 293, but IFNγ deficient mice suffer persistent,
low-level viral replication that results in fibrosis in several tissues 294–297. Furthermore,
IFNγ-receptor-deficient mice develop B cell lymphomas >5 months post-infection that
are similar to EBV-induced lymphoproliferative disease in immunodeficient humans 298.
This study implicates IFNγ in the control of γHV-induced lymphoproliferative disease,
but a thorough characterization of the CD8 T cell mechanisms required for control of
these diseases is lacking. Unlike many tumor models, where T cell priming occurs
following recognition of the tumor, in the case of γHV infection the T cell response is
elicited by the virus infection. Memory cells generated by virus replication are then
required to eliminate tumors that arise many months or even years later. It is therefore
important to know whether the same effector mechanisms control both the virus infection
and the tumor, and whether virus-specific T cells possess the functional flexibility to
control these very different types of insult.
Immunodeficiency in humans resulting from AIDS is characterized by CD4 T cell
depletion and associated with γHV-induced neoplasms 286. In this context, CD8 T cells
fail to control the growth of γHV-positive tumors. This breakdown in CD8 T cell
immunosurveillance can be modeled in CD4 depleted mice that are infected with MHV68 299. Initially, MHV-68 infection is controlled. However, control gradually declines and
the virus reactivates to detectable levels in the lungs at 6 weeks post-infection. No defect
in virus-specific CD8 T cell numbers or cytotoxic function has been observed in MHV68 infected mice lacking CD4 T cell help. However, our previous studies have identified
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a suppressive CD8 T cell subset in these mice that inhibits immunosurveillance in an IL10 dependent fashion. These suppressive CD8 T cells partially account for waning viral
control 300,301. While virus reactivation is evident in CD4 deficient mice infected with
MHV-68, these mice do not develop lymphoproliferative disease or lymphomas 299. This
suggests T cell mediated suppression of lymphomagenesis requires different mechanisms
to those needed to control virus replication. Existing models of tumorigenesis in MHV-68
infected mice require severe functional impairments in the CD8 T cell compartment,
precluding detailed studies identifying the key T cell effector mechanisms that are
necessary for tumor control 298,302–306. Therefore, we generated a novel model where
control of B cell lymphomas can be dissected in immunosufficient and CD4 T cell
deficient hosts.
The contributions of different memory CD8 T cell subsets to the control of
persistent γHV infection are poorly defined. γ-herpesviruses are evolutionarily ancient
307,308

and have evolved carefully calibrated mechanisms to persist for the lifespan of the

host with periodic, productive reactivation and minimal pathology 125,309. Lethal γHVmediated pathologies caused by disruption of the host memory T cell compartment
illustrate the reliance of γHV on host T cells for maximal reproductive success 310–312. It
is unknown what role tissue-resident T cells (TRM) play in maintaining this delicate
balance between host and pathogen. Resident memory CD8 T cells are generated during
the initial adaptive immune response to a pathogen and primarily populate the tissue in
which the pathogen was first encountered 313. In this way, the immune system specifically
barricades tissues likely to reencounter a pathogen—the skin, mucosal surfaces and
organs—with pathogen-specific defenses primed to rapidly produce an effector response.
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Therefore, the specific replicative biology of a pathogen, particularly patterns of tissue
tropism during infection, influences the distribution of TRM. For example, in the context
of infection with the α-herpesvirus HSV-1, virus initially undergoes lytic replication in
the skin epithelium while rapidly entering the innervating sensory ganglia. Although the
initial lytic infection is controlled, HSV-1 persists as a latent infection in neural ganglia
and may periodically reactivate to form lesions of lytic viral replication 314. HSV-1specific TRM populate the sites of both lytic and latent replication, the skin epithelium and
the neural ganglia respectively, and contribute to long-term control of HSV-1 reactivation
314–316

.
The pathogenesis of γ-herpesviruses consists of an initial lytic replication phase

in epithelial cells which rapidly spreads to B lymphocytes 317. Latency is primarily
established in B cells, however, some latent MHV-68 is present in lung epithelial cells,
macrophages and dendritic cells 318. In particular, germinal center and memory B cells
harbor high levels of latent MHV-68 319–321. Given the known importance of TRM for the
control of α-herpesvirus latency, a relevant question is if CD8 T cells with tissueresident memory characteristics occupy sentinel positions proximal to the sites of MHV68 latency in the lung and secondary lymphoid organs. Another question is if the
depletion of CD4 T cells compromises the TRM compartment in a way that contributes to
MHV-68 recrudescence. This is an especially important question given that it has
previously been reported that CD4 T cells are critical during influenza infection for
positioning TRM in the lung and heterosubtypic immunity 322.
Previous work by Rosato et al. established that memory OT-I cells, established
following infection of mice with a non-persisting virus expressing SIINFEKL peptide,
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both populate dermal tumors and can be utilized for tumor immunotherapy in tumors
devoid of OT-I cognate antigen expression 323. It was also determined that OT-I
activation sensitized tumors to checkpoint blockade with anti-PD-L1. Further work from
Rosato et al. identified CD8 T cells specific for human γ-herpesviruses in a broad range
of human cancers, suggesting CD8 T cells specific for common human pathogens may be
a useful therapeutic target in cancer patients. Short of performing human studies, the
question of whether a natural CD8 T cell response to a γ-herpesvirus can be harnessed
therapeutically remains unanswered. A hurdle to answering this question is that human
γ-herpesviruses do not infect common laboratory animal models, such as mice. To
address this challenge, we utilized the MHV-68 γ-herpesvirus infection model and
asked if ORF61-specific memory CD8 T cells could be utilized therapeutically in the
context of intradermal B16 melanoma.
The subsequent experimental sequence describes the generation and
characterization of a B lymphoma cell line on the highly tractable C57BL/6 genetic
background, that expresses the dominant CD8 T cell epitope from MHV-68.
Tumorigenesis is driven by overexpression of the Myc oncogene, which mimics higher
expression of Myc observed in γHV-associated Burkitt’s lymphoma and diffuse large B
cell lymphomas 284,324. We used this tool to determine the mechanisms of CD8-mediated
control of B cell lymphomas in mice latently infected with MHV-68 by authentic, γHVspecific CD8 T cells. Additionally, intravascular staining was utilized to examine the TRM
response to MHV-68 in both intact and CD4 depleted mice. Intravascular staining has
previously been described for distinguishing vascular-accessible versus tissue-resident
cell populations and has been especially useful for identifying TRM 254. In the lung, cells
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in the parenchyma are not stained by antibody injected intravascularly 325. In the spleen,
highly vascularized areas, such as the red pulp, are distinguishable from less accessible
areas such as the germinal center-containing white pulp 254,326. Using this technique, we
characterized a previously unidentified TRM population in the lungs of MHV-68 infected
mice. Furthermore, we describe novel changes in the TRM compartment in both the lung
and spleen in CD4 depleted mice which differ from previously described changes
observed during influenza infection. Finally, we demonstrate that authentic, γherpesvirus-specific CD8 T cells populate mouse B16 melanoma and can be repurposed
for tumor immunotherapy.
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Results
B cell lymphoma expressing an epitope from MHV-68 is controlled in vivo by CD8 T
cells
Prior studies of CD8 T cell control of lymphomagenesis in the context of γHV
infection have been limited. Previously developed models required severe host
immunodeficiency to enable growth of MHV-68-transformed cells, extended amounts of
time to develop or produce lymphomas in only a proportion of treated mice 298,302–306.
Here, a B-cell lymphoma line was derived from E-Myc transgenic mice as described
248,249

and subsequently transduced with retroviral vectors containing an MHC class I-

restricted epitope from the ORF61 protein of MHV-68 327 and luciferase (see methods).
Expression of the ORF61 epitope was confirmed using an ORF61-specific LacZ
inducible T cell hybridoma 252, followed by an X-gal assay 253 (Fig. 3.1). The resulting Bcell lymphoma line expresses the B cell surface markers CD19 and B220 (Fig. 3.2A) and
is henceforth referred to as EM61. To test if MHV-68-specific memory CD8 T cells
controlled EM61 in vivo, two groups of mice with latent MHV-68 infections were
challenged with EM61 i.p. (Fig. 3.2B). One group received CD8 depleting antibody
beginning one day prior to tumor injection. Tumor growth was monitored with luciferin
injections and IVIS imaging (Fig. 3.2C). All CD8 depleted mice succumbed to EM61
whereas MHV-68 immune mice without depletion controlled EM61 and were uniformly
protected (Fig. 3.2D). These data indicate that MHV-68 immune mice are capable of
controlling EM61 and that CD8 T cells are required for this control.
Numbers of OFR61-specifc CD8 T cells increase at the site of EM61 challenge
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As CD8 T cells were necessary for EM61 control, we next measured the ORF61specific CD8 T cell population at the site of tumor challenge. Latently infected MHV-68
mice were challenged with EM61 i.p. and four days later spleens and peritoneal lavages
were collected and stained to identify the ORF61-specific population (Fig. 3.3A-B). In
the peritoneum, the site of EM61 challenge, an increase in the number of ORF61-specific
CD8 T cells was observed (Fig. 3.3C). This increase was not observed in the spleen (Fig.
3.3D). ORF61-specific CD8 T cells were not increased as a percentage of the total CD8 T
cell population in either compartment (Fig. 3.3E-F). In the peritoneum, elevated numbers
of total CD8 T cells were observed in EM61 challenged mice, whereas total CD8 T cell
numbers were unchanged in the spleen (Fig. 3.3G-H). In naïve mice challenged with
EM61 the level of ORF61-specific T cells was at background levels, equivalent to
unchallenged naïve nice (data not shown), indicating the tumor cells alone did not elicit
an ORF61-specific T cell response. These data indicate the EM61-specific CD8 T cell
response in MHV-68 infected mice is characterized by an influx in total CD8 T cells in
the peritoneum that results in an increase in ORF61-specific CD8 T cells.
Cellular immune landscape during EM61 control in the context of latent γ-herpesvirus
infection
To understand the cellular immune dynamics associated with EM61 control in the
context of latent γHV infection, an experiment was performed in which groups of mice
either latently infected with MHV-68 or uninfected were challenged with EM61 and
control groups of infected and uninfected mice were left unchallenged. Four days after
EM61 challenge, peritoneal lavages and splenocytes were analyzed by flow cytometry for
numbers and proportions of relevant immune cell types. Notably, dendritic cells,
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identified as F4/80-, Gr-1-, MHC-II+, CD11c+ (Fig. 3.4A) 328, were present at significantly
higher numbers in the peritoneal lavages of mice both latently infected with MHV-68 and
challenged with EM61 than in all other conditions (Fig. 3.5A-B). A small population of
CD11c+ CD19+ B cells was observed in slightly higher numbers in the spleens, but not
the peritoneal cavities, of MHV-68 infected mice relative to uninfected mice (data not
shown). B cells with this phenotype identified previously in the spleens of mice at the
peak of the anti-MHV-68 response, produced antiviral IgG2a and were necessary for
effective control of the virus 329. Regulatory T cells (Treg), defined as CD4+, CD25hi,
FOXP3+ (Fig. 3.4B), are associated with tumor growth and exert immunosuppressive
pressure on tumor-specific CD8 T cell responses 330. Therefore, we queried if there were
changes in the numbers of this T cell subset in groups receiving EM61. No significant
changes in Treg numbers in either the peritoneum or the spleen were observed between
any of the conditions (Fig. 3.5C-D). Either viral infection or tumor growth can promote
myelopoiesis and expansion of monocytic CD11b+, Ly6Chi, Ly6G- cells and neutrophilic
CD11b+, Ly6Clo, Ly6G+ cells 331–333. These populations of myeloid cells perform
important inflammatory or immunosuppressive functions. We tested whether EM61
promotes these populations, identifying monocytic cells as CD11b+, Ly6Chi, Ly6G- and
neutrophilic cells as CD11b+, Ly6Clo, Ly6G+ (Fig. 3.4C). Monocytic cells were elevated
in the peritoneum of MHV-68 infected mice, either with or without EM61, relative to
either uninfected group (Fig. 3.5E). In the spleen, monocytic cells were elevated in
groups with either latent MHV-68 infection alone or with EM61 challenge, relative to
both uninfected groups (Fig. 3.5F). Neutrophilic cells were elevated in the peritoneum in
uninfected mice challenged with EM61 relative to all other groups (Fig. 3.5G). In
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contrast, splenic neutrophilic cells were increased in the groups with latent MHV-68
infection only, EM61 challenge only, or both, relative to uninfected mice without EM61
(Fig. 3.5H). Previously it has been observed that mice latently infected with MHV-68 are
cross-protected from challenge with yersinia pestis and listeria monocytogenes for a
period of months after infection. This protection was due in part to a heightened state of
macrophage activation 334,335. We also observed signs of macrophage activation in the
peritoneal cavities of mice latently infected with MHV-68, indicated by increased
expression of MHC class II (I-A/I-E) on F4/80+ cells pre-gated on CD11b+ Gr-1- cells
(Fig. 3.5I). No increase in macrophage MHC class II was noted in the spleen (Fig. 3.5J,
Fig. 3.4). To test if a non-specific, cross-protective effect contributed to EM61 control in
latently infected mice, we challenged latently infected and uninfected groups of mice
with EM (the same B cell lymphoma line as EM61 minus the ORF61 epitope). Both
MHV-68 infected and uninfected groups of mice succumbed to EM with no difference in
protection (Fig. 3.6). This indicates that heightened macrophage activation in the latently
infected mice does not contribute in a non-specific manner to control of EM61. This
survey of the immune environment in the context of latent γHV infection identified
cellular shifts in response to EM61, a model γHV-associated lymphoma.
Either IFNγ or perforin are necessary for protection from EM61 challenge
Control of viruses by CD8 T cells is mediated by effector mechanisms such as
perforin/granzyme, IFNγ, TNFα and FasL 289. During control of acute MHV-68 infection
in the lung, perforin/granzyme, IFNγ and FasL play redundant roles in C57BL/6 mice 290–
292

. Persistent MHV-68 infection requires IFNγ and perforin/granzyme to control site-

specific aspects of chronic virus replication and latent infection 293. Additionally,
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persistently infected IFNγ receptor-deficient mice develop lymphoproliferative disease
containing latently infected cells 298. The question remains, however, as to which
mechanisms CD8 T cells employ to control γHV-associated lymphoma. To address this
question in the MHV-68 model, wild type (WT) and perforin knockout (KO) mice
latently infected with MHV-68 were challenged with EM61. Separate WT and perforin
KO groups received IFNγ-neutralizing antibody after latent infection was established in
addition to EM61 challenge. A control WT group uninfected by MHV-68 was also
challenged with EM61. While WT uninfected mice succumbed to EM61 challenge,
groups of MHV-68 infected mice lacking either perforin or IFNγ were able to control
EM61 and were protected (Fig. 3.7A-B). Interestingly, latently infected mice lacking
both IFNγ and perforin succumbed to EM61, but with significantly slower kinetics than
uninfected mice (Fig. 3.7A-B). This experiment shows that either IFNγ or
perforin/granzyme are necessary to control γHV-associated B cell lymphoma.
Perforin is a more potent effector mechanism than IFNγ for control of EM61
Next, we investigated if perforin/granzyme and IFNγ were equally protective.
Latently infected WT, perforin KO and IFNγ KO mice were challenged with 1X107
EM61 cells (100X the dose used previously) and protection was tracked. This more
stringent test of CD8 T cell effector mechanisms revealed that perforin KO mice were
susceptible to high dose lymphoma challenge, while the majority of IFNγ KO mice
remained protected (Fig. 3.8A).
We next tested if IFNγ contributed to the protection advantage that infected
perforin KO mice retained over uninfected WT mice. Blockade of IFNγ in perforin KO
mice resulted in a protection disadvantage relative to perforin KO mice that approached
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statistical significance but retained a protection advantage relative to uninfected control
mice (Fig. 3.8B). This is consistent with our earlier results (Fig. 3.7A-B) which indicate
IFNγ contributes to EM61 protection and suggest a minor role for effector mechanisms
other than perforin/granzyme and IFNγ. Together, these data indicate that IFNγ and
perforin/granzyme control EM61 in a hierarchical fashion whereby the actions of either
are redundant for the control of EM61, but perforin/granzyme is more potent and required
for control of larger tumor burdens.
Perforin KO ORF61-specific CD8 T cells are intrinsically defective at controlling EM61
We noted that the number of ORF61-specific CD8 T cells in the latently infected
peritoneal cavities of perforin KO mice was significantly lower than in those of the IFNγ
KO mice (Fig. 3.9A-B). Interestingly, although infected IFNγ deficient mice had
numbers of ORF61-specific cells in the peritoneum equivalent to WT, there were
markedly fewer in the spleen (Fig. 3.9B). This is likely due to reduction in T cell
recovery because of splenic fibrosis and atrophy that occur in IFNγ KO mice infected
with MHV-68 294,295. Nevertheless, these mice could efficiently control EM61 challenge
(Fig. 3.8A).
To control for the possibility that loss of protection against EM61 in the perforin
KO mice was caused by lower ORF61-specific T cell numbers in the peritoneum relative
to IFNγ KO mice, we tested the ability of perforin-deficient CD8 T cells to kill EM61
cells in vivo. CD8 T cells were purified from WT and perforin KO mice latently infected
with MHV-68 and stained with a tetramer for ORF61-specific CD8 T cells. CD8 T cells
were then normalized to contain equal numbers (1.5X105) of ORF61-specific cells and
transferred i.p. into uninfected WT recipients. As a control, one group of mice received a
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transfer of CD8 T cells from uninfected mice. These recipients were then immediately
challenged with EM61 i.p. and the ability of the transferred CD8 T cells to limit EM61
growth was assessed by IVIS (Fig. 3.9C). In this assay, we observed that perforin KO
ORF61-specific CD8 T cells were indeed less capable of controlling EM61 relative to
WT ORF61-specific CD8 T cells (Fig. 3.9D). These data confirm that perforin KO
ORF61-specific CD8 T cells are intrinsically less efficient controllers of EM61.
CD4 T cell deficient mice that lose control of persistent infection resolve EM61 challenge
Mice lacking CD4 T cells and infected with MHV-68 initially control viral burden
with similar kinetics to CD4 replete mice. However, this control ultimately breaks down
resulting in viral recrudescence ~40 days postinfection 299. Breakdown in viral control is
partially due to an IL-10 driven suppressive immune environment that acts on MHV-68specific CD8 T cells 300,301. In these experiments, we tested if CD8 T cells controlled
EM61 without CD4 T cell help during viral recrudescence. EM61 was efficiently
controlled (Fig. 3.10A-B), despite viral recrudescence in CD4 depleted mice (Fig.
3.10C). We considered the possibility that viral recrudescence in the lung may indicate a
tissue-specific immunosuppressive environment. To test if the lungs were susceptible to
EM61 growth, we injected EM61 intravenously and monitored the lungs for tumor
growth by IVIS. We did not find evidence of EM61 growth in the lungs at 4 or 7 days
post-challenge (Supplemental Fig. 3.11A-B). We concluded that the immune suppressive
effects of the CD4 T cell depleted environment were insufficient to compromise control
of EM61.
Intravascular staining defines vascular accessible ORF61-specific T cells in different
tissue compartments following MHV-68 infection
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The CD8 T cell tissue-resident memory (TRM) response to MHV-68 is
uncharacterized. To address this gap in knowledge, intravascular staining was performed
30 days after MHV-68 infection. Lung, spleen, inguinal lymph node and blood were
collected from mice following intravascular staining for CD8β via tail vein injection to
confirm successful execution of this technique. For successful intravascular staining
experiments, vascular accessible cells in the blood should stain >95% CD8β+, while
vascular inaccessible compartments, such as the lymph node should stain ≤1% CD8β+ 254.
CD8 T cells were identified by ex vivo CD8α staining and separated on the basis of
intravascular CD8β staining into vascular accessible (CD8β+) and inaccessible (CD8β-)
(Fig. 3.12A). This analysis confirmed that >95% of CD8 T cells in the blood stained
CD8β+, while ≤1% of cells extracted from lymph node stained CD8β+. ORF61-specific
CD8 T cells were identified in the IV+ (CD8β+) and IV- (CD8β-) CD8 T cell fractions by
tetramer staining in lung, spleen, lymph node and blood (Fig. 3.12B). Additional staining
on the ORF61-specific CD8 T cell fractions labeled cells expressing and co-expressing
the TRM surface molecules CD69, an antagonist of the sphingosine-1-phosphate receptor,
and CD103, the αEβ7 integrin which interacts with E-cadherin expressed on epithelial
cells. Generally, we detected increased proportions of cells expressing these molecules in
the IV- fractions of the sampled compartments, except for blood, where no TRM
population is expected (Fig. 3.12C). Overall, these results confirmed that IV- ORF61specific CD8 T cells were detectable at a memory timepoint after MHV-68 infection.
CD69 expressing CD8 T cells become dominant subset in the lung parenchyma after
MHV-68 infection

70

We next characterized the temporal dynamics of ORF61-specific lung TRM. Lungs
were collected from MHV-68 infected mice at a series of memory timepoints following
intravascular staining for CD8β via tail vein injection. Tetramer staining detected
ORF61-specific CD8 T cells in the IV- fraction. We determined that both the percent and
total number of ORF61-specific TRM in the lung declined over time (Fig. 3.13A), in
concordance with several reports describing transiency of the lung TRM compartment
325,336,337

. Additionally, we detected an increase in the proportion of IV- ORF61-specific

TRM expressing CD69 and a decrease in the proportion co-expressing CD69 and CD103
with increasing elapsed time post-infection (Fig. 3.13B). These results indicate that lung
TRM responses to γ-herpesvirus infection follow temporal patterns of tissue occupancy
similar to other respiratory infections.
Intravascular staining identifies enrichment of CD69+ ORF61-specific CD8 T cells in
splenic white pulp
Tissue-resident memory T cell populations expressing CD69 have been reported
to populate the red and white pulp of the spleen in response to viral infection 338. A
feature of γHV infection is that latent infection persists for the life-span of the host in
splenic memory and germinal center B cells 320. Therefore, we characterized the
distribution and phenotype of ORF61-specific CD8 T cells in the red and white pulp of
the spleen using intravascular staining. We found that the majority of ORF61-specific
CD8 T cells stained IV+, indicating localization to the red pulp, however, ~10-15% were
IV- and localized to the white pulp at all timepoints measured (Fig. 3.14A). We observed
~85% ORF61-specific CD8 T cells expressed the memory and TRM surface receptor
CXCR3+ 339 in the white pulp, compared to only 50-60% in the red pulp (3.14B).
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Additionally, ~40% of ORF61-specific CD8 T cells in the white pulp expressed CD69,
versus ~10% in the red pulp (Fig. 3.14C), suggesting the white pulp ORF61-specific cells
may contain a larger fraction of resident cells than red pulp. In a separate experiment,
without intravascular staining, splenic ORF61-specific CD8 T cells were analyzed 30
days post-infection with MHV-68 for expression of CD62L and CD69 (Fig. 3.14D). We
observed a distinct population (~14%) of splenic ORF61-specific CD8 T cells expressing
the TRM and tissue-retention surface molecule CD69 without expression of the central
memory T cell (TCM) marker CD62L. Also notable, very few cells (~3%) coexpressed
CD69 and CD62L, further suggesting that CD69 expressing cells are a distinct population
from the ORF61-specific TCM.
Progressive loss of CD8 T cell-mediated control of MHV-68 in the absence of CD4 T
cells is associated with phenotypic alteration of ORF61-specific CD8 T cells in
compartments inaccessible to intravascular staining
A previous report noted that after influenza infection of CD4 depleted mice there
were fewer CD103+ TRM in the lung, TRM in the lung localized less efficiently to the lung
airway epithelium and that mice were less protected from heterosubtypic rechallenge 322.
Therefore, we next considered that viral recrudescence in the absence of CD4 T cells may
result from a defect in the TRM compartment (Fig. 3.15A). Analysis of changes to the
ORF61-specific CD8 T cell populations in the spleen revealed that while the total number
of cells did not significantly change with CD4 depletion, the percentage of cells in the
white pulp increased (Fig. 3.15B&C). Phenotypic characterization revealed that the
percent of ORF61-specific CD8 T cells expressing CD69 increased in both the red and
white pulp in the absence of CD4 T cells (Fig. 2.15D). Furthermore, there was a
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significant decrease (~20%) of ORF61-specific CD8 T cells expressing CXCR3 in the
white pulp (Fig. 3.15E). We also characterized parenchymal-associated ORF61-specific
CD8 T cells from the lung (Fig. 3.15F-K). The percent of CD8 T cells in the lung IVfraction staining positive for ORF61 tetramer was equivalent between CD4 depleted and
intact mice, however, the total number of ORF61-specific CD8 T cells was elevated (Fig.
3.15F). This indicates that without CD4 T cells there is general recruitment of CD8 T
cells into the lungs of MHV-68 infected mice. Phenotypically, the IV- ORF61-specific
CD8 T cell population in CD4 depleted mice was composed of a smaller percentage of
CD103+ CD69+ cells, a larger percentage of CD103- CD69+ cells and a smaller
percentage of CD103- CD69- cells than in intact mice (Fig. 3.15G-I). Because of
increased total ORF61-specific CD8 T cells in the lungs of CD4 depleted mice, no subset
of cells defined by CD69 and CD103 expression was present in lower numbers compared
to intact mice (Fig. 3.15G-I). In fact, we detected an increase in the number of CD103CD69+ cells in lungs of CD4 depleted mice relative to intact mice (Fig. 3.15H). A smaller
percentage of the IV- ORF61-specific CD8 T cell population in CD4 depleted mice
expressed CXCR3, however, the total number of cells expressing CXCR3 was increased
(Fig. 3.15J). Interestingly, the mean fluorescence intensity of CXCR3 on CXCR3+ cells
in the CD4 depleted mice was lower, indicating lower per cell expression of CXCR3 in
the CXCR3+ fraction (Fig. 3.15J). A similar observation was made for CD103
expression, where the per cell expression of CD103 in the CD103+ fraction in CD4
depleted mice was lower than in the intact mice (Fig. 3.15K). Overall, this section
identified numerical and phenotypic changes in the composition of ORF61-specific cells
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in the red and white pulp of the spleen as well as in the lung parenchyma in mice infected
with MHV-68 in the absence of CD4 T cell help.
Intradermal B16 tumors are populated by ORF61-specific CD8 T cells and respond to
intratumoral ORF61 peptide injection
Previous work by Rosato et al. established that memory OT-I cells established
following infection of mice with vesicular stomatitis virus expressing SIINFEKL peptide
(VSV-Ova) can be utilized for tumor immunotherapy, with or without anti-PD-L1, in
tumors devoid of OT-I cognate antigen expression 323. The question of whether an
endogenous CD8 T cell response to a γ-herpesvirus can be harnessed therapeutically
remains unanswered. To address this question, we utilized the MHV-68 γ-herpesvirus
infection model and tested if ORF61-specific memory CD8 T cells could be galvanized
for therapy of intradermal B16 melanoma. Mice were infected with MHV-68 and 30 days
later injected intradermally with 1.5X105 B16 melanoma cells. On days 7, 9 and 11 posttumor injection mice were administered intratumoral (i.t.) injections of ORF61 peptide
and intravascular (i.v.) injections of anti-PD-L1 either alone or in combination.
Intratumoral SIINFEKL peptide injections and intravascular PBS injections were given
as controls. We observed at day 14 post-tumor injection, the last day all tumors could be
measured, that mice receiving combination ORF61 peptide and anti-PD-L1 had a
significantly smaller mean tumor area than mice receiving control injections or mice
receiving anti-PD-L1 alone (Fig. 3.16A). While there was no difference in survival
between groups of mice receiving control injections alone and mice receiving anti-PDL1, both groups receiving ORF61 peptide survived longer than mice receiving anti-PDL1 alone (Fig. 3.16B). The group given combination ORF61 peptide and anti-PD-L1
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survived significantly longer than the group given control injections and the group
receiving ORF61 peptide alone had an increase in survival compared to the group
receiving control injections alone that approached statistical significance (Fig. 3.16B). At
endpoint, spleen, tumor-draining inguinal lymph node (tdLN) and tumor infiltrating
lymphocytes (TIL) were collected and tetramer staining was used to identify ORF61specific CD8 T cells in these tissues (Fig. 3.16C). We determined that ORF61-specific
CD8 T cells were detectable as expected in spleen, but that they were also present at
appreciable frequencies in tdLN and TIL in all treatment groups (Fig. 3.16C). This
indicates that ORF61-specific CD8 T cells infiltrate even untreated tumors and indicates
that these cells are additionally positioned in proximal lymph nodes. Thus, supporting the
observation from Rosato et al. that human tumors are occupied by γ-herpesvirus-specific
CD8 T cells. These results further support the therapeutic candidacy of pathogen-specific
CD8 T cells present in human tumors and provide proof of principle in a bone fide rodent
γ-herpesvirus infection model.
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Discussion
Previous models of γHV-induced lymphoma are severely limited. They either
require excessive amounts of time (>5 months) to develop low percentages (10%) of
tumors in immunocompetent mice 302,303, or require severe immunodeficiency, excluding
the possibility to study how an unmanipulated, γHV-specific immune response controls
such malignancies 298,304–306. In this study, we have developed a B cell lymphoma model
that expresses an immunodominant MHV-68 CD8 T cell epitope and grows in
immunocompetent mice. Furthermore, we confirmed that in MHV-68-immune mice,
control of this B cell lymphoma (EM61) was dependent upon CD8 T cells. This allowed
us to dissect the mechanisms used by γHV-specific CD8 T cells to limit growth of a
model γHV-associated lymphoma, EM61.
We found that effector mechanisms necessary for control of EM61 contrast
substantially with control of both acute and latent MHV-68. There is a large degree of
redundancy in the role played by perforin/granzyme and IFNγ in control of acute MHV68 infection. In contrast, perforin/granzyme clearly plays a dominant role in control of B
cell lymphoma with a secondary role for IFNγ. An accessory role for IFNγ is interesting
because during persistent MHV-68 infection, both IFNγ- and perforin-deficient mice
exhibit enhanced viral reactivation 293. Additionally, mice deficient in IFNγ signaling
develop B cell lymphoma after >5 months and suffer from persistent, low-level viral
replication that ultimately causes fibrosis in several tissues 294,296–298. Perforin deficient
mice, however, do not display elevated levels of persistent replication during viral latency
despite an elevated latent viral load 293. Together, it is clear that IFNγ is a central
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mediator of long-term control of virus replication, but perforin/granzyme plays a central
role in protection from B cell lymphoma.
Previous studies indicate perforin/granzyme and IFNγ both contribute to
immunosurveillance of spontaneous lymphoma development in WT C57BL/6 mice
340,341

. When spontaneously arising lymphomas from perforin KO mice were transferred

into WT mice, they were readily controlled by recipient CD8 T cells 340. However,
lymphomas that spontaneously arose in IFNγ deficient mice were poorly controlled after
transfer into immunocompetent WT mice, suggesting that perforin/granzyme exerts a
stronger immunoselective pressure than IFNγ during lymphomagenesis 341. This is
consistent with our study which provides evidence that perforin/granzyme is the
dominant mechanism used by γHV-specific CD8 T cells to control lymphoma and IFNγ
plays a subdominant role. The perforin/granzyme mechanism has also been shown to
control lymphomas arising in some transgenic mouse models of lymphomagenesis. In
these studies, mice overexpressing the oncogenes v-Abl and Bcl2 or defective in the
tumor suppressor gene Mlh1 exhibited accelerated lymphoma development when crossed
with perforin KO strains 342. Eμ-Myc mice display a higher incidence of lymphoma
development on a RAG1- or NKG2D-deficient background, indicating that immune
surveillance limits lymphomagenesis 343,344. However, Eμ-Myc mice on a perforindeficient background are not more susceptible to lymphoma development 342. Absence of
a role for perforin in this system contrasts with its important role in control of EM61. A
possible reason for this discrepancy is the fact that our studies measured control of an
established tumor cell line, whereas the published study measured de novo
lymphomagenesis. Therefore, it is possible perforin is of less importance in controlling

77

the early stages of lymphomagenesis, but more important once tumors have emerged.
Other effector mechanisms, such as FasL or TNFα may suppress lymphomagenesis, and
a tertiary role for mechanisms such as these is suggested by our data showing
perforin/IFNγ double-deficient mice control tumor better than naïve controls.
Our study provides a profile of the immune cell landscape in mice latently
infected with MHV-68 and challenged with EM61. Lymphoma challenge in latently
infected mice resulted in an influx of CD8 T cells into the peritoneum. While the CD8 T
cell influx was not antigen-specific, it nevertheless increased the number of ORF61specific CD8 T cells in the peritoneum, which then prevented tumor growth. Latent
MHV-68 infection alone was sufficient to activate macrophages in the peritoneum and
was not enhanced by tumor inoculation. However, macrophage activation was not
sufficient to control tumor growth, and conferred no protection against a lymphoma
lacking the ORF61 epitope. Recruitment of dendritic cells to the peritoneum required
both MHV-68 infection and tumor, and neither insult alone was sufficient. Infection and
tumor growth likely induce different patterns of chemokine production, and both virus
and tumor are necessary for the correct combination to recruit dendritic cells.
Viral infection and tumor growth promote myelopoiesis and expansion of
monocytic CD11b+, Ly6Chi, Ly6G- cells and neutrophilic CD11b+, Ly6Clo, Ly6G+ cells
331–333

. Depending on the specific immune signals, the expanded population may be either

inflammatory or immunosuppressive. Certain tumors induce the expansion of
immunosuppressive myeloid cells, termed myeloid derived suppressor cells (MDSCs),
which dampen T cell activity 331. These MDSCs are divided into polymorphonuclear
MDSCs (PMN-MDSCs) and mononuclear MDSCs (M-MDSCs), the former similar to
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neutrophils and the latter similar to monocytes 345. Inflammatory monocytes and
neutrophils are important for controlling aspects of influenza virus, poxvirus and West
Nile virus infection 332,346–351. In contrast, certain viruses, such as hepatitis C virus (HCV)
and human immunodeficiency virus (HIV), cause an expansion of immunosuppressive
MDSC populations similar to those induced by tumors 352–360. Previous work observed
that a myeloid population, consisting of cells with both the monocytic CD11b+, Ly6Chi,
Ly6G- and the neutrophilic CD11b+, Ly6Clo, Ly6G+ phenotypes, expanded in response to
MHV-68 but failed to suppress CD8 T cell activation by αCD3 in vitro 361. Consistent
with this study, we also detected an expansion of these myeloid cell populations in mice
infected with MHV-68. In the spleen and peritoneum MHV-68 infection drove an
expansion of monocytic CD11b+, Ly6Chi cells and this expansion was maintained in mice
additionally challenged with EM61. EM61 alone was not sufficient to drive expansion of
monocytic CD11b+, Ly6Chi cells. Cells with a neutrophilic CD11b+, Ly6G+ phenotype
were expanded in the peritoneum in response to EM61 alone, however, this expansion
was inhibited in MHV-68 infected mice. In the spleen, neutrophilic CD11b+, Ly6G+ cells
were expanded in mice receiving MHV-68, EM61 or both in combination. These results
indicate that there is an expansion of potential PMN-MDSCs in response to EM61, but no
expansion of cells with a phenotype consistent with M-MDSCs.
Long-term suppression of MHV-68 replication by CD8 T cells requires CD4 T
cell help, and without CD4 T cells virus reactivation occurs in the lungs. We have shown
previously that CD4 T cell deficiency leads to the induction of an aberrant IL-10
producing CD8 T cell population. Neutralization of IL-10 signaling in these mice
prevents virus reactivation, indicating these cells play an important role in suppressing
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CD8 T cells that control the virus 300,301. Interestingly, this inhibitory environment did not
prevent control of EM61 in CD4-deficient mice. The effect of IL-10 on CD8 T cells can
be inhibitory or activating depending on the context in which the signal is presented 362.
IL-10 inhibits the immune system’s ability to control persistent LCMV (clone 13)
infection. Treatment with anti-IL-10R antibody resulted in control of virus, whereas no
treatment maintained high viral titers. This corresponded with an increase in LCMVspecific CD8 T cells expressing IFNγ and TNFα 363. In other contexts, however, sources
indicate that IL-10 supports CD8 T cell function. Combination of IL-10 and IL-2
supports CD8 T cell effector function. Specifically, CD8 T cells activated in vitro in the
presence of the IL-10/IL-2 combination increase expression of granzyme B and
downregulate genes associated with T cell exhaustion 364. In vitro activation with
supplemental IL-10 alone has been shown to increase expression of granzymes and IFNγ
365

. Furthermore, systemic administration of IL-10 has shown therapeutic promise against

certain tumors by directly expanding and promoting the expression of IFNγ/granzymes in
CD8 T cells 365,366. Together, these observations indicate that IL-10 may support certain
persistent viral infections and contribute to the control of certain tumors. It is possible
that the growing EM61 tumor remodels the local immune environment that modulates the
effect of IL-10 on ORF61-specific CD8 T cells. The tumor microenvironment may either
negate the suppressive influence of IL-10, or even provide the appropriate context for IL10 to promote the anti-tumor CD8 T cell response.
Future studies utilizing EM61 will prove useful for determining the regulation of
immune surveillance against lymphoma development during long-term γHV infection.
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They will also allow us to develop adoptive T cell therapies tailored to prevent γHVassociated B lymphomas in transplant patients.
The contribution of tissue-resident memory CD8 T cells (TRM) to the long-term
control of γ-herpesviruses (γHV) remains an open question. Periodic, productive
reactivation in the tonsil epithelium and subsequent shedding of infectious virions into
saliva is a major route of EBV transmission in humans 312. Tonsillar homing of EBVspecific CD8 T cells expressing CD103 was first described by Alan Rickinson’s group in
2005 367. Subsequent studies have elaborated on this finding, demonstrating that EBVspecific CD8 T cells expressing either CD103 and CD69 or CD69 alone are present in the
tonsil and spleen, the major sites of viral persistence 368. Interestingly, expression of
CXCR5, a homing molecule facilitating cell traffic into B cell follicles, is elevated on
EBV-specific CD8 T cells as compared to CD8 T cells recognizing a different persistent
virus, cytomegalovirus (CMV), in the human tonsil 369. Microscopy data indicates most
CD8 T cells in human tonsil are localized outside of B cell follicles 368, suggesting
elevated CXCR5 expression on EBV-specific TRM may prime entry into B cell follicles
for a rapid antiviral response during lifelong γHV control. The expression of CXCR5 on
EBV-specific CD8 T cells in the spleen remains poorly defined.
In the present investigation, we utilized MHV-68 to dissect γHV-specific TRM
during the latent phase of viral infection in mice. We detected a prominent population of
parenchyma-associated ORF61-specific CD8 T cells with or without expression of
CD69/CD103 in the lungs as well as a subset of CD69+ splenic ORF61-specific CD8 T
cells, lacking CD62L expression, in the red and white pulp during MHV-68 latency.
Previous studies demonstrated splenic residency of CD62L- CD69+ CD8 T cells specific
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for lymphocytic choriomeningitis virus (LCMV) 338,370. Further studies could support the
tissue-resident status of the ORF61-specific CD8 T cells we identified in lung and spleen.
Microscopy could be employed to confirm localization of ORF61-specific CD8 T cells in
the lung and spleen. Another useful technique is parabiosis. Parabiosis joins the
circulatory systems of two congenically distinct mice and allows for recirculating
immune cells to equilibrate between the two parabionts 313,371. In this system, the
recirculating effector memory (TEM) and central memory (TCM) CD8 T cell subsets from
one parabiont cross the circulatory bridge and enter the circulation and secondary
lymphoid organs of the partner parabiont. However, TRM populations remain in their
tissue of residency, do not enter the circulation of the partner parabiont and are not
detected in the partner’s corresponding tissue. This technique discerns the contribution, if
any, of circulating cells transiently upregulating TRM markers, such as CD69/CD103.
Parabiosis of MHV-68 memory mice could confirm the residency of the populations
identified in our studies. One consideration for such parabiosis studies is the nature of
γHV latency. Parabiosis is typically performed between immune and naïve mice,
however, in the case of MHV-68 infection, preliminary studies would be needed to
determine if a naïve parabiont is susceptible to reactivation of latent MHV-68 from the
immune parabiont. If reactivation occurs, active infection of the naïve parabiont would
presumably populate the available memory niches with MHV-68-specific CD8 T cells
from both the immune and naïve partners. This would obscure interpretation of tissue
residency. To circumvent this issue, two congenically distinct immune mice could be
used for parabiosis. Another tool that may be useful for addressing this concern is nonpersistent MHV-68. The non-persistent strain contains a frameshift mutation in ORF73
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encoding a protein responsible for maintenance and segregation of the viral genome
during latency 372. Loss of latency should ameliorate concerns of reactivation during a
parabiosis experiment. An additional aim of future parabiosis studies would be to
determine if ORF61-specific CD8 T cells in LN are tissue-resident. As MHV-68 is
maintained latently in B cell follicles, there is biologic incentive for maintenance of
sentinel lymph node resident CD8 T cells specific for MHV-68. In both the spleen and
lymph nodes, profiling expression of CXCR5 would provide valuable understanding of
how TRM populations are positioned or primed relative to follicles. There is precedent for
CXCR5-mediated entry of virus-specific CD8 T cells into B cell follicles in the context
of simian immunodeficiency virus (SIV) 373, and CD8 T cells without specificity for SIV
engineered to express CXCR5 efficiently migrate to the site of SIV persistence, B cell
follicles 374. Later work demonstrated that SIV-specific CD8 T cells engineered to
express CXCR5 could both home to B cell follicles and efficiently suppress SIV
replication 375. Altogether, these studies demonstrate that natural or induced expression of
CXCR5 is an efficient mechanism for targeting persistent virus in B cell follicles. It is
therefore interesting to consider the role of natural CXCR5+ γHV-specific CD8 T cells in
secondary lymphoid organs and furthermore if engineering CXCR5 expression into a
γHV-specific CD8 T cell product could be useful therapeutically. While our data indicate
the majority of splenic CD69+ ORF61-specific CD8 T cells are in the red pulp, we did
note the fraction of cells expressing TRM markers CXCR3 and CD69 was elevated
substantially in the white pulp. This may suggest the white pulp, containing B cell
follicles, is a particularly important region in which to maintain TRM populations.
Alternatively, TRM in the spleen may typically be maintained at an elevated percentage in
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the white pulp, regardless of pathogen specificity. This is challenging to assess as there is
a dearth of studies utilizing intravascular staining to characterize splenic TRM.
In the absence of CD4 T cell help, MHV-68 reactivates to detectable levels in the
lungs of latently infected mice. In the context of influenza infection, lack of CD4 T cell
help results in fewer CD103+ TRM in the lung, less efficient localization of TRM to the lung
airway epithelium and less protection from heterosubtypic rechallenge 322. Using
intravascular staining, we noted phenotypic and numeric differences in the ORF61specific CD8 T cell populations in the spleen and lung in the absence of CD4 T cell help.
In the spleen, CD4 depletion resulted in a greater proportion of ORF61-specific cells in
the white pulp. While virus does not reactivate to detectable levels in the spleen in the
absence of CD4 T cells 299, it is possible low levels of reactivation in B cell zones may
either promote attraction to, or proliferation of, ORF61-specific CD8 T cells in the white
pulp. Low reactivation levels were previously observed in IL-15 deficient mice infected
with MHV-68 for >60 days, where viral antigen production in the spleen was found to be
> 3-fold higher by quantitative PCR than in intact mice 376. Alternatively, previous
studies have noted that 24 hours following rechallenge, antigen-specific memory CD8 T
cells migrate to the T cell zones of the white pulp, apparently driven in part by the
migration pattern of antigen-bearing dendritic cells 377–379. There is some evidence,
however, that by 60 hours post-rechallenge memory cells have undergone proliferation
and migrated out of the white pulp 379. Possibly, the elevated levels of ORF61-specific
CD8 T cells we observed in the white pulp of CD4 depleted mice represents a state of
elevated flux into the white pulp of reactivated memory CD8 T cells that occurs in a
chronic fashion during reactivation of MHV-68. In both the red and white pulp of the
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spleen, we detected increased expression of CD69 in CD4 depleted mice. Further
experimentation is needed to discern if increased CD69 expression represents an
increased depot of TRM in the absence of CD4 T cell help or if this results from exposure
to low levels of cognate antigen exposure. To test this, acyclovir or a different antiviral
treatment could be used to prevent reactivation of MHV-68 in CD4 depleted mice 380,381.
Treatment would commence in CD4 depleted mice at an immune memory timepoint after
control of initial lytic infection and prior to reactivation is detected (likely ~day 25-30
post-infection299) and subsequent analysis would determine if elevated CD69 expression
is due to CD4 depletion or production of viral antigen.
In the lungs of CD4 depleted mice, we detected an overall increase in CD8 T cells
with a significantly higher percentage of the extravascular ORF61-specific CD8 T cells
expressing CD69 and lower percentages of CD69/CD103 double positive and double
negative cells. This finding is significant because Laidlaw et al (2014) made contrasting
observations in a previous report 322. This report found influenza-specific CD8 T cells
were present in the lung parenchyma in equal numbers in the absence of CD4 T cell help,
however, there were fewer influenza-specific CD103+ TRM. Additionally, this study noted
fewer CD69 and CXCR3 expressing influenza-specific cells in the lung parenchyma.
This defect in TRM in the absence of CD4 T cell help resulted in fewer influenza-specific
CD8 T cells localizing to the airway epithelium and less protection from heterosubtypic
challenge. Our study indicates that a decrease in the number of lung-resident CD8 T cells
expressing canonical TRM markers in the absence of CD4 T cell help is not a
generalizable phenomenon and that the role of CD4 T cell help varies depending on type
of infection. Interestingly, some aspects of our study were consistent with Laidlaw et al’s
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study. For example, in cells expressing CD103 and CXCR3 the per cell expression of
both markers was lower. This indicates CD8 T cells expressing these markers may either
be receiving active signaling to downregulate their expression, or that insufficient signal
was received for normal expression. Both CD103 and CXCR3 are important for optimal
positioning of T cells in the lung. Expression of CD103 promotes retention of lung TRM
as it binds to E-cadherin expressed on lung epithelial cells lining lung airways and alveoli
382

, while CXCR3 expression promotes localization to the respiratory tract 383. Further

investigation is needed to determine if lung-resident ORF61-specific CD8 T cells have a
defect in trafficking to lung airways without CD4 T cells, similar to the observations
made by Laidlaw et al (2014) 322. These studies could utilize microscopy to assess
distance of TRM to airway epithelia and the collection of BAL to determine if ORF61specific TRM are correctly positioned in the respiratory tract. As noted previously for the
spleen, studies utilizing acyclovir will be especially important for the lung, as MHV-68
does reactivate to detectable levels without CD4 T cell help. These studies would
disentangle the effects of viral reactivation and lack of CD4 T cell help on the TRM
compartment.
The final study we present in this section utilized the MHV-68 γ-herpesvirus
infection model to extend the studies of Rosato et al (2019) 323. We demonstrate that an
endogenous memory CD8 T cell response to an authentic γ-herpesvirus infection can be
repurposed for tumor immunotherapy. This model may serve as a platform for further
studies attempting to improve the engagement of virus-specific CD8 T cells for
immunotherapy. Engaging additional MHV-68-specific CD8 T cells through co-injection
of multiple immunodominant epitopes can be tested in this model. Furthermore,
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experiments where mice are infected with multiple herpesviruses, such as MHV-68,
HSV-1 and CMV could be performed to test reactivation of memory cells to multiple
families of herpesvirus. Experiments comparing the properties of TILs seeded by VSVOVA infection versus MHV-68 may identify differences between the OT-I and
endogenous CD8 T cell responses, such as differences in checkpoint expression or
exhaustion characteristics, that prove instructive for most effectively engaging the γherpesvirus-specific CD8 T cells in patients for immunotherapy.
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Figure 3.1: ORF61-specific LacZ-inducible T cell hybridomas recognize EM61. The
ability of EM61 to stimulate ORF61-specific LacZ hybridomas was compared to EM (the
same B cell lymphoma line as transduced with a control retroviral vector not containing
the ORF61 epitope) negative control and an EM + ORF61 peptide pulse positive control
in an X-Gal assay.
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Figure 3.2
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Figure 3.2: CD8 T cells are required for control of EM61 in MHV-68-immune mice. (A)
Expression of B cell surface markers by EM61 evaluated with flow cytometry. EM61
cells were stained for expression of indicated surface markers (solid lines) and compared
with isotype controls (dashed lines). Mean fluorescence intensity and standard deviation
are shown for technical triplicates. (B) MHV-68 immune mice were generated by
infecting mice intranasally (i.n.) and waiting 30 days until viral latency. These mice were
then challenged with EM61 intraperitoneally (i.p.). (C) At day 30 postinfection, two
groups of infected mice were challenged with EM61 (i.p.). One group also received
αCD8 depleting antibody. Growth of EM61 was monitored by injections of luciferin and
subsequent imaging by IVIS. Time to humane endpoint was also followed in these mice
(D). Representative data is depicted from one of two independent repeats, each using five
mice per condition. ** p≤0.01.
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Figure 3.3
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Figure 3.3: ORF61-specific CD8 T cells increase at the site of EM61 challenge.
Peritoneal lavages and spleens were collected from mice latently infected and challenged
with EM61 i.p. Numbers and percentages of ORF61-specific CD8 T cells from these
compartments were obtained by tetramer staining and compared to unchallenged, latently
infected mice. Representative tetramer staining for ORF61-specific CD8 T cells is
depicted for the peritoneum (A) and the spleen (B). The number of ORF61-specific CD8
T cells isolated from EM61 challenged and unchallenged mice were compared in the
peritoneum (C) and the spleen (D). ORF61-specific CD8 T cells as a percentage of CD8
T cells were also compared in the peritoneum (E) and spleen (F). The number of CD8 T
cells isolated from EM61 challenged and unchallenged mice were compared in the
peritoneum (G) and the spleen (H). Data are representative of three independent
experiments, each using five mice per condition. All samples were subjected to doublet
discrimination and gated on viable cells during analysis. *** p≤0.001 and ns p>.05.
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Figure 3.4
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Figure 3.4: Gating strategy for identification of immune cell subsets by flow cytometry.
Groups of mice that were either uninfected or infected with MHV-68 for 30 days were
challenged with EM61 and control groups of infected and uninfected mice were left
unchallenged. Four days after EM61 challenge, peritoneal lavages and splenocytes were
analyzed by flow cytometry for numbers and proportions of relevant immune cell types.
Here, gating strategies for the cell populations analyzed are shown. Dendritic cells (A),
-

-

+

+

were identified as F4/80 , Gr-1 , MHC-II , CD11c . Regulatory T cells (Treg) (B), were
+

hi

+

+

defined as CD4 , CD25 , FOXP3 . (C) Neutrophilic cells were identified as CD11b ,
lo

+

+

hi

-

Ly6C , Ly6G and monocytic cells as CD11b , Ly6C , Ly6G . The mean fluorescence
+

-

intensity of MHC class II (I-A/I-E) expression on CD11b , Gr-1 and F4/80

+

macrophages shown in Fig. 3I-J was measured using the gating shown in (D). All
samples were subjected to doublet discrimination and gated on viable cells during
analysis.
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Figure 3.5
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Figure 3.5: A survey of the cellular immune landscape during EM61 control and latent
MHV-68 infection. Groups of mice either latently infected with MHV-68 or uninfected
were challenged with EM61 and control groups of infected and uninfected mice were left
unchallenged. Four days after EM61 challenge, peritoneal lavages and splenocytes were
analyzed by flow cytometry for numbers and proportions of immune cell populations.
Numbers of dendritic cells and regulatory T cells from each condition are shown for
peritoneal lavages (A & C) and spleens (B & D). Percentages of monocytic CD11b+,
Ly6Chi, Ly6G- cells and neutrophilic CD11b+, Ly6Clo, Ly6G+ cells as a proportion of
+

CD11b cells are shown in the peritoneum (E & G) and spleen (F & H). Expression of
MHC-II on macrophages from peritoneal cavities (I) and spleens (J) are shown on a per
cell basis. Gating strategies for each population are discussed in results and representative
gating is depicted in Supplemental Fig. 1. Data is representative of three independent
repeats, each using five mice per condition. All samples were subjected to doublet
discrimination and gated on viable cells during analysis. * p≤0.05, ** p≤0.01, ***
p≤0.001, **** p≤0.0001.
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Figure 3.6
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Figure 3.6: There is no intrinsic tumor resistance mediated by a cross-protective effect in
latently-infected mice. To test if a non-specific, cross-protective effect contributed to
EM61 control in latently infected mice, we challenged latently infected and uninfected
groups of mice with EM (the same B cell lymphoma line as EM61 minus the ORF61
epitope). Time to endpoint was monitored. Each group consisted of five mice and the
experiment was repeated twice.
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Figure 3.7
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Figure 3.7: Either IFNy or perforin are dispensable for EM61 control. Two groups of
5

WT and two groups of Perforin KO mice were challenged with 1X10 EM61 i.p. at 30
days post MHV-68 infection. One WT and one Perforin KO group also received blocking
αIFNγ antibody. As a control, a WT, uninfected group was administered EM61 i.p.
Growth of EM61 was monitored by IVIS (A) and protection from tumor growth was
tracked (B). Data is representative of two independent experiments, each using five mice
per condition. ** p≤0.01.
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Figure 3.8
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Figure 3.8: Perforin/granzyme is more potent than IFNγ for control of EM61. (A)
Protection from tumor growth is depicted for groups of WT, IFNγ KO or perforin KO
7

mice. Mice were administered 1X10 EM61 30 days postinfection (100X higher than Fig.
4). Uninfected WT mice were also challenged with EM61 as a control. (B) Protection
from tumor growth is shown for groups of WT and perforin KO mice challenged with
7

1X10 EM61 30 days postinfection. One group of perforin KO mice was also
administered blocking αIFNγ antibody. A group of uninfected WT mice were challenged
as a control. Two independent experiments, each using five mice per condition, were
combined and presented for A & B. ** p≤0.01, *** p≤0.001, **** p≤0.0001.
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Figure 3.9
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Figure 3.9: Perforin deficient CD8 T cells have an intrinsic deficit in EM61 control.
ORF61-specific CD8 T cells were enumerated from the peritoneal cavities (A) and
spleens (B) of WT, perforin KO and IFNγ KO mice 30 days postinfection. In a separate
experiment, CD8 T cells were isolated from the spleens of WT or perforin KO mice 30
days postinfection using EasySep™ Mouse CD8+ T Cell Isolation Kits (Stemcell
Technologies, Cat. #19853) according to the manufacturer’s instructions. These isolated
CD8 T cells were then stained with tetramer to detect the percentage that were ORF615

specific. This percentage was used to transfer equal numbers (1.5X10 ) of either WT or
perforin KO ORF61-specific CD8 T cells into uninfected WT recipient mice i.p. As a
control for tumor growth, one group of mice received a transfer of naïve CD8 T cells i.p.
from uninfected mice. These recipients were then immediately challenged with 1X10

7

EM61 i.p. and the ability of the transferred CD8 T cells to limit EM61 growth was
monitored (C) and quantified (D) using IVIS. For the quantification shown in (D),
rectangular regions of interest (ROI) of identical dimensions were applied to each mouse
using Living Image software (PerkinElmer) and then adjusted so the top of each ROI was
centered on an individual mouse’s sternum. Total photon flux through these ROIs were
obtained, log10- transformed and graphed. Asterisks denote values which differed
significantly between recipients of perforin KO and WT ORF61-specific CD8 T cell
transfer as determined by two-tailed unpaired Student’s t tests between the two sets of
recipients for each timepoint. A & B depict the results of two pooled experiments with 3
mice per group per experiment. C & D are representative of two independent experiments
which each used five mice per group. ** p≤0.01, **** p≤0.0001.
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Figure 3.10
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Figure 3.10: Immunosuppression in CD4 T cell-depleted mice is insufficient to
compromise CD8 T cell-mediated control of EM61. Intact WT mice and CD4 T cell7

depleted mice were infected with MHV-68 and challenged 42 days later with 1X10

EM61. Uninfected control mice were also challenged with EM61. Tumor growth was
monitored after EM61 challenge by IVIS (A) and protection from tumor growth tracked
(B). At 42 days postinfection, lung viral titers were measured by plaque assay in both
CD4 T cell-depleted mice and intact WT mice. Data is representative of two independent
experiments. Each experiment used nine mice infected with MHV-68 for both the CD4 T
cell-depleted and WT groups. Three mice from each of these groups were used at day 42
for determination of lung viral titers (C). Subsequently, the remaining six mice from each
group and six uninfected control mice were challenged with EM61. Mice from each
condition were imaged in two groups per timepoint and the resulting images were
combined and presented in A. * p≤0.05, **** p≤0.0001.
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Figure 3.11
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Figure 3.11: No EM61 growth detected in the lungs of CD4 T cell deficient mice after
intravenous challenge. Intact WT mice and CD4 T cell-depleted mice were infected with
7

MHV-68 and challenged 42 days later with 1X10 EM61 intravenously. Uninfected
control mice were also challenged. On days 4 and 7 post-challenge, mice were
administered 300μg of luciferin by i.p. injection followed by a period of exactly 2
minutes before lungs were removed, placed on individual petri dishes and luminescent
signals were acquired using IVIS. EM61 growth in the lungs was quantified by applying
identical circular regions of interest (ROI) to each petri dish containing a single set of
lungs using Living Image software (PerkinElmer) (A). Total photon flux through these
ROIs were obtained, log10- transformed and graphed (B). Each group for each timepoint
consisted of three mice. ** p≤0.01.
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Figure 3.12
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Figure 3.12: Intravascular staining defines vascular accessible ORF61-specific T cells in
different tissue compartments. Lung, spleen, inguinal lymph node and blood were
collected from mice 30 days after infection with MHV-68 following intravascular
staining for CD8β via tail vein injection. (A) CD8 T cells were identified by ex vivo CD8
α staining and separated on the basis of intravascular CD8β staining into vascular
accessible (CD8β+) and inaccessible (CD8β-). (B) ORF61-specific CD8 T cells in the IV+
(CD8β+) and IV- (CD8β-) CD8 T cell fractions. (C) Expression of CD103 and CD69 on
IV+ and IV- ORF61-specific CD8 T cells identified in B.
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Figure 3.13
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Figure 3.13: CD69 expressing CD8 T cells become dominant subset in the lung
parenchyma after MHV-68 infection. Lungs were collected from MHV-68 infected mice
at a series of memory timepoints following intravascular staining for CD8β via tail vein
injection. CD8 T cells associated with the lung parenchyma were identified as IV- (CD8β). Tetramer staining detected ORF61-specific CD8 T cells in the IV- fraction. (A) The
percent of ORF61-specific CD8 T cells in the total IV- CD8 T cell population (left) and
the absolute number of ORF61-specific CD8 T cells per lung (right) were plotted over
time. (B) The percentage (left) and number (right) of ORF61-specific CD8 T cells
expressing and co-expressing CD69 and CD103 was tracked over time. Two independent
experiments with groups of 3 mice were performed and then pooled for analysis. Error
bars represent standard error from the mean.
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Figure 3.14
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Figure 3.14: Intravascular staining defines a distinct population of splenic CD8 T cells
specific for MHV-68. Spleens were collected from MHV-68 infected mice at a series of
memory timepoints following intravascular staining for CD8β via tail vein injection. CD8
T cells from the spleen were divided during analysis into IV+ (CD8β+) and IV- (CD8β-)
fractions. Tetramer staining detected ORF61-specific CD8 T cells in these fractions. (A)
The percentage of IV- ORF61-specific CD8 T cells of total ORF61-specific CD8 T cells
in the spleen and the absolute number of ORF61-specific CD8 T cells in the IV+ and IVfractions were tracked over time. (B) Percent CXCR3+ of ORF61-specific CD8 T cells in
the IV+ and IV- fractions was tracked over time and compared to CXCR3 expression on
the IV- fraction from lung at the same points in time post-infection. (C) Percent CD69+ of
ORF61-specific CD8 T cells tracked over time in the IV+ and IV- fractions. (D) In a
separate experiment, without intravascular staining, splenic ORF61-specific CD8 T cells
were analyzed 30 days post-infection with MHV-68 for expression of CD62L and CD69.
For intravascular staining studies, two independent experiments with groups of 3 mice
were performed and then pooled for analysis. For experiment in (D), spleens from 7 mice
were analyzed. Error bars represent standard deviation from the mean.
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Figure 3.15
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Figure 3.15: Progressive loss of CD8 T cell-mediated control of MHV-68 in the absence
of CD4 T cells is associated with phenotypic alteration of ORF61-specific CD8 T cells in
compartments inaccessible to intravascular staining. Intact WT mice and CD4 T celldepleted mice were infected with MHV-68. After 42 days, spleens and lungs were
collected from both groups following intravascular staining for CD8β via tail vein
injection. In the lung, CD8 T cells associated with the lung parenchyma were identified
as IV- (CD8β-). In the spleen, CD8 T cells were divided during analysis into IV+ (CD8β+)
and IV- (CD8β-) fractions. Tetramer staining detected ORF61-specific CD8 T cells in the
IV+ and IV- fractions in lung and spleen. (A) The experimental schema outlining the CD4
depletion strategy. (B) Absolute numbers of ORF61-specific CD8 T cells obtained per
spleen from both the IV+ and IV- fractions. (C) Percent IV- of the total ORF61-specific
CD8 T cell splenic population. (D) Percent CD69+ of splenic ORF61-specific CD8 T
cells in both the IV+ fraction (left) and IV- fraction (right). (E) Percent CXCR3+ of
splenic ORF61-specific CD8 T cells in both the IV+ fraction (left) and IV- fraction
(right). (F) Percent of IV- ORF61-specific CD8 T cells of the total IV- CD8 T cell
population (left) and absolute number of ORF61-specific CD8 T cells per lung (right).
(G) Percent CD103+ CD69+ of IV- ORF61-specific CD8 T cells (left) and absolute
numbers per lung (right). (H) Percent CD103- CD69+ of IV- ORF61-specific CD8 T cells
(left) and absolute numbers per lung (right). (I) Percent CD103- CD69- of IV- ORF61specific CD8 T cells (left) and absolute numbers per lung (right). (J) Representative
flow-plots from lungs of mice either receiving CD4 depletion or left intact (top) of
CXCR3 expression on IV- ORF61-specific CD8 T cells. (bottom-left) Quantitation of
percent CXCR3+ IV- ORF61-specific CD8 T cells. (bottom-middle) absolute number of

117

CXCR3+ IV- ORF61-specific CD8 T cells. (bottom-right) mean-fluorescence intensity
(MFI) of CXCR3 expression in the CXCR3+ IV- ORF61-specific CD8 T cell fraction.
(K) Representative flow-plots from lungs of mice either receiving CD4 depletion or left
intact (left) of CD103 expression on IV- ORF61-specific CD8 T cells. (right) quantitation
of CD103 MFI from the CD103+ fraction. Two independent experiments with groups of 3
mice were performed and then pooled for analysis. ns p>0.05, * p≤0.05, ** p≤0.01, ***
p≤0.001 & **** p≤0.0001.
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Figure 3.16
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Figure 3.16: Intradermal B16 tumors are populated by ORF61-specific CD8 T cells and
respond to intratumoral ORF61 peptide injection. Mice infected 30 days prior with
MHV-68 were injected intradermally with 1.5X105 B16 melanoma cells. On days 7, 9
and 11 post-tumor injection mice were administered intratumoral injections of ORF61
peptide and intravascular injections of anti-PD-L1. Tumor growth, where dashed lines
indicate days treatment was administered (A) and survival (B) were monitored
subsequently. At endpoint, spleen, tumor-draining inguinal lymph node (tdLN) and tumor
infiltrating lymphocytes (TIL) were collected and the percent of CD8 T cells specific for
ORF61 of the total CD8 T cell population was detected via tetramer staining (C). Groups
of 8-12 mice were used. Error bars represent standard error from the mean. ns p>0.05, *
p≤0.05, ** p≤0.01, & *** p≤0.001.
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§IV
Characterizing transcriptional and epigenetic control of memory CD8 T cell
differentiation by the BTB-ZF family transcription factor Zbtb20
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Abstract
Members of the BTB-ZF transcription factor family regulate the immune system.
Previously, our lab identified a role for BTB-ZF family member Zbtb20 in the
differentiation, recall responses and metabolic profile of CD8 T cells. Here, we report a
characterization of the transcriptional and epigenetic signatures controlled by Zbtb20 at
single-cell resolution during the effector and memory phases of the CD8 T cell response
to Listeria monocytogenes. Furthermore, we use CUT&RUN to identify genomic targets
of Zbtb20 in CD8 T cells. In the absence of Zbtb20, transcriptional programs associated
with memory CD8 T cell formation were broadly upregulated throughout the CD8 T
response. A signature of open chromatin was maintained in regions encoding genes
controlling T cell activation, consistent with the known impact on differentiation.
Memory CD8 T cells lacking Zbtb20 were further characterized by open chromatin
regions with overrepresentation of AP-1 transcription factor motifs and elevated RNAand protein-level expression of the corresponding AP-1 components. Finally, we describe
motifs and genomic annotations from the DNA targets of Zbtb20 in CD8 T cells.
Together, these data establish the transcriptional and epigenetic networks contributing to
the control of CD8 T cell responses by Zbtb20.
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Introduction
Through a coordinated effector response, CD8 T cells mediate control over viral
or bacterial infection and tumors. This process involves recognition of antigen by naïve
CD8 T cells followed by clonal expansion of antigen-specific CD8 T cells into a large
pool of effector cells, which elaborate effector molecules to eliminate the pathogen or
transformed cells. Subsequently, the effector CD8 T cell (TEFF) pool contracts leaving a
long-lived memory CD8 T cell (TM) pool. Memory CD8 T cells are capable of rapidly
mounting robust secondary responses and are vital for protection from previously
encountered pathogens 384. Because of the protective capacity of the TM, factors
controlling their differentiation from naïve to long-lived memory are of great interest for
vaccine development and immunotherapy 1. Herein, we characterize the contributions of
one such factor, the transcription factor Zbtb20 (broad complex, tramtrack, bric-abrac/poxvirus and zinc finger 20), to the transcriptional and epigenetic control of CD8 T
cell differentiation.
Effector and memory CD8 T cell populations are each composed of multiple
subsets. During the effector response, CD8 T cells are partitioned along a differentiation
spectrum ranging from more terminally differentiated KLRG1hi CD127lo terminal
effector cells (TECs) to less terminal KLRG1lo CD127hi memory precursor effector cells
(MPECs). As the effector response transitions to the memory phase, most cells with the
TEC phenotype undergo apoptosis, while MPEC cells are more likely to survive and
form TM 4–6. Memory CD8 T cell subsets include effector memory CD8 T cells (TEM) and
central memory CD8 T cells (TCM). These subsets are recirculating and found in the
blood and the spleen. Compared to TEM, TCM have a greater proliferative capacity, are
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less cytotoxic and can be distinguished from TEM by elevated expression of lymphoidhoming molecules CCR7 and CD62L 385. At memory, CD8 T cells can be further
classified by expression of the fractalkine receptor CX3CR1 29–31. Expression of CX3CR1
on TM defines a population of effector-like TM with elevated levels of granzyme B
expression and enhanced killing of infected cells 31.
Several transcription factors are known to regulate the differentiation process.
Among them, Tbet, Zeb-2 and Id2 promote TEFF and/or TEC generation, while Zeb1,
Tcf1, Eomesodermin and Runx3 promote TM and/or MPEC formation 67,386. Additionally,
we previously characterized the transcription factor Zbtb20 as a regulator of the CD8 T
cell differentiation process. Deletion of Zbtb20 during CD8 T cell differentiation resulted
in increased MPEC formation, decreased TEC formation, changes in metabolism and TM
capable of an enhanced secondary response 246. There are other important signaling
events downstream of T cell activation that culminate in activation of transcriptional
regulators of T cell function. One such event begins with ligation of the T cell receptor
and costimulation. Subsequent signaling results in the activation of the nuclear factor of
activated T cells (NFAT) and AP-1, which together bind composite DNA motifs and
synergistically promote the expression of IL-2 and other effector genes 387.
The transcription factor Zbtb20 has an N-terminal BTB protein-interaction
domain and five C-terminal zinc-finger DNA-binding domains 213,214. Members of this
transcription factor family such as Bcl-6, BAZF, and PLZF are known to play important
roles in the immune system and in other cell types, regulating cellular differentiation,
oncogenesis, and the maintenance of stem cells 388. Importantly, numerous BTB-ZF
proteins are key factors in CD4 and CD8 T cell development and function 208. To date,
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studies on Zbtb20 in lymphocytes other than CD8 T cells, have determined that Zbtb20 is
essential for B cell differentiation into plasma cells 243 and for a population of IL-10
producing regulatory T cells 242. However, few direct genomic targets of Zbtb20 are
described 233,236,238,240,389 and no direct targets are described in CD8 T cells, confounding
efforts to fully characterize the mechanism(s) through which Zbtb20 controls
lymphocytes.
In this report, we extended our characterization of the control Zbtb20 exerts over
CD8 T cell differentiation. We employed single cell RNA sequencing (scRNA-seq)
coupled with cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq)
390

and single cell ATAC sequencing to define differences in the transcriptional and

epigenetic landscapes of differentiating, Zbtb20 deficient, CD8 T cells. Furthermore,
cleavage under targets and release under nuclease (CUT&RUN) 391 was used to identify
direct genomic targets of Zbtb20 in CD8 T cells. Together, these techniques determined
Zbtb20 deficient CD8 T cells have a distinct transcriptional and epigenetic profile
compared to wild type CD8 T cells at both effector and memory phases of differentiation.
In particular, memory CD8 T cells deficient in Zbtb20 upregulated components of the
AP-1 transcription factor complex and had a characteristic AP-1 epigenetic signature.
Furthermore, we found that genomic targets of Zbtb20 in CD8 T cells were associated
with the regulation of the CD8 T cell response.
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Results
Zbtb20 controls transcriptional and epigenetic landscapes of effector and memory CD8 T
cells
Deletion of Zbtb20 in CD8 T cells responding to listeria results in a greater
proportion of memory precursor effector cells (MPECs), enhanced mitochondrial and
glycolytic metabolism, increased mitochondrial fuel flexibility and larger secondary
responses 246. Here, we comprehensively profiled the transcriptional changes underlying
these observed effects. Naïve GZB-cre Zbtb20-flox CD45.1 OT-I (KO) or WT CD45.1
OT-I cells (WT) were adoptively transferred into recipient mice, which were
subsequently infected with LM-ActA-OVA. At day 10 (effector) and day 30 (memory)
post-infection, single-cell RNA sequencing (scRNA-seq) and single cell ATAC
sequencing (scATAC-seq) were performed on KO and WT OT-I cells isolated from
recipient spleens and labeled with Total-seq antibodies to CD62L, CD127 and KLRG1.
Uniform manifold approximation and projection (UMAP) 260 representation and cluster
analysis of scRNA-seq and scATAC-seq data identified transcriptomic differences (Fig.
4.1A & 4.1C) and epigenetic differences (Fig. 4.1B & 4.1D) between the four groups.
Transcriptomic differences were more pronounced when comparing day 10 and day 30
than when comparing KO and WT at the same timepoint (Fig. 4.1A & 4.1C).
Epigenetically, WT and KO separated on the basis of differential chromatin accessibility
at day 30 and to a lesser extent at day 10 (Fig. 4.1B & 4.1D). We observed transcriptomic
(Fig. 4.1E & 4.1G) and epigenetic (Fig. 4.1F & 4.1H) shifts in the distribution of WT and
KO that prompted us to further examine timepoint-specific differences between KO and
WT.
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Transcriptional profile of effector and memory CD8 T cells is controlled by Zbtb20
Transcriptional differences between KO and WT at day 10 (effector) and day 30
(memory) were further characterized by clustering day 10 KO and WT and day 30 KO
and WT independently. At day 10, Total-seq staining for CD127 (Fig. 4.2E & 4.2M) and
KLRG1 (Fig. 4.2F & 4.2M) provided proteomic context for UMAP representations of
scRNA-seq data and indicated day 10 clusters 1 and 2 contained the majority of terminal
effector cells (TECs) and clusters 0 and 3 contained mostly memory precursor effector
cells (MPECs) (Fig. 4.2A-B). Clusters 1 and 2 contained fewer KO than WT cells, while
cluster 3 contained more KO than WT (Fig. 4.2B). This observation is consistent with our
previous report, which indicated KO cells form proportionally fewer TECs and more
MPECs 246. Comparing total KO and WT cells at day 10 revealed KO cells expressed
higher levels of memory-associated transcripts (Ly6a, Cd27, Ccr7, Lef1, Bcl2, Tcf7,
Runx3, Eomes and Il7r) and lower levels of effector T cell associated transcripts,
encompassing multiple members of the killer cell lectin-like receptor family (Klre1,
Klrd1, Klrk1, Klrc2, Klrg1, Klrb1c and Klrc1), effector molecules (Gzma, Gzmb, Prf1
and Ifng), Cx3cr1 and transcription factor Zeb2 (Fig. 4.2I).
Individual clusters at day 10 enriched for WT cells such as clusters 1 & 2
displayed the highest surface levels of KLRG1 as determined by Total-seq staining (Fig.
4.2B, 4.2F & 4.2M). Furthermore, clusters 1 & 2 were both distinguished from other
clusters by elevated transcripts for Zeb2, Gzmb, Cx3cr1, and S1pr5 (Fig. 2K). Cluster 1
was distinct in its increased expression of Id2, while cluster 2 had higher expression of
effector molecule Gzma (Fig. 4.2K). Clusters 0 and 3 were CD127+ by Total-seq labeling
and low for KLRG1 (Fig. 4.2E-F & 4.2M). Cluster 0 and 3 expressed higher transcript
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levels of Cd27, Fosb, Il7r and Tcf7 (Fig. 4.2K). Cluster 0 was also characterized by
significantly elevated levels of Btf3, Bcl2 and Cxcr3 (Fig. 4.2K). Uniquely identifying
transcripts in cluster 3 included Dapl1, Ccr7, Fos, Jun and Sell (Fig. 4.2K). We conclude
from our analysis of day 10 differences between KO and WT cells that KO cells are
characterized by higher expression of memory-associated transcripts, lower expression of
effector-associated transcripts and are less represented in TEC-associated clusters.
At day 30, clusters 2 and 7 contained the majority of KLRG1+ cells, while clusters 0, 1
and 5 expressed CD127 with little KLRG1 expression at both the protein-level and the
gene-level (Fig. 4.2C-D, 4.2G-H, 4.2L & 4.1N). Most cells in KLRG1-labeled clusters
were WT (Fig. 4.2D). Comparison of total KO and WT cells at day 30 indicated that KO
cells were strongly enriched for expression of AP-1 components Fos, Fosb, Jun, Jund
and Junb (Fig. 4.2J). Additional enriched genes in day 30 KO cells include Btf3 and
Eomes (Fig. 4.2J). Day 30 WT cells had increased expression of memory genes Il7r, Sell
and Ly6a, but also expressed increased effector genes such as Zeb2, Id2, Cx3cr1, Klrg1,
S1pr5 and S1pr1 (Fig. 4.2J). Importantly, Nfkbia (encoding the repressor of NF-κB,
IκBα) was elevated at both day 10 and day 30 timepoints in KO cells, consistent with the
reported repression of this gene by Zbtb20 240. Strikingly, KLRG1- clusters 0 and 1
contained predominantly KO and WT cells respectively (Fig. 4.2D). Elevated expression
of AP-1 components Fos, Fosb, Jun, Jund and Junb formed a strong transcriptional
signature distinguishing predominantly KO cluster 0 from predominantly WT cluster 1
(Fig. 4.2L). KO cells were the predominant population in cluster 5 (Fig. 4.2D), a cluster
uniquely defined by elevated expression of Dapl1 (Fig. 2L), similar to day 10 cluster 3
(Fig. 2K). Cluster 5 shared transcriptional similarities with cluster 0 such as elevated
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expression of AP-1 components Fos, Fosb, Jun, Jund and Junb (Fig. 4.2L). Additionally,
cluster 5 and 0 shared elevated expression of Nfkbia, Pik3ip1 and Rexo2 (Fig 4.2L). Our
analysis at day 30 indicates Zbtb20 deficient memory CD8 T cells have a signature
increase in genes encoding components of AP-1 and memory-associated genes while
preserving reduced expression of key effector-associated transcripts.
Decreased transcript expression of the fractalkine receptor Cx3cr1 was detected in
KO cells at both days 10 and 30. Patterns of CX3CR1 expression are useful for
identifying differences in CD8 T cell differentiation, therefore, we characterized
expression of CX3CR1 on OT-I populations with flow cytometry. Groups of mice
received naïve KO and WT OT-I cells and were subsequently administered LM-actAOVA as previously described. At day 10 and day 30 post-infection, splenocytes were
collected and the expression of CX3CR1 on KO and WT OT-I cells was identified using
flow cytometry. We observed a decreased percentage of KO cells expressing CX3CR1 at
both day 10 (Fig. 4.2O) and day 30 (Fig. 4.2P). Analysis of protein-level expression of
CX3CR1 confirmed transcriptomic findings and indicates skewing of the effector and
memory responses in KO cells extends to this important chemokine receptor.
Compass algorithm predicts metabolic systems regulated by Zbtb20 in CD8 T cells
In our previous work, we identified an association between Zbtb20 and regulation
of metabolism in CD8 T cells responding to infection 246. Pathway-level analysis of
scRNA-seq data utilizing the VAM method 261 indicated a number of pathways associated
with metabolism from both C5 and Hallmark collections were increased at day 10 in KO
cells (Fig. 4.3A-B & 4.4A-B). At day 30, we noted that certain C5 pathways related to
reactive oxygen species, aerobic respiration and electron transport chain were increased
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in KO cells (Fig. 4.5A-B), while hallmark pathways for xenobiotic metabolism,
adipogenesis, bile acid metabolism, oxidative phosphorylation and glycolysis were
increased in WT cells (Fig. 4.6A-B). We further utilized the Compass algorithm to predict
differences in the cellular metabolic states between KO and WT cells at day 10 and day
30. Compass 265, a flux balance analysis framework 392, is optimized for predicting the
potential activity of a metabolic reaction from single cell genomics data. To do this,
Compass accounts for metabolic gene expression in scRNA-seq datasets and the global
metabolic reaction network from the Recon 2 266 metabolic reconstruction database. We
first compared WT cells from the day 10 (effector) and day 30 (memory) timepoints (Fig.
4.7A-B) to establish a Compass metabolic signature for memory versus effector CD8 T
cells. Pathways were ranked according to the difference between the percentage of
reactions significantly upregulated and the percentage of reactions significantly
downregulated at day 30 versus day 10 (Fig. 4.7A). The differences in percentages of
reactions upregulated and downregulated were visualized in a rank plot (Fig. 4.7B). In
total, there were 20 pathways with an increased percentage of reactions up at day 30, 3
pathways with no difference in percentage of reactions up at day 30 and 34 pathways
with an increased percentage of reactions up at day 10 (Fig. 4.7A-B). The top 5 pathways
with an increased percentage of elevated reactions at day 30 included vitamin B6
metabolism, biotin metabolism, valine-leucine-isoleucine metabolism, starch and sucrose
metabolism and histidine metabolism (Fig. 4.7A). The top 5 pathways with an increased
percentage of reactions elevated at day 10 were N-glycan degradation, ROS
detoxification, vitamin D metabolism, chondroitin sulfate degradation and keratan sulfate
degradation (Fig. 4.7A). Furthermore, this analysis associated pathways with day 10 WT
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cells, such as pentose phosphate pathway, glycolysis/gluconeogenesis and pyruvate
metabolism, that are known to be important for effector CD8 T cells 8,393 (Fig. 4.7A).
Likewise, pathways important for memory CD8 T cells, such as fatty acid oxidation, fatty
acid synthesis and glutathione metabolism were elevated in day 30 WT cells 112,394 (Fig.
4.7A).
Comparing KO and WT at day 10 by Compass, the majority of pathways (51 of
57) had increases in the percentage of elevated reactions in KO cells, while 4 of 57
pathways had an increased percentage of downregulated reactions in KO cells (Fig. 4.8AB). This finding is consistent with our observations from pathway analysis which
identified a number of metabolic pathways upregulated in KO cells (Fig. 4.3A-C). Top
elevated pathways from Compass included propanoate metabolism, N-glycan synthesis,
N-glycan degradation, purine synthesis and CoA synthesis. At day 30, the majority of
pathways (36 of 57) had a decreased percentage elevated reactions in KO cells, while 18
of 57 pathways had an increased percentage of upregulated reactions in KO cells (Fig.
4.8C-D). Top decreased pathways included ROS detoxification, chondroitin sulfate
degradation, heparan sulfate degradation, taurine and hypotaurine metabolism and Oglycan synthesis, while top increased pathways include cytochrome metabolism, inositol
phosphate metabolism, pyrimidine synthesis, folate metabolism and glyoxylate and
dicarboxylate metabolism (Fig. 4.8C). Interestingly, Compass identified decreases in
pathways such as ROS detoxification and oxidative phosphorylation in KO cells (Fig.
4.8C), similar to pathway analysis (Fig. 4.4A-C). However, Compass predicted an
increase in pathways related to glycolysis such as pyruvate metabolism and
glycolysis/gluconeogenesis in KO cells, while pathway analysis indicated Hallmark-
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glycolysis was decreased in KO cells (Fig. 4.4B & 4.4D). Overall, Compass analysis
predicts KO cells increase metabolic activity in a majority of pathways at day 10, and
then decrease metabolic activity in a majority of pathways at day 30 relative to WT cells.
Zbtb20 modulates CD8 T cell epigenetic profile during differentiation
Epigenetic differences between KO and WT at day 10 (effector) and day 30
(memory) were dissected using scATAC-seq by clustering day 10 KO and WT and day 30
KO and WT independently (Fig. 4.9A-D). Comparing total KO and WT at day 10 and
day 30, we noted significant increases in the accessibility of the WT genome associated
with Cmtm6, encoding a protein that maintains PD-L1 expression 395, and Cdk5rap1,
encoding a protein that is involved in cell cycle arrest and is associated with the shortlived effector T cell program 396 (Fig. 4.9E-F). Furthermore, we detected a corresponding
increase in transcript expression of Cdk5rap1 from WT cells at both day 10 and 30 (Fig.
4.2I-J). Comparison of total KO and WT cell genome accessibility indicated an increased
accessibility in KO at day 10 of Mid1, a gene important for contractile ring formation
during cytokinesis 397, promoting cytotoxic granule exocytosis and CD8 T cell migration
398,399

(Fig. 4.9E). Additional genes with increased accessibility in KO cells at both day

10 and day 30 included Ubash3b (also known as suppressor of T cell receptor signaling 1
or Sts1), Pik3ip1 and Atp2b4 (also known as PMCA4) (Fig. 4.9E-F). Broadly, these three
genes encode proteins involved in attenuating the CD8 T cell response to antigen.
Specifically, Ubash3b negatively regulates T cell receptor signaling via
dephosphorylation of ZAP70 400,401, Pik3ip1 restricts T cell activation by inhibiting
PI3K/Akt 402 and Atp2b4 is a plasma membrane calcium exporter whose expression
attenuates IL-2 production by establishing homeostatic intracellular calcium levels after T
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cell receptor signaling 403. Importantly, the increased chromatin accessibility of these
three genes in KO cells corresponded to increased RNA transcription at memory (Fig.
4.2J). Comparison of the epigenetic landscape between total KO and WT cells suggests
KO cells have an epigenetic signature associated with the attenuation of T cell activation,
consistent with reduced terminal differentiation and promotion of memory.
At day 10, cluster analysis identified WT-majority cluster 3 (Fig. 4.9C) as defined
by increased chromatin accessibility in TEC-associated genes such as Zeb2, S1pr5 and
Klrg1 and decreased chromatin accessibility in MPEC-associated genes such as Zeb1,
Tcf7 and Bcl2 (Fig. 4.4G). This finding, that TEC-like cluster 3 is poorly populated by
KO cells, is consistent with our findings from day 10 transcriptomics, which indicated
KO cells were a minority in TEC scRNA clusters (Fig. 4.2). At day 30, KO and WT cells
were largely separated into KO clusters 1, 2 and 4 and WT clusters 0 and 3 (Fig. 4.4D).
WT cluster 3 and KO cluster 2 were defined by increased accessibility associated with
effector genes Zeb2 and S1pr5 (Fig. 4.9H), suggesting these clusters represent effector
memory CD8 T cells. However, WT cluster 3 was distinguished from KO cluster 2 by
increased accessibility of effector genes Cdk5rap1 and Klrg1 and decreased accessibility
of memory genes Bcl2, Il7r, Zeb1, Ccr7 and Tcf7 (Fig. 4.9H), indicating that WT cluster
3 is characterized by a more effector-like epigenetic program than KO cluster 2. Thus,
WT effector memory CD8 T cells are epigenetically distinct from KO effector memory at
day 30.
Zbtb20 deletion results in AP-1 DNA motif signature in memory CD8 T cells
We next sought to identify transcription factors (TFs) that may be important for
mediating the differences we observed in CD8 T cell differentiation in the absence of
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Zbtb20. To do this, we searched for overrepresented DNA sequence motifs in ATAC
peaks associated with KO and WT at days 10 and 30 using chromVAR 404. This revealed
overrepresentation of pro-memory ZEB1 and TCF7 TF-binding motifs in KO cells at day
10 (Fig. 10A-B). We did not detect elevated Zeb1 transcript expression in KO cells at day
10 (data not shown), but did detect decreased expression of Zeb2, which is known to play
a reciprocal role to Zeb1 and mediate terminal effector differentiation 386 (Fig. 4.10C).
Furthermore, we did detect elevated transcript expression of the Tcf7 transcript (Fig.
4.10C). These data suggest increased activity of known memory TFs in KO cells at day
10, consistent with our previous observation that KO form more MPEC and fewer TEC at
day 10.
Overrepresented motifs in KO cells at day 30 included a number of motifs
associated with AP-1 TF family members (Fig. 4.11A). Members of the AP-1 TF family
regulate CD8 T cell activation, cytotoxicity and proliferation 387. Specifically, motifs
associated with JUN, JUNB, JUND, FOS and FOSB were detected in areas of chromatin
more accessible in KO cells (Fig. 4.5B). As previously described (Fig. 4.2J), transcripts
encoding these AP-1 components are elevated in KO cells (Fig. 4.11C). This prompted us
to test protein-level expression of the identified AP-1 TFs. Antibody staining and flow
cytometry on KO and WT cells 30 days after LM-actA-Ova infection revealed that all
AP-1 TFs with overrepresented DNA motifs and elevated transcript levels in KO cells
had concomitant increases at the protein level (Fig. 4.11D-E). As we had previously
detected a decrease in CX3CR1 expression in KO cells, we further tested if AP-1 TFs
were differentially expressed between CX3CR1hi and CX3CR1lo subsets of memory CD8
T cells. With the notable exception of FosB, AP-1 TF expression was generally elevated
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in the WT CX3CR1lo memory CD8 T cell compartment (Fig. 4.12A). This pattern was
mirrored in KO memory CD8 T cells (Fig. 4.12B). We also determined that AP-1 TF
expression in KO cells was generally elevated in both the CX3CR1hi and CX3CR1lo
compartments (Fig. 4.12C-D), indicating that elevated AP-1 expression is a general
feature of Zbtb20 deletion. Together, these data identify an increase in AP-1 TF activity
in Zbtb20 deficient memory CD8 T cells.
CUT&RUN identifies genomic targets and de novo DNA-binding motifs associated with
Zbtb20 in CD8 T cells
The genomic targets of Zbtb20 in CD8 T cells are not known and few targets are
described for other cell types 233,236,238,240,389. To address this gap in knowledge, we
utilized CUT&RUN (Cleavage Under Targets and Release Under Nuclease) 391. This
technique generates fragments of DNA associated with transcription factor complexes
(expected to be smaller than ~100bp) and fragments with nucleosome association
(expected to be >150bp) 391. Therefore, DNA fragments from targeting Zbtb20 in CD8 T
cells were collected and divided into two size classes, <125bp and >150bp, for analysis
(Fig. 4.13A, Fig. 4.14). A similar approach was taken for targeting Zbtb20 in HEK 293
cells (Fig. 4.15A-B). Combining peaks from both fragment classes, irreproducible
discovery rate (IDR) analysis identified 438 peaks in CD8 T cells (Fig. 4.14A) and 688
peaks in HEK 293 cells (Fig. 4.15A). De novo motif analysis of the peak set generated
with <125bp fragments identified two DNA motifs of interest in CD8 T cells (Fig.
4.13B). Interestingly, similar motifs were discovered de novo from analysis of the peak
sets generated in HEK 293 cells from <125bp fragments and >150bp fragments (Fig.
4.15), however, these motifs were not identified in the CD8 T cell peak set generated
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from >150bp fragments. From the CD8 T cell and HEK 293 de novo motif discovery, we
deduced core consensus motifs GGAGGCTGAGGCAGG and
GCTGGGA(T/C)TACAGG as associated with Zbtb20 binding.
Next, we utilized Genomic Regions Enrichment of Annotations Tool (GREAT) 282
to analyze the functional significance of cis-regulatory regions identified by Zbtb20targeted CUT&RUN in CD8 T cells. This analysis highlighted enrichment of Zbtb20
binding events with GO Biological Process term ‘negative regulation of immune system
process’ and GO Molecular Function term ‘biotin binding’ (Fig. 4.13C). Additionally, a
number of MGI Mouse Phenotype terms associated with abnormal T cell function were
detected (Fig. 4.13C). Signal tracks for select genes in GO Biological Process term
‘negative regulation of immune system process’ (Lpxn, Dusp10 and Il10) and GO
Molecular Function term ‘biotin binding’ (Pcx and Acacb) were visualized using R
package Gviz 279 (Fig. 4.13D). This analysis indicates Zbtb20 binding events are within
cis-regulatory regions functionally associated with immune regulation.
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Discussion
Our previous work examined the transcriptional landscape of Zbtb20 deficient
CD8 T cells (KO) compared to wild type CD8 T cells (WT) during the effector response
246

. Here, we extended our analysis of the transcriptional landscape of the CD8 T cell

response in the absence of Zbtb20 to the memory response and additionally performed
epigenetic analysis at both effector and memory phases. Furthermore, we confirmed key
observations from our single cell studies at the protein level and provided the first
description, to our knowledge, of Zbtb20 genomic targets in CD8 T cells. Together, this
work forms a basis for future studies seeking to harness Zbtb20 in therapeutic
applications.
Prior analysis of the effector response identified that the absence of Zbtb20
skewed CD8 T cell differentiation toward the generation of MPECs and away from the
generation of KLRG1 expressing TECs 246. In this study, we defined broad transcriptional
differences between WT and KO CD8 T cells at the memory phase. Similar to KO cells
during the effector phase, memory phase KO cells were poorly represented in KLRG1
expressing clusters and predominantly populated clusters expressing CD127. We noted
that at both the effector and the memory timepoints, KO cells were the predominant
population in clusters 3 and 5 respectively. Both day 10 cluster 3 and day 30 cluster 5
were strongly characterized by the expression of death associated protein-like 1, Dapl1.
This is interesting because the expression of Dapl1 was strongly downregulated in TM
that formed after secondary stimulation versus TM that formed following primary
stimulation 405. Secondary stimulation of TM also resulted in more CD62Llo TEM and
fewer CD62Lhi TCM 405. Thus, Dapl1 appears to be associated with the TCM program of
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primary TM. Other studies have shown that Th17 cells with potent tumor clearing
capacity and that memory CD8 T cells- with both central memory and stem cell memory
characteristics- resulting from lymphatic endothelial cell priming highly upregulate
Dapl1 406,407. Our data further indicate that Dapl1 expression in the CD62Lhi memory
compartment contributes to the identification of a transcriptionally distinct subpopulation
of TM expressing CD62L whose formation is restrained by Zbtb20. Our previous data
indicated Zbtb20 KO OT-I primary memory cells had an enhanced recall response to
challenge with an orthogonal pathogen expressing ovalbumin peptide 246. It is interesting
to speculate that this enhanced secondary response may be supported by a larger
proportion of KO cells differentiating into a Dapl1 expressing subset of memory T cells.
Future studies will examine the consequences of Zbtb20 deletion on the effectiveness of
tertiary and quaternary T cell responses.
Analysis of the transcriptional profiles of KO and WT cells indicated the
expression of Cx3cr1 transcripts, encoding for the fractalkine receptor CX3CR1, was
lower in KO cells. This difference was further verified at a protein level by flow
cytometry. Work in models of viral infection have noted that either intermediate or high
expression of CX3CR1 can be used to classify TM subsets with differential abilities to
self-renew and traffic into peripheral tissues 29. In the context of listeria infection,
expression of CX3CR1 reportedly identifies a population of TM that predominantly
partitions into the red pulp in the spleen 30, expresses elevated levels of granzyme B and
mediates enhanced target cell killing 31. The absence of Zbtb20 results in fewer CD8 T
cells expressing CX3CR1 during differentiation and may have implications for the
effector functions and trafficking potential of the resulting memory population.
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A rapid secondary response to previously encountered pathogens is a critical feature of
memory CD8 T cells. Epigenetic modifications underly this rapid secondary response.
For example, increased epigenetic accessibility is associated with regions of the genome
encoding for effector molecules in memory CD8 T cells relative to naïve cells 408,409. In
humans, a similar observation has also been made in long-lived, vaccine-induced, Yellow
Fever-specific, memory CD8 T cells 410. In our study, we compared the epigenetic
profiles of differentiating CD8 T cells with and without Zbtb20 expression at effector and
memory phases. We observed a striking epigenetic signature associated with attenuation
of T cell activation in Zbtb20 deficient CD8 T cells. This signature consisted of open
chromatin in regions encoding Ubash3b, Pik3ip1 and Atp2b4 at both the effector and
memory timepoints. At memory, we also noted elevated levels of transcription of these
genes in KO cells. It is interesting that this signature consists of genes regulating multiple
levels of T cell activation; Ubash3b prevents recruitment of linker for activation of T cells
(LAT) by TCR complex associated ZAP70, Pik3ip1 inhibits PI3K/AKT signaling
important for co-stimulation and Atp2b4 attenuates activation mediated through elevated
cytosolic calcium levels 401–403,411. Downstream of T cell activation through TCR and costimulatory signals are transcriptional regulators of the effector response such as ternary
NFAT:AP-1 complexes 412. In our analysis of motifs overrepresented in areas of
chromatin with increased accessibility in memory KO cells, we noted numerous motifs
associated with AP-1 binding. Furthermore, RNA- and protein-level expression of the
corresponding AP-1 components were elevated. Interestingly, we observed in our
scRNA-seq data that one memory cluster was composed of ~90% WT cells (cluster 1),
while an adjacent cluster contained ~90% KO (cluster 0) and was defined in part by
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increased expression of several AP-1 components. This KO cluster 0 appears to be more
similar to the previously discussed cluster 5 on the basis of a shared increase in the
expression of AP-1 components. The transcription factor activator protein-1 (AP-1) binds
DNA as an obligate dimer of two basic-Leucine Zipper (bZIP) transcription factors. The
bZIP proteins that form AP-1 dimers include members of the Jun (cJun, JunB and JunD),
Fos (cFos, FosB, Fra-1 and Fra-2), activating transcription factor (ATF2, ATF3 and
BATF) and Jun dimerization protein partner (JDP1 and JDP2) families 413. Members of
the AP-1 protein family have different abilities to homo- or heterodimerize and to
transactivate AP-1 responsive genes 414. The current view is that cellular context and
relative expression of AP-1 components determines the complex activity of the AP-1
transcription factor 415. In CD8 T cells, molecular profiling of naïve, effector, memory
and exhausted CD8 T cells identified elevated expression of Fosb, Junb and Fos in
memory CD8 T cells relative to exhausted and effector CD8 T cells 416. Additional work
has shown that NFAT orchestrates a program of T cell exhaustion in the absence of AP-1
binding partners 54 through positive regulation of the TOX/NR4A T cell exhaustion axis
417,418

, leading to displacement of AP-1 binding by NR4A 419. In the setting of

immunotherapy, chimeric antigen receptor (CAR) T cell exhaustion can be ameliorated
by adjusting the dosage of particular AP-1 components, namely, cJun in a model of CAR
T cell exhaustion 420. Furthermore, AP-1 appears to be critical for maintaining epigenetic
priming that supports T cell effector function 421,422. Together, these studies highlight the
importance of AP-1 component expression for the correct functioning of memory CD8 T
cells and CAR T cells. Our data indicate CD8 T cells deficient in Zbtb20 are
characterized by increased expression of numerous AP-1 components. The contribution
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of this elevated AP-1 signature to the enhanced effector cytokine production and
secondary responses will be the subject of future study. An especially pertinent question
is how the absence of Zbtb20 affects CD8 T cell exhaustion, as many facets of exhaustion
are linked to AP-1. Our AP-1 expression data also indicates that CX3CR1lo memory CD8
T cells are characterized by high expression of AP-1 components cFos, cJun, JunB and
JunD and low expression of FosB. This expression pattern of AP-1 components hints that
memory CD8 T cell subsets defined by CX3CR1 may have differential AP-1 component
dosage requirements.
The genomic targets of Zbtb20 are poorly characterized with few direct targets
described 233,236,238,240,389. To our knowledge, no report has examined the chromatin
occupancy of Zbtb20 in CD8 T cells. Here, we used the antibody-directed, nucleasebased CUT&RUN procedure 391, a powerful, high-resolution method for determining the
chromatin localization of proteins and nucleosome modification patterns, to characterize
Zbtb20 binding sites in CD8 T cells and human epithelial kidney cells (HEK 293). An
unbiased motif search in these Zbtb20 CUT&RUN experiments identified two motifs
shared between both cell types, indicating these could represent consensus Zbtb20 DNAbinding motifs. Proteins containing BTB protein interaction domains may have multiple
protein binding partners 185. For example, Zinc-finger and BTB domain containing
transcription factor BCL6 is known to bind co-repressor proteins through its BTB domain
423

. In the case of Zbtb20, the BTB domain is known to mediate homodimerization,

however, binding to other interaction partners remains largely uncharacterized 214. For
some transcription factors, binding with different partners is known to change the DNA
recognition site 424. Possibly, the two motifs discovered here represent recognition sites
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for Zbtb20 with different protein binding partners. Future experiments will seek to
experimentally validate Zbtb20 binding to the Zbtb20-associated motifs discovered here
and to identify proteins that interact Zbtb20.
Future studies will further clarify Zbtb20 genomic binding by experimentally
testing Zbtb20 binding to motifs discovered in this study. Furthermore, this study
indicates the absence of Zbtb20 in CD8 T cells may alter memory recall responses by
promoting the formation of a subset of CD62Lhi memory cells with high expression of
AP-1 components and Dapl1. Isolating this subset and comparing its recall capacity to
other CD62Lhi memory cells will determine the importance of this subset to the control of
CD8 T cell fate mediated by Zbtb20.
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Figure 4.1
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Figure 4.1: Transcriptomic and epigenetic differences between effector and memory
CD8 T cells with and without Zbtb20. Mice received naive WT OT-I (WT) or Zbtb20deficient OT-I cells (KO) and were then infected with LM-actA–OVA. Spleen cells were
harvested during the effector (day 10) and memory response (day 30), OT-I cells
purified, and single cell CITE-seq/RNA-seq/ATAC-seq performed as described. (A & B)
KO and WT cells collected from days 10 and 30 represented in the same UMAP space by
transcript expression (A) and chromatin accessibility (B). (C & D) Cluster analysis of KO
and WT cells collected from days 10 and 30 in the same UMAP space by transcript
expression (C) and chromatin accessibility (D). (E & F) The distribution of day 10 and
day 30 WT by transcript expression (E) and chromatin accessibility (F). (G & H) The
distribution of day 10 and day 30 KO by transcript expression (G) and chromatin
accessibility (H).
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Figure 4.2
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Figure 4.2: Transcriptional control of differentiating CD8 T cells by Zbtb20. Mice
received naive WT OT-I (WT) or Zbtb20-deficient OT-I cells (KO) and were then
infected with LM-actA–OVA. Spleen cells were harvested during the effector (day 10)
and memory response (day 30), OT-I cells purified, and single cell CITE-seq/RNA-seq
performed as described. (A & C) UMAP embeddings of merged KO and WT profiles at
day 10 (A) and day 30 (C) colored by KO and WT status. (B & D) UMAP embeddings
colored by cluster and displaying distribution of KO and WT cells within each expression
cluster at day 10 (B) and day 30 (D). (E-H) Feature plots displaying recovery of antibody
derived tags (ADTs) for protein-level expression of surface molecules CD127 and
KLRG1 at day 10 (E & F) and day 30 (G & H). (I & J) Expression plots comparing
gene-level expression of indicated genes between KO and WT at day 10 (I) and day 30
(J) for genes with significant differences in expression. (K & L) Expression plots
comparing gene-level expression for select clusters at day 10 (K) and day 30 (L). (M &
N) Expression of ADTs for CD62L, KLRG1 and CD127 are displayed for select clusters
for days 10 (M) and 30 (N). (O-R) Flow cytometry was used to detect protein-level
expression of CX3CR1 on KO and WT cells at day 10 and 30 post-infection with LMactA–OVA. (O) Percent of KO and WT cells expressing CX3CR1 at day 10 (O) and day
30 (P). For flow cytometry experiments, results are representative of two independent
experiments where n=4-5 for each condition. * p≤0.05, ** p≤0.01, *** p≤0.001, ****
p≤0.0001 and ns p>0.05.
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Figure 4.3
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Figure 4.3: Differential C5 pathways at day 10. Heatmaps display cell-level pathway
enrichment scores for gene sets in the C5 pathway collections in the Molecular Signature
Database (MSigDB) at day 10. All pathways displayed are differentially expressed
between KO and WT with cells ordered based on cluster membership (A) or KO/WT
status (B). All pathways displayed are significantly differentially expressed between KO
and WT (FDR < 0.15).
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Figure 4.4
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Figure 4.4: Differential Hallmark pathways at day 10. Heatmaps display cell-level
pathway enrichment scores for gene sets in the Hallmark pathway collections in the
Molecular Signature Database (MSigDB) at day 10. All pathways displayed are
differentially expressed between KO and WT with cells ordered based on cluster
membership (A) or KO/WT status (B). All pathways displayed are significantly
differentially expressed between KO and WT (FDR < 0.15).
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Figure 4.5
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Figure 4.5: Differential C5 pathways at day 30. Heatmaps display cell-level pathway
enrichment scores for gene sets in the C5 pathway collections in the Molecular Signature
Database (MSigDB) at day 30. All pathways displayed are differentially expressed
between KO and WT with cells ordered based on cluster membership (A) or KO/WT
status (B). All pathways displayed are significantly differentially expressed between KO
and WT (FDR < 0.15).
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Figure 4.6
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Figure 4.6: Differential Hallmark pathways at day 30. Heatmaps display cell-level
pathway enrichment scores for gene sets in the Hallmark pathway collections in the
Molecular Signature Database (MSigDB) at day 30. All pathways displayed are
differentially expressed between KO and WT with cells ordered based on cluster
membership (A) or KO/WT status (B). All pathways displayed are significantly
differentially expressed between KO and WT (FDR < 0.15).
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Figure 4.7
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Figure 4.7: COMPASS comparison of day 10 effector with day 30 memory WT OT-I.
COMPASS was used to analyze the WT OT-I (WT) scRNA-seq day 10 and day 30
datasets. (A) Differential activity of metabolic reactions grouped by Recon2 pathways.
Reactions are colored according to the sign of their Cohen’s d statistic, where a positive
sign indicates upregulation in day 30 memory vs day 10 effector WT. (B) Rank plot
displaying the difference between the percentage of reactions significantly upregulated
and the percentage of reactions significantly downregulated in day 30 memory vs day 10
effector WT.
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Figure 4.8
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Figure 4.8: Zbtb20 controls metabolic transcriptome of CD8 T cells. COMPASS was
used to analyze the KO and WT scRNA-seq datasets. (A & C) Differential activity of
metabolic reactions grouped by Recon2 pathways. Reactions are colored according to the
sign of their Cohen’s d statistic, where a positive sign indicates upregulation in KO vs
WT at day 10 (A) and day 30 (C). (B & D) Rank plots displaying the difference between
the percentage of reactions significantly upregulated and the percentage of reactions
significantly downregulated in Zbtb20 KO OT-I vs WT OT-I at day 10 (B) and day 30
(D).
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Figure 4.9
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Figure 4.9: Epigenetic differences in the absence of Zbtb20. Mice received naive WT
OT-I (WT) or Zbtb20-deficient OT-I cells (KO) and were then infected with LM-actA–
OVA. Spleen cells were harvested during the effector (day 10) and memory response
(day 30), OT-I cells purified, and single cell ATAC-seq performed as described. (A & B)
UMAP embeddings of merged KO and WT profiles at day 10 (A) and day 30 (B) colored
by KO and WT status. (C & D) UMAP embeddings colored by cluster and displaying
distribution of KO and WT cells within each expression cluster at day 10 (C) and day 30
(D). (E & F) Accessibility plots plots comparing gene-level accessibility of indicated
genes between KO and WT at day 10 (E) and day 30 (F). (G & H) Accessibility plots
comparing gene-level accessibility for select clusters at day 10 (G) and day 30 (H).

160

Figure 4.10
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Figure 4.10: Zeb1/2 signature in day 10 effector CD8 T cells lacking Zbtb20. Regions of
differentially accessible chromatin between KO and WT were subjected to chromVAR
analysis. (A) Transcription factor motifs identified by chromVAR in regions of chromatin
more accessible in KO cells 10 days post-infection with LM-actA-Ova. (B) ChromVAR
scores for motifs depicted in A. (C) Violin-plots for RNA-expression level of
transcription factors components at day 10 either corresponding to (Tcf7), or associated
with (Zeb2), motifs identified by chromVAR analysis in B.
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Figure 4.11
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Figure 4.11: Zbtb20 controls AP-1 signature in memory CD8 T cells. Regions of
differentially accessible chromatin between KO and WT were subjected to chromVAR
analysis. (A) Transcription factor motifs identified by chromVAR in regions of chromatin
more accessible in KO cells 30 days post-infection with LM-actA-Ova. (B) ChromVAR
scores for motifs depicted in A. (C) Violin-plots for RNA-expression level of AP-1
transcription factor components at day 30 corresponding to motifs identified by
chromVAR analysis. (D) Flow cytometry was used to detect protein-level expression of
AP-1 transcription factor components corresponding to motifs identified by chromVAR
analysis 30 days post-infection with LM-actA-Ova. Data was normalized to the mean
WT MFI. (E) Representative histograms depicting protein-level expression of AP-1
transcription factor components for data presented in D compared to control sample
stained only with secondary antibody. For flow cytometry experiments, results are shown
for two pooled independent experiments where n=9-10 for each condition. ** p≤0.01 and
*** p≤0.001.
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Figure 4.12
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Figure 4.12: Distribution of AP-1 subunit expression in memory CD8 T cells. (A)
Expression of AP-1 components measured by mean fluorescence intensity (MFI)
compared between CX3CR1lo and CX3CR1hi WT. (B) Expression of AP-1 components
measured by MFI compared between CX3CR1lo and CX3CR1hi KO. (C) Expression of
AP-1 components measured by MFI compared between CX3CR1lo KO and CX3CR1lo
WT. (D) Expression of AP-1 components measured by MFI compared between
CX3CR1hi KO and CX3CR1hi WT. * p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001 and
ns p>0.05.
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Figure 4.13: CUT&RUN identifies genomic targets and de novo DNA-binding motifs
associated with Zbtb20 binding in CD8 T cells. CUT&RUN was used to identify regions
of DNA bound by Zbtb20 in CD8 T cells. (A) Heat maps and signal of two replicate
CUT&RUN datasets for IDR peaks generated with <125bp fragments. (B) De novo motif
discovery analysis in Zbtb20 CUT&RUN peaks in CD8 T cells with E values reported by
MEME. (C) Enriched terms for ontologies obtained using GREAT analysis of proximal
and distal binding events obtained for Zbtb20 in CD8 T cells. (D) Select signal tracks
showing Zbtb20 CUT&RUN signal compared to IgG control for genes in GO pathways
identified in C. Peak calls from MACS2 where Zbtb20 CUT&RUN signal was
significantly enriched over IgG control are denoted by the peak tracks.
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Figure 4.14
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Figure 4.14: CD8 T cell CUT&RUN summary. CUT&RUN was used to identify regions
of DNA bound by Zbtb20 in CD8 T cells. (A) Table indicating number of IDR peaks
identified from two replicate samples for CUT&RUN fragments separated into <125 bp
and >150 bp size classes. (B) Heat maps and signal for IDR Zbtb20 CUT&RUN peaks
generated from fragments separated into <125 bp and >150 bp size classes and signal
from all fragments generated by targeting histone methylation H3K4me3 as a technical
positive control. (C) De novo motif discovery analysis in Zbtb20 CUT&RUN peaks
generated from <125bp fragments in CD8 T cells with E values reported by MEME and
central enrichment as reported by CentriMo. (D) Percent of IDR peaks from <125bp
fragments containing motifs described in C. (E) Proportion of peaks falling in specific
genomic contexts for peaks generated from CUT&RUN fragments separated into <125
bp and >150 bp size classes.
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Figure 4.15
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Figure 4.15: HEK 293 CUT&RUN summary. CUT&RUN was used to identify regions of
DNA bound by Zbtb20 in HEK 293 cells. (A) Table indicating number of IDR peaks
identified from two replicate samples for CUT&RUN fragments separated into <125 bp
and >150 bp size classes. (B) Heat maps and signal for IDR Zbtb20 CUT&RUN peaks
generated from fragments separated into <125 bp and >150 bp size classes and signal
from all fragments generated by targeting histone methylation H3K4me3 as a technical
positive control. (C) De novo motif discovery analysis in Zbtb20 CUT&RUN peaks
generated from <125bp fragments in CD8 T cells with E values reported by MEME and
central enrichment as reported by CentriMo. (D) De novo motif discovery analysis in
Zbtb20 CUT&RUN peaks generated from >150bp fragments in CD8 T cells with E
values reported by MEME and central enrichment as reported by CentriMo. (E) Percent
of IDR peaks from <125bp and >150bp fragments containing motifs described in C and
D. (F) Proportion of peaks falling in specific genomic contexts for peaks generated from
CUT&RUN fragments separated into <125 bp and >150 bp size classes.
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Discussion and future directions
Broadly, the work presented in preceding chapters contributes to the scientific
community’s understanding of CD8 T cells during control of infection and tumor
clearance. There are several avenues along which this work may be extended.
Chapter 3
Chapter 3 describes the generation of a model of B cell lymphoma control by
gammaherpesvirus (γHV)-specific CD8 T cells generated in response to murine
gammaherpesvirus 68 (MHV-68) infection. This model allowed us to test the
mechanisms used by γHV-specific CD8 T cells to control B cell lymphoma in a tractable
murine model. This type of study was not feasible previously due to the prohibitive
technical considerations of other models of γHV associated lymphoproliferative disease.
We found that γHV-specific CD8 T cells exhibit considerable flexibility with regards to
effector mechanisms used to control MHV-68 infection compared to γHV-associated B
cell lymphoma. The B cell lymphoma model developed in this study, EM61, will be a
useful tool for future studies aimed at improving adoptive T cell therapies for patients
with post-transplant, γHV-associated B cell lymphomas. The memory CD8 T cell
response controlling persistent γHV infection is characterized by TM with a
predominantly TEM phenotype, higher memory cell turnover and retention of important
effector function 425,426. In the context of persistent antigen in a tumor microenvironment,
tonic signaling leads to mitochondrial dysfunction and loss of T cell self-renewal and
function 107,427,428. Therefore, persistent antigen during γHV infection or cancer result in
different functional outcomes for TM. The metabolic program governing γHV-specific TM
has not yet been characterized. Future studies may focus on understanding what
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metabolic properties underlie the enduring function of γHV-specific TM and seek
metabolic avenues to improve this response for therapy versus lymphoproliferative
disease using the EM61 model.
Chapter 3 further examines tissue resident memory CD8 T cells (TRM) in γHV
infection. The contribution of TRM to the control of γHV infection is poorly understood,
although descriptions of EBV-specific CD8 T cells with surface molecule expression
prototypical of TRM have been described in tissues relevant to EBV pathogenesis 367,368.
CD8 T cells may be invaluable to current efforts to generate vaccination strategies for
controlling EBV infection in the general population (see chapter 1). It is therefore crucial
to determine what role γHV-specific CD8 T cells play in the control of γHV infection to
understand if this is a subset of CD8 T cells that may predict successful immunization.
We identified γHV-specific TRM in mice infected with MHV-68. Future studies will
further characterize these TRM phenotypically and use techniques such as parabiosis and
microscopy to refine our understanding of their migratory capacity and positioning with
tissues. Furthermore, additional studies should survey a broader range of tissues to
understand the extent to which tissues receive γHV-specific TRM oversight. It would be
especially interesting to test skin, brain and spinal cord. Detection of γHV-specific TRM in
the brain and spinal cord may be interesting due to the relationship between EBV and
multiple sclerosis (MS), as the central nervous system is the primary target of this
inflammatory, demyelinating disease 429. Rosato et al (2019) found virus-specific TRM
residing in the skin and tumor could be reactivated to augment checkpoint blockade
therapy in mouse models 430. This study also showed that in humans EBV-specific CD8 T
cells could be detected in a range of tumors including head and neck, breast and
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glioblastoma 430, suggesting yHV infection may provide a source of therapeutically useful
CD8 T cells in a range of tissues. Given our data, which indicates MHV-68-specific CD8
T cells can be similarly leveraged to improve immunotherapy, it will be useful to
understand if MHV-68-specific TRM populate skin and contribute to the observed
therapeutic effect. In addition to the experimental considerations discussed in chapter 3, it
may be useful to administer MHV-68 infection intravenously rather than intranasally.
While the intranasal route is the typical infection route used, other studies have
performed intracranial, intraperitoneal and intravenous infections 152,431,432.
Administration of MHV-68 infection through other routes may more efficiently seed
MHV-68-specific TRM in diverse tissues and better model the dispersal of EBV-specific
CD8 T cells observed in human cancers.
In summary, the data presented in chapter 3 describes three major advances. First, the
generation of a novel tool for dissecting the interaction between γHV-specific CD8 T
cells and γHV-driven B cell lymphoma. Second, the first characterization of γHVspecific TRM in the MHV-68 model and third, that authentic, γHV-specific CD8 T cells
can be mobilized to augment immunotherapy, in agreement with previous proof-ofprinciple studies.
Chapter 4
The work described in chapter 4 employed single cell transcriptomic (scRNA-seq)
and single cell epigenomic (scATAC-seq) techniques to holistically assess differences in
CD8 T cell state during differentiation with and without the transcription factor Zbtb20.
Furthermore, genomic targets of Zbtb20 in CD8 T cells were determined using
CUT&RUN. Briefly, these techniques determined that in the absence of Zbtb20,
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transcriptional hallmarks of memory CD8 T cell formation were broadly upregulated
throughout the CD8 T response. Open chromatin regions were associated with genes
known to control T cell activation and contained an overrepresentation of AP-1
transcription factor motifs, which corresponded to increased transcript and protein levels
of AP-1 components. Analysis of Zbtb20-targeted CUT&RUN retrieved genomic
annotations associated with T cell and immune cell regulation and identified DNA motifs
conserved between CD8 T cells and human embryonic kidney epithelial cells (HEK 293).
Considering first the CUT&RUN findings; there are several follow-up studies that
will be useful. From a technical standpoint, there is likely utility in further optimizing the
CUT&RUN procedure itself. Our study targeted an N-terminal 3XFLAG tag on Zbtb20
for CUT&RUN. We did not experiment with adding linkers or making C-terminal-tagged
constructs. Our rational for focusing on the N-terminus was to avoid introducing residues
near the DNA-binding zinc finger (ZF) motifs and risk disrupting natural ZBTB20-DNA
interactions. As discussed in chapter 1, there is reason to believe that bulky protein
complexes interacting through the BTB domains of BTB-ZF proteins may block antibody
binding in some circumstances. This was the case in immunoprecipitation experiments
performed on BTB-ZF family member LRF. This study noted that immunoprecipitation
required C-terminal tagging with a short linker 203. While we successfully generated
sequenceable fragments in our experiment, likely because of the high sensitivity of the
CUT&RUN technique and potentially because of different protein interaction preferences
between Zbtb20 and LRF, it is possible the resolution of Zbtb20-targeted CUT&RUN
would benefit from testing constructs with different tagging and linker conformations.
Testing C-terminal tags with short 10-25 amino acid linkers, similar to those used in scFv
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molecules 433, could be particularly interesting as the resolution of ZF DNA-binding
footprints may be enhanced with this strategy and lead to more consistent central
enrichment of discovered motifs. CUT&RUN was initially selected over conventional
ChIP-seq because of the greater sensitivity of the CUT&RUN technique, leading to
enhanced detection of targets with non-ChIP grade antibodies 391. This was important as
no ChIP-grade antibody to Zbtb20 was, or is currently, commercially available. Initial
CUT&RUN assays performed with commercially available anti-Zbtb20 antibodies
targeting endogenous Zbtb20 failed to produce peaks appreciable over control IgG (data
not shown). While generating enhanced CUT&RUN signal by testing additional linker
and tagging conformations likely represents the next best strategy, ChIP-seq may be
another useful option when using the extensively ChIP-validated antibodies that
recognize FLAG-tags. I would speculate that ChIP-seq may be less sensitive to inhibition
by bulky protein complexes potentially associating with Zbtb20 than CUT&RUN which
is based on an antibody-tethered nuclease with limited mobility reaching DNA around
obstacles. This has to be balanced, however, with the fact that ChIP-seq assays have
lower sensitivity at baseline than CUT&RUN.
Two motifs were identified via a de novo motif search from both CD8 T cells and
HEK 293 cells. These sequences may represent consensus Zbtb20 DNA-binding motifs
and future work will test direct binding to and regulation of genes adjacent to these
motifs by Zbtb20. Several studies have used co-transfection of Zbtb20 with reporter
plasmids driven by cognate Zbtb20 DNA sequence to test the repressive or activating
potential of Zbtb20 for a particular DNA sequence 223,233,234,237–240. A similar approach
may be useful here. One approach is to design constructs with the discovered motifs
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cloned upstream of a reporter (likely luciferase) for transfection into HEK cells with or
without Zbtb20 co-transfection. This system could provide valuable information about
the cis-acting potential of Zbtb20 binding to the discovered motifs. Knockdown of
Zbtb20 using siRNA or other means in HEK 293 cells transfected with reporter
constructs may provide further confirmation of regulatory function. Considerations for
the design of the reporter constructs include the number of motif repeats included and
spacing between motifs. Assuming each ZF domain in a Zbtb20 homodimer binds one
motif, creating a library of constructs with varying numbers and distances between motifs
may provide information pertinent to the biochemistry of Zbtb20 binding. While
preliminary tests with HEK 293 likely will be easiest for technical reasons, progressing to
similar tests in CD8 T cells using transduction will confirm regulation in both cell types.
To directly test the binding of Zbtb20 protein to DNA, the Electrophoretic Mobility Shift
Assay (EMSA) may be useful, as this assay detects the interactions between protein and
nucleic acids and has been used in the context of Zbtb20 previously 237. Interestingly,
EMSA failed to confirm direct, sequence-specific interactions between Zbtb20 and DNA
for some described targets 234. This may indicate Zbtb20 regulates transcription in some
settings by acting as a cofactor, binding to other DNA-binding TFs. Protein binding
through ZF domains has been reported for other BTB-ZF proteins 185. Another method,
available commercially, for testing Zbtb20-DNA binding is yeast one-hybrid. This
methodology leverages libraries of DNA sequences as ‘bait’ upstream of promotors for
survival or reporter genes. Protein fusions are made of a protein of interest and a
transcriptional activator for the survival or reporter gene. These fusions are then added to
the to a yeast library of target sequences. Yeast containing DNA sequences bound by

179

fusion proteins are detected via the reporter readout, collected and then sequenced to
identify the DNA sequence. Our discovered motifs could be incorporated into such a
library, accomplishing simultaneous testing of our motifs and a library of sequences.
These experiments will determine if Zbtb20 directly recognizes the motifs discovered
during our de novo motif search. An important aspect of Zbtb20 biochemistry to
investigate is what proteins it is capable of partnering with. This will become especially
important if the experiments outlined for testing binding to our discovered motifs fail to
detect direct DNA binding, as this may suggest binding is mediated through an
interaction partner.
Proteins in the BTB-ZF family are known to homo- or heterodimerize with BTB-ZF
proteins and each major domain of the protein- BTB, linker and ZF- can independently
interact with proteins 185. Thus, understanding the possible protein-protein interactions
mediated by any given member of the BTB-ZF family is vital for understanding the scope
of its function. This is highlighted by the example of Zbtb32, which interacts with Blimp1 and cooperatively exerts important functions in CD8 T cells 211. One approach for
identifying interaction partners of Zbtb20 is to extend the yeast one-hybrid suggested
previously to include yeast two-hybrid studies. This approach has been used in a limited
capacity for the study of interacting Zbtb20 isoforms 214 and in a broader capacity for
identifying novel interaction partners in the context of BTB-ZF family member LRF 203.
Similar to yeast one-hybrid, yeast two-hybrid is a commercially available experimental
platform. However, whereas yeast one-hybrid aims to identify or confirm protein-DNA
binding, yeast two-hybrid is a platform for dissecting protein-protein interaction. Using
yeast two-hybrid technology, novel Zbtb20-protein interactions may be uncovered.
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Another approach to identifying novel protein interaction partners is immunoprecipitation
followed by mass spectrometry 434. This approach does not require fusion of the protein
of interest, however, it does require crosslinking and can be more costly relative to yeast
two-hybrid.
Another aspect of Zbtb20 biology that remains incompletely described is how Zbtb20
itself is regulated transcriptionally. In B cells, Chevrier et al. (2014) determined that IRF4
regulated Zbtb20 expression 243. It is unknown if a similar regulatory process occurs in
CD8 T cells, although this possibility is intriguing as IRF4 is activated in response to
TCR signals in T cells and drives TEC formation, potentially consistent with our data that
indicates Zbtb20 restrains MPEC formation 435. Thus, it remains possible that TCR
signals and Zbtb20 expression are directly linked.
An interesting finding from our single cell studies is that Zbtb20 deficient CD8 T
cells (KO) have increased chromatin accessibility associated with AP-1 DNA motif
sequences, implying increased AP-1 activity. We also detected a corresponding increase
in the transcript levels of several AP-1 components, which was conserved at the proteinlevel. We noticed that protein levels of several AP-1 components (cFos, cJun, JunB and
JunD) were elevated in CX3CR1lo memory OT-I, whereas protein levels of FosB were
elevated in CX3CR1hi memory OT-I. This may suggest that different dosages of
particular AP-1 components support the memory compartments delineated by CX3CR1
expression. To our knowledge, the role of AP-1 component dosage in supporting memory
CD8 T cell subsets is an unexplored aspect of AP-1 biology. That being said, AP-1
components have been observed as elevated in memory CD8 T cells compared to
exhausted and effector CD8 T cells in large-scale transcriptomic screens 416. Furthermore,
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there is one study that employed a model of CAR T cell exhaustion and found the
exhaustion defect could be overcome by modulating the AP-1 component dosage 420.
Thus, there is precedent that AP-1 component dosage may impact T cell function,
whether it can influence CD8 T cell differentiation or be harnessed in a translational
immunotherapeutic setting remains to be seen. Future studies may seek to establish a
broader understanding of the expression of other AP-1 components (20 components were
not queried in our study, all of which may not be expressed in CD8 T cells) in different
subsets of memory CD8 T cells and extend the study to include the effector phase and
secondary response. The function of the elevated AP-1 signature in KO cells remains to
be determined. We have tested the hypothesis that elevated AP-1 activity in KO may
contribute to the enhanced cytokine production observed in our previous study 246. We
generated a dose-response curve to an inhibitor of the activator of AP-1, Jun N-terminal
kinase (JNK), reasoning that differences in IL-2, IFNγ and TNFα that were dependent on
AP-1 would be abolished, while differences dependent on other TFs, such as Nf-κB 436,
would be conserved (Supplemental Figure 1). In this test we did not observe differences
in the presence of inhibitor, indicating elevated AP-1 may be more important for a
different cellular function. AP-1 is also implicated in cellular proliferation 437 and future
studies might consider testing if either resting memory cells or memory cells during
recall have different proliferative capacities.
Chapter 4 advances the field of CD8 T cell biology by providing a comprehensive
description of how the TF Zbtb20 contributes to the CD8 T cell response at both
transcriptomic and epigenetic levels. Furthermore, the direct genomic targets of Zbtb20
in CD8 T cells were identified, revealing two Zbtb20-associated DNA motifs. This
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contributes to the field of CD8 T cell biology and may have broader implications for
diverse cell types that Zbtb20 plays important roles in, such as neurons, hepatocytes and
cardiomyocytes among others. Analysis of where these motifs are located and in what
number should be broadly informative for all fields relative to Zbtb20 biology. Future
studies aimed at identifying Zbtb20 binding partners may reveal binding partners
available in CD8 T cells that are unavailable in other cell types. This might suggest a
strong role for heterodimerization and tertiary interactions in mediating DNA-motif
binding preference.
There are additional areas of CD8 T cell biology that the regulatory functions of
Zbtb20 may be applicable to. One area is the differentiation and function of tissueresident memory CD8 T cells (TRM). Our transcriptomic studies indicate differential
expression of Runx3, a TF important for TRM formation in some tissues 77, between KO
and WT during both the effector and the memory response. Furthermore, TRM precursors
are preferentially retrieved from the MPEC population in at least some contexts, such as
the skin and intestine 5,438,439. Furthermore, literature associates BTB-ZF proteins with the
formation of TRM, as in the case of HIC1 promoting intestinal TRM formation 83. We
tested the capacity of Zbtb20 deficient Pmel transgenic CD8 T cells to form TRM and seed
a B16 melanoma tumor in the melanoma associated vitiligo (MAV) model 440. In this
context, we did not observe differences in TRM formation or tumor seeding, but also did
not detect differences in KLRG1/CD127 expression typical of the Zbtb20 phenotype
(data not shown). Similar to our studies with listeria KO and WT cells responding to
other models of viral infection, such as vesicular stomatitis virus (VSV) and modified
vaccinia Ankara (MVA) appear to exhibit differences in patterns of KLRG1 and CD127
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expression during the effector response (Supplemental Figure 2). CD8 T cells that form
TRM in response to both of these infection models have been characterized 430,441–444 and it
would be interesting to test Zbtb20 deficient TRM formation in these models, where
differences in KLRG1/CD127 expression recapitulate. In line with these studies, it would
be useful to elaborate on our previous findings, which indicate KO cells have an
enhanced recall response to orthogonal virus challenge, by isolating KO and WT OT-I at
memory and transferring equal numbers to naïve recipients before recall. This would
provide information on the per cell recall capability of KO cells.
Significant efforts were made towards understanding if Zbtb20 could positively
impact adoptive cell therapy. We were especially interested in this avenue of
investigation given our previously obtained data showing that day 80, LM-actA-OVAinduced, memory KO OT-I were more effective versus MC38-OVA than memory WT
OT-I. We aimed to extend these findings to systems relevant to immunotherapy. To do
this, in vitro cultured KO or WT OT-1 were adoptively transferred into mice bearing
intradermal B16-OVA melanoma tumors or subcutaneous MC38-OVA tumors and
monitored for tumor growth (Supplemental Figure 3). In some experiments with B16OVA, an LM-actA-OVA boost was employed (Supplemental Figure 3). In these systems,
we did not detect a tumor control advantage conferred by absence of Zbtb20. This
prompted us to examine the memory cell transfer system used previously to control
MC38-OVA growth. An equivalent number of day 30 KO and WT cells were transferred
into mice bearing subcutaneous MC38-OVA tumors with either four and nine days of
growth. In this system, memory OT-I transfer cleared MC38-OVA tumors regardless of
KO or WT status or the number of days post-tumor inoculation (Supplemental Figure 4).
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Although a direct comparison has yet to be performed, this may indicate that the day 30
memory cells are more potent than the day 80 memory cells used in previous studies.
Seeking another avenue to test the killing capacity of KO versus WT, we developed an in
vitro MC38-OVA killing assay with readouts by flow cytometry and Incucyte continuous
live cell monitoring. In one set of experiments, we tested the ability of KO versus WT to
perform serial killing (‘serial killing’ being distinct from the type of serial killing
performed by one cell killing numerous target cells). In these experiments, KO and WT
OT-I cells killed activated adherent MC38-OVA target cells over a period of three days
then harvested, purified and seeded in plates containing fresh MC38-OVA target cells.
Repeating this process multiple times allowed us to test if a single population of CD8 T
cells gained an advantage from Zbtb20 deficiency over multiple rounds of stimulation.
We did not detect that Zbtb20 cells gained an advantage in cell killing, however, we did
note decreased PD-1 expression on KO cells and changes in the expression of some
TIGIT family members that showed corresponding changes during the in vivo response to
listeria (Supplemental Figure 5). In a related set of experiments, we tested if KO cells
gained a target cell killing advantage in the presence of the metabolic inhibitors used in
our previous study. We reasoned that KO cells maintaining enhanced metabolic function
in the presence of these inhibitors (previously shown by our group) may translate to
better target cell killing during metabolic fuel choice restriction. In these experiments, we
found no difference in the number of target cells remaining or the number of CD8 T cells
at the end of the coculture period for a given inhibitor condition (Supplemental Figure 6).
We did, however, note that KO cells expressed lower levels of PD-1 across all inhibitor
conditions (Supplemental Figure 6). The difference in PD-1 expression may imply KO
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cells have a difference in sensitivity to PD-L1. MC38 tumor cells are known to express
PD-L1 in vivo 445, it remains to be tested if, or to what extent, it is expressed by the MC38
used in this study. Overall, these studies indicate that in vitro cultured KO cells do not
have a tumor control advantage in the systems tested. Possibly, this suggests that KO
cells differentiating in vivo encounter signals not present in vitro that contribute to them
developing an enhanced recall response. Future studies may focus on confirming that day
80 KO cells have a tumor control advantage and perform a direct comparison with day
30, 55, and 100+ memory cells to determine if the memory recall advantage in the tumor
setting is a function of time post-activation.
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Supplemental Figure 1

239

Supplemental Figure 1: Dose response of cytokine secretion from memory KO and WT
to JNK inhibitor. KO and WT memory cells generated in response to LM-actA-OVA
infection were harvested from spleens and restimulated in vitro with SIINFEKL peptide
(1μg/mL), IL-2 (10 U/mL) and JNK inhibitor (InSolution JNK Inhibitor II, #420128,
Sigma-Aldrich) for 5 hours prior to cytokine staining following the intracellular staining
technique outlined in the methods for chapter 4. (A) Gating strategy for identifying
populations of live KO or WT producing indicated cytokines. (B) IL-2 dose response to
JNK inhibitor. (C) TNFα dose response to JNK inhibitor. (D) IFNγ dose response to JNK
inhibitor. Data points consist of 5 technical replicates per concentration of JNK inhibitor.
Data is representative of two individual experiments.
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Supplemental Figure 2
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Supplemental Figure 2: Zbtb20 KO OT-I responding to VSV-OVA and MVA-OVA
infection produce more MPEC and fewer TEC during the effector response. Mice
received naive WT OT-I (WT) or Zbtb20-deficient OT-I cells (KO) and were infected
with either VSV-OVA intravascularly or MVA-OVA intraperitoneally one day later.
Blood was collected during the effector response and stained to identify markers of TEC,
MPEC and early effector cell (EEC) differentiation. (A) Distribution between TEC,
MPEC and EEC of the effector population of KO and WT cells responding to VSVOVA. (B) Distribution between TEC, MPEC and EEC of the effector population of KO
and WT cells responding to MVA-OVA. Nine mice per KO and WT were used for VSVOVA infection experiments. Five mice per KO and WT were used for MVA-OVA
infections experiments. All data are representative of at least two independent
experiments. * p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001 and ns p>0.05.
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Supplemental Figure 3
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Supplemental Figure 3: Zbtb20 KO OT-I versus WT OT-I in multiple tumor therapy
models. Zbtb20 KO OT-I or WT OT-I were activated with SIINFEKL peptide and
expanded in vitro with IL-2 (25U/mL) before adoptive transfer (retroorbital) into mice
bearing either intradermal B16-OVA (A-C & G-I) or MC38-OVA (D-F) tumors. In some
experiments with B16-OVA tumors an LM-actA-OVA boost was administered the day
after adoptive cell transfer (G-I). (A) Experimental timeline for B & C. (B) Individual
tumor growth curves for each therapy administered. (C) Survival of mice receiving
indicated adoptive cell transfer. (D) Experimental timeline for E & F. (E) Individual
tumor growth curves for each therapy administered. (F) Survival of mice receiving
indicated adoptive cell transfer. (G) Experimental timeline for H & I. (H) Individual
tumor growth curves for each therapy administered. (I) Survival of mice receiving
indicated adoptive cell transfer. Data are representative of three individual experiments
performed for A-B and G-I and two individual experiments performed for D-F. * p≤0.05,
** p≤0.01, *** p≤0.001, **** p≤0.0001 and ns p>0.05.
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Supplemental Figure 4
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Supplemental Figure 4: Transfer of memory KO OT-I and WT OT-I for therapy of
MC38-OVA tumors. (A) Mice received naive WT OT-I (WT) or Zbtb20-deficient OT-I
cells (KO) and were infected with LM-actA-OVA intravascularly. 30 days later, memory
OT-I cells were purified with magnetic enrichment and 1X106 KO or WT were
transferred into groups of mice bearing MC38-OVA tumors grown subcutaneously for
either 4 or 9 days. (B) Average tumor diameter in mice receiving adoptive cell transfer 4
days after tumor inoculation. (C) Average tumor diameter in mice receiving adoptive cell
transfer 9 days after tumor inoculation. Ten mice per group were used.
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Supplemental Figure 5
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Supplemental Figure 5: Serial killing assay with in vitro phenotyping and
corresponding in vivo phenotyping. (A) Splenocytes from Zbtb20 KO OT-I and WT OT-I
mice were activated in vitro with SIINFEKL peptide for 48 hours after which, OT-I were
collected and reseeded in 24-well plates with fresh media containing IL-2 (25 U/mL) at
1X106 cells/mL. After a 3 day expansion period, KO and WT OT-I were collected and
added to 24-well plates containing 4X105 adherent MC38-GFP-OVA at either 1:1 or
0.25:1 effector to target ratios. For some 24-well plates, an Incucyte live-cell imaging
system was used to track CD8 T cell-mediated killing of MC38-GFP-OVA using cytotox
red (#4632, Sartorius) dead cell indicator in a temporal fashion for 3 days. After the 3 day
incubation period, OT-I cells were collected from a separate set of 24-well plates
containing KO or WT at either 0.25:1 or 1:1 ratios that were not used for the Incucyte
assay. These OT-I cells were counted and phenotyped. Live OT-I cells seeded at a 1:1
ratio, where complete MC38-GFP-OVA cell killing was achieved, were purified with a
FICOLL gradient and then used to seed another round of Incucyte cell killing assays. (B)
A representative image from a single field of vision (FOV) at a single time point showing
how GFP fluorescence was used to identify MC38-GFP-OVA and how cytotox red dead
cell indicator fluorescence was overlayed to identify the total area with overlapping
fluorescence (Overlap μM2/well) containing dead MC38-GFP-OVA. (C) Cell killing
monitored over 3 days for three rounds of cell killing. (D & E) Expression of indicated
surface molecules on KO and WT seeded at 1:1 (D) or 0.25:1 (E) ratios with MC38-GFPOVA over the course of 3 rounds of cell killing. (F & G) Expression of indicated TIGIT
family members on KO and WT OT-I responding to LM-actA-OVA infection at either an
effector (F) or a memory (G) timepoint. 3 technical replicates were used for Incucyte
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tracking and 4 technical replicates for phenotyping. Data is representative of two
independent experiments. * p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001 and ns
p>0.05.
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Supplemental Figure 6
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Supplemental Figure 6: Comparison of KO versus WT in vitro killing capacity with
inhibition of different metabolic pathways. (A) KO and WT OT-I cells were activated and
cultured with IL-15 as depicted. Once expanded, a cell killing assay was initiated in 24well plates using a 0.25:1 effector to target ratio where the target cells were 4X105
adherent MC38-GFP-OVA. Metabolic inhibitors were added to final concentrations as
follows; Etomoxir- 4 μM, BPTES- 3 μM, UK5099- 2 μM and 2-DG- 350 μM. (B & C)
After a 3 day cell killing period, surviving OT-I (B) and MC38-GFP-OVA (C) were
enumerated. (D) Expression of PD-1 on CD8 T cells at the end of the culture period for
each inhibitor condition. Data is representative of two individual experiments.
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